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The imminent threat of antibiotic resistant pathogens that have emerged in clinical 
settings over the past several decades demands novel solutions in the form of both 
species- and/or strain-specific diagnostic technologies and treatments. Such new 
developments would aid in the improved management of bacterial infections by accurate 
diagnosis and targeted bacterial killing, which would mitigate the continued spread of 
antibiotic resistance as a result of broad-spectrum antibiotic application The cell surface 
of bacteria presents a unique opportunity towards development of these modalities, as 
bacterial cell walls possess both universal and unique features that can be targeted by 
chemical functionalities without the requirement of cell penetration. This work has 
sought to take advantage of naturally existing and non-natively installed bacterial cell 
wall chemical functionalities for which we can develop novel chemoselective chemistries 
and unique peptides that incorporate those chemical functionalities to enable targeted, 
biocompatible methods of bacterial labeling and targeting. 
We initially began these endeavors with the goal of improving upon existing 
readily reversible iminoboronate chemistry with acetylphenyl boronic acid (APBA), 
which selectively labels bacteria that contain amine-presenting cell wall lipids (e.g. PE 
and Lys-PG). In our efforts to improve upon the binding potency of this chemical motif, 
we synthesized a panel of APBA analogues with varying substituents to modulate amine-
binding affinity. We additionally characterized these analogues capacity to form 
thiazolidinoboronates with free and N-terminal cysteine.  
Furthermore, we applied an APBA dimer presenting phage library towards 
identification of potent and selective APBA-presenting peptide binders of 1) a cationic 
antimicrobial peptide (CAMP) implicated in cancer, human beta defensin 3 (hBD3), and 
2) colistin-resistant strains of bacteria that attain their resistance through a variety of 
different mechanisms. This high-throughput technology afforded identification of 
peptides that are indeed protein or species/strain selective binders, thus enabling targeted 
labeling of these important biomolecules. 
 In our continued efforts to identify highly potent and selective bacterial targeting 
chemistries, we also developed an irreversible chemistry that enables the incorporation of 
chemical motifs, APBA and semicarbazide, into the cell walls of bacteria through cell 
wall remodeling mechanisms, which then undergo rapid conjugation with fluorescent and 
turn-on fluorescent reactive partners. While this alternative approach to bacterial 
detection requires a primary cell-wall incorporation step, the incorporation and 
subsequent labeling of these chemical motifs are both highly efficient, which enhances 
the potency of this bacterial labeling approach 
The chemical approaches to targeted bacterial labeling herein highlight our ability 
to develop several species- and strain-selective bioorthogonal chemical probes towards 
the goal of discovering targeted bacteria binding modalities. Beyond identification of 
such targeted bacterial binding molecules, we hope to translate these findings into 
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1.1 The Challenge Posed by Antibiotic Resistance 
Over the past several decades, antibiotic resistance has emerged as one of the 
most significant threats to worldwide human health. In the US alone, cases of bacterial 
infections reach upwards of 2 million each year, resulting in ~30,000 deaths per year as a 
direct result of the emergence of antibiotic resistance.1,2 To combat this pressing issue, 
scientists aim to tackle the eradication of bacterial infections via several approaches, 
including prevention of infections, observing resistance patterns, improving appropriate 
antibiotic use, and most importantly, developing novel antibiotics and diagnostics. 
Importantly, despite the significant need for the development of new antibiotics, 
the actual number of new FDA approved antibiotics has been steadily decreasing over the 
past several decades (Figure 1-1). This deficiency in antibiotic development is due to a 
wide number of factors including increasingly complicated bacterial targets due to 
multifaceted resistance mechanisms, as well as the challenge of targeting a specific 
species of bacteria while bypassing all others towards efforts to maintain commensal 
bacterial populations. Given these many challenges, our group has sought to develop 
chemistries that would aid in the development of targeted molecular tools that would 
allow us to differentiate between not only different species of bacteria, but also between 
antibiotic resistant and sensitive bacteria. In order to do so, we must first understand the 
emergence of antimicrobial resistance, including which species and strains of bacteria are 
hardest to tackle, in addition to how antibiotics have traditionally been discovered and 





















Figure 1-1. Declining antibiotic approvals from 1983 – 2007 (Image from Ref. 3).3 
 
 
1.1.1 Discovery of Antibiotics: Past and Present 
In the “Golden Age” of antibiotic innovation antibiotics were discovered through 
screening of natural sources, such as soil and plants. While the widely renowned 
antibiotic penicillin was identified through a more serendipitous discovery methodology, 
the Waksman platform, a method that was so revolutionary it won a Nobel Prize in 1952, 
provided a systematic screening approach, which eventually led to the discovery of 
streptomycin.4 The Waksman platform, which was the first “high throughput” antibiotic 
discovery methodology, essentially screened for compounds in soil that would inhibit the 
growth of lab-cultured bacteria. When growth inhibition was observed, the soil 
compound was isolated and tested in its pure form.5 
Over the proceeding several decades, this method produced upward of ten new 
major classes of antibiotics, including beta lactams, macrolides, tetracyclines, in addition 
to several others (Table 1-1); however, over time the platform’s production dropped off, 
	 4 
leading to a decline in new antibiotic/antibiotic class discoveries. Concurrent with this 
drop off in new discoveries, microbe resistance to available antibiotics emerged. For a 
period of time, synthesis of novel antibacterial analogues was able to temporarily quell 
the major antibiotic resistance uprising.  
The last major class of antibiotics to be discovered since this “Golden Age” of 
antibiotic discovery were the lipopetides, a class that includes the important drug 
daptomycin, which was discovered in 1986, but not approved for clinical use until 2003.6 
During this significant innovation gap, the spread of antimicrobial resistance has greatly 
outpaced the discovery of new and effective drugs. This in turn has led scientists to 
invent and execute new discovery methodologies – if we can no longer rely on natural 
sources or rational design manipulation of existing scaffolds to find new drugs, the 
question is how do we challenge these bad bugs, and more importantly, which bacterial 





















Table 1-1. Discovery and resistance timeline for important classes of antibiotics (adapted 
from Ref. 7).7 






β-lactams 1928 1945 Broad spectrum 
Sulfadrugs 1932 1942 Gram positive 
Aminoglycosides 1943 1946 Broad spectrum 
Tetracyclines 1944 1950 Broad spectrum 
Chloramphenicols 1946 1950 Broad spectrum 
Macrolides 1948 1955 Broad spectrum 
Glycopeptides 1953 1960 Gram positive 
Oxazolidinones 1955 2001 Gram positive 
Rifamycins 1957 1962 Gram positive 
Quinolines 1961 1968 Broad spectrum 
Streptogramins 1963 1964 Gram positive 
Lipopeptides 1986 1987 Gram positive 
 
1.1.2 Mechanisms of Antibiotic Activity and Acquired Bacterial Resistance 
Although they are quite simple organisms, bacteria contain a wide variety of 
distinct targets for the development of novel antibiotics, which are well conserved across 
different species of bacteria. Due to this high level of conservation between the varying 
bacterial species, antibiotics are oftentimes effective for all species of bacteria (broad 
spectrum), while some select antibiotics are effective only against Gram-positive species. 
In the latter case, the antibiotic typically cannot permeate the thick outer cell wall of 





Figure 1-2. Structure of (a) Gram-negative and (b) Gram-positive bacterial cell walls 
(image from Ref. 8).8 
 
 
There are a wide variety of intracellular bacterial targets, which are accessed by 
antibiotics that are capable of bypassing the inner cell membrane. These targets include 
nucleic acid synthesis, RNA polymerase, protein synthesis and folate synthesis (Figure 
1-3).9 These intracellularly active drugs including aminoglycosides, sulfonamides, and 
quinolones, all function to disrupt the metabolic activity of the bacterial cell, eventually 
leading to cell death. In order to evade killing by such antibiotics, bacteria generally 
evolve mechanisms to keep the drugs from entering the cell by either altering the 
permeability of their membranes, or by up-regulating drug efflux pumps that will quickly 
remove the antibiotic upon its entry into the cell.10 Alternatively, if the antibiotic is 
successfully taken up into the cells without up-regulation of efflux, bacteria are capable 
of modifying the antibiotic target.11 For example, in the case of aminoglycosides, the 
subunits of the ribosome can be modified (eg. methylation of specific nucleotide bases) to 
achieve resistance to aminoglycoside antibiotics by inhibiting binding of the antibiotic 
and maintaining the unwanted activity of the target.12,13 
a) b) 
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Extracellularly active antibiotics alternatively function by compromising the cell 
wall to prohibit its synthesis, or by directly disrupting the membrane, causing leakage of 
the cellular contents.14 Some of the most well known antibiotics, such as the beta lactam 
class, are inhibitors of cell wall synthesis; notably, these types of antibiotics are greatly 
susceptible to development of resistance due to the up-regulation of inhibited or 
inactivated enzymes, such as the beta lactamases.15 Another common mechanism of 
resistance to extracellularly active antibiotics is modification of the extracellular 
antibiotic target.11 One important example of target modification leading to antibiotic 
inactivation is that of vancomycin, which targets the D-Ala-D-Ala dipeptide of 
membrane anchored Lipid II. By mutating the terminal D-Ala to a D-Lac residue, 
bacteria are able to evade vancomycin binding, thus leading to the rise of vancomycin 
resistant bacterial strains of S. aureus and Enterococcus.16,17 
Overall, while there are many mechanisms of antibiotic activity, there are 
similarly a wide array of antibiotic resistance mechanisms that bacteria have evolved in 
response to these drugs. Looking towards the future, it is important to not only develop 
targeted antibiotics for specific strains and species of bacteria to minimize the chance of 
resistance development, but it is also important to identify novel targets and mechanisms 
of action that are minimally susceptible to future resistance development.  
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Figure 1-3. Mechanisms of antibiotic action and resistance (image from Ref. 9).9 
 
 
1.1.3 Emergence of Antibiotic Resistant Bacterial Infections and Multidrug Resistance 
 
Antibiotic resistance was first documented for the antibiotic sulfadrugs in 1942, 
shortly after their introduction to the clinic, and other classes of antibiotics have followed 
suit by displaying resistance shortly after, or even before, initial clinical use.7 The main 
source of widespread resistance across hundreds of bacterial species and strains is the 
ability of closely related bacteria to undergo horizontal gene transfer. Recent functional 
metagenome screens have identified that environmental antibiotic resistance genes have 
>99% nucleotide identity to those in pathogenic isolates, thus supporting the role of gene 
transfer in the dissemination of antibiotic resistance.18 Most notably, the combination of 
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the transfer of multiple resistance genes to the same organism can lead to the formation 
of dangerous multidrug resistant bacterial species.19 
The antibiotic resistant “ESKAPE” pathogens (Enterococcus species, 
Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species) have experienced rapid spread in recent years, and 
are notoriously resistant to several or in some cases, such as certain species of A. 
baumannii, all clinically available antibiotics.20 This widespread antibiotic resistance 
problem has generated a significant number of infections each year, and ultimately leads 
to several thousand deaths per year (Table 1-2). As the problem of antibiotic resistant 
bacterial strains grows, we are challenged to find inventive solutions to a vastly 
complicated problem.  
 
Table 1-2. Infection and mortality data on antibiotic resistance across various strains 
(data obtained from Ref. 2). 
 
Bacterial Species Antibiotic 
Resistance 
Infections per Year Deaths per Year 
Clostridioides 
difficile 
MDR 500,000 15,000 
Enterobacteriaceae* Carbapenem 9,000 600 
Acinetobacter* MDR 7,300 500 
Enterococcus Vancomycin 20,000 1,300 
Pseudomonas 
aeruginosa* 
MDR 6,700 440 
Staphylococcus 
aureus 
Methicillin 80,500 11,300 
Streptococcus 
pneumoniae 
MDR 19,000 7,000 





1.1.4 Novel Mechanisms of Targeted Antibiotic Discovery 
A wide array of new approaches for discovering novel antibiotics and antibiotic 
classes have been pursued in the past several years. For the former case, novel antibiotics 
generally originate from previously applied antibiotics that are reformulated in 
combination with another drug that works to mitigate the resistance pathway observed for 
the antibiotic. For example, the new drug Avycaz combines the cephalosporin 
ceftazidime with a β-lactamase inhibitor in order to maximize the activity of the drug 
with minimal interference via resistance mechanisms.21  
Alternatively, researchers have also opted to continue mining natural resources in 
search of new antibiotic scaffolds that may provide the key to the resistance problem. 
Recently, revival of arylomycins, a class of bacterially secreted macrocyclic lipopeptide 
antibiotics originally discovered in 2002, has transformed these once believed ineffective 
narrow-spectrum compounds into highly potent drugs for treating the most challenging 
gram-negative ESKAPE pathogens.22 Structurally arylomycins contain a macrocyclic 
tripeptide core (with two phenols on the aromatic rings of the core), an N-terminal 
lipopeptide tail and a C-terminal carboxylic acid. To improve upon their activity, 
arylomycin was modified at the lipopeptide tail to successfully improve binding affinity 
and thus activity towards gram-negative bacterial species. Indeed, in contrast to FDA 
approved, commercially available antibiotics, including the aforementioned drug Avycaz, 
the optimized arylomycin maintained potent activity against an array of MDR isolates of 
K. pneumoniae, A. baumannii, P. aeruginosa and E. coli. Thus, improving previously 
mined unsuccessful natural products can lead to new, potent compounds for treating 
challenging MDR infections. 
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Expanding natural source screenings with new technologies has also been 
successful in the discovery of new, potent compounds. New approaches to growing 
uncultured organisms via cultivation of the species in their natural environment has led to 
an increase in bacterial recovery from 1% to 50%; through this method, the novel 
antibiotic texiobactin was discovered.23 This natural product antibiotic displays excellent 
activity towards MDR gram-positive bacteria, including Mycobacterium tuberculosis and 
Clostridium difficile. Moreover, texiobactin showed superior S. aureus killing to the 
highly potent drug vancomycin. Importantly, texiobactin did not induce any detectable 
resistance in a variety of bacterial species.  
While natural sources can continue to be mined for bacterially active compounds, 
we also need to invent novel approaches to specifically detect and target various species 
and strains of bacteria in order to mitigate the challenges posed by antibiotic resistance. 
To develop novel antibiotics that are specific for one species or strain of bacteria versus 
another, we envisioned applying chemistry that enables chemoselective reactivity 
towards our distinct target of interest; however, in order to develop such chemistries, we 
first needed to define a specified target. Given the complications of intracellular delivery 
in drug discovery, we have focused our efforts on targeting the natural or unnaturally 
installed unique chemical motifs that are displayed on the surface of bacteria, including 
lipid composition, lipid modifications, and surface protein or sugar modifications in the 
former case, or installed bioorthogonal handles in the latter, which can be specifically 




1.2 Development of Boronic Acid-Mediated Chemoselective Chemistries for Selective 
Bacterial Detection 
 
In order to improve our ability to produce target-specific features of antibiotic 
resistant bacteria, we need chemistry that can specifically go after the unique chemical 
markers that define certain species of bacteria. In the past few decades, bioorthogonal 
chemistry innovation has come to the forefront of biochemical discovery, as it enables the 
study and understanding of a wide variety of biomolecules and biochemical processes in 
their native environments.24 Indeed, such innovations have promoted the study of 
proteins, sugars, lipids, metabolites and post-translational modifications; however, over 
time these widely lauded biocompatible chemistries have been found to exhibit a variety 
of drawbacks to achieving true biocompatibility25, thus prompting our continued search 
for better bioorthogonal chemistries through the exploration of boronic acid-mediated 
biocompatible conjugation reactions.  
1.2.1 Origins and Principles of Biocompatible Chemoselective Reactivity 
Bioorthogonal chemistry can be traced back to the model protein GFP and 
tetracysteine motifs, both of which were discovered and applied for the study of proteins; 
however, more recent searches have focused on chemistries that can be applied as 
bioothogonal tools for the study of a wider array of biomolecules (e.g. sugars, lipids). 
There are a number of key principles for the development of bioorthogonal chemistries: 
1) the chemistry should be selective for its reactive partner and exhibit no cross-
reactivity; 2) the products of the reaction should be relatively stable; 3) the reagents 
should be non-toxic, and produce non-toxic products; 4) the chemistry should yield a fast 
reaction rate in biological conditions (37 oC, physiological buffer) at low concentrations 
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(nM-µM); and 5) the reagents should be stable in these same biological conditions.26  
Towards the development of such chemoselective reactions, two distinct 
approaches have been taken: application of bioorthogonal reactions that afford 
conjugation to natural chemical moieties, and installation of unnatural chemical moieties 
through various mechanisms (e.g. chemical, genetic, metabolic) to which a biocompatible 
chemoselective reaction partner can conjugate (Figure 1-4).24 In the former case, 
intrinsically reactive functional groups, such as amines, alcohols and thiols presented on 
biomolecules are used as handles for chemoselective labeling by an orthogonal reactive 
partner. Some key examples include reductive amination, transamination and 
isothiocyanate chemistry; however, these methods are often applied in protein labeling, 
where selectivity for a single residue is challenging given that there are often several 
copies of amino acids in a protein sequence. In the latter case, unnatural chemical 
functionalities can be selectively incorporated into biomolecules, and subsequently 
labeled chemoselectively with a complementary probe containing a bioorthgonal 
functionality.  Widely used examples of these types of bioorthogonal reactions include 
the Staudinger ligation and the array of azide-alkyne chemistries (eg. CuAAC, SPAAC). 
While this class of bioorthogonal chemistries enables higher selectivity for the desired 
















Figure 1-4. Comparison of bioorthogonal chemistries involving selective labeling of 
endogenous and exogenously installed ligands. 
 
 
1.2.2 Drawbacks of “Traditional” Bioorthogonal Chemistries 
There are a variety of drawbacks associated with these outlined bioorthogonal 
chemistries, which prohibit their application as truly biocompatible chemical 
functionalities in certain biological contexts (Scheme 1-1).25 Some examples include the 
necessity of high concentrations of copper (I) in applications of CuACC, which may 
create toxicity issues, or the slow reaction rates of certain SPAAC chemistries. Indeed, 
most “bioorthogonal” chemistries actually struggle to achieve true biocompatibility due 
to toxicity at the concentrations necessary to produce fast reaction rates, or conversely the 
reagents are non-toxic, but the reaction rate is quite slow. Ultimately, we strive to achieve 
optimization of both bioorthogonality parameters to ensure maximal effectiveness and 








Endogenous Ligand: Chemoselective bioconjugation with naturally existing chemical moiety (eg. amino acids, sugars, lipids)
Exogenous Ligand : Biochemical installation of bioorthogonal chemical moiety (eg. alkynes, azides, etc.) followed by 
chemoselective conjugation to biorthogonal tag
Genetic, metabolic 
or chemical incorporation Bioorthogonal Tagging
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•  Moderately acidic pH required 
(4-6) 
•  Slow reaction rates (10-4-20 
M-1s-1) 
•  Aniline catalyst required to 
improve reaction rate 






•  Slow reaction rates (10-3 
M-1s-1) 
•  Phosphines susceptible to 
hydrolysis 




•  Copper catalysts and ligands 
required to achieve fast 
reaction rates (10-200 M-1s-1) 
Strain-Promoted Azide-Alkyne Click Chemistry 
•  Slow to moderate reaction 
rates (10-2-2 M-1s-1) 
 
 
Inverse Electron Demand Diels Alder 
•  Tetrazines may be susceptible 
to hydrolysis 








































1.2.3 Emergence of Boronic Acid Chemistries For Chemoselective Bioorthogonal 
Conjugation 
 
With a continued interest in the discovery of novel biocompatible conjugation 
reactions, our research has focused on exploration of a new class of such reactions, which 
exploits the unique reactivity of aryl ketones and aldehydes with an ortho-boronyl 
substituent (Figure 1-5). For these boronic acid-mediated bioorthogonal reactions, 2- 
formyl and 2-acetyl phenylboronic acid (2-FPBA and 2-APBA) have been found to 
conjugate with a variety of amines and α-nucleophiles with rate constants >103 M-1s-1, 
which is orders of magnitude greater than that of the aforementioned azide-alkyne click 
chemistry.27  
 
Figure 1-5. Diverse conjugation chemistries of 2-FPBA/2-APBA display varied product 
stability and reaction reversibility. The conjugation partners include functional groups of 
biomolecules, as well as non-natural nucleophiles designed for bioorthogonal conjugation 









































In addition to the fast reaction rates, these boronic acid accelerated reactions 
conjugate to a variety of reactive partners, which affords diverse product structures with 
distinct thermodynamic and kinetic stabilities. Both covalent and reversible covalent 
approaches have been taken in the discovery of boronic acid accelerated bioorthogonal 
chemistries, with each having their own advantages. While irreversible, covalent 
chemistries afford higher binding potency, they often induce high toxicity as a result of 
off-target labeling and subsequent immunogenicity. Conversely, reversible covalent 
chemistries suffer diminished potency, yet do not exhibit significant biological toxicity 
due the transient and reversible nature of binding. This ability to tune reaction profiles 
affords the boronic acid accelerated bioorthogonal chemistries a unique capability to be 
applied for a wide array of different biocompatible applications in accordance with the 
designated biological target (e.g. amines, N-terminal cysteines, exogenously installed α-
nucleophile)25, as well as the desired kinetic and thermodynamic properties.27 
 One example of a bioorthogonal boronic acid-accelerated reaction that will be 
further explored and applied throughout this manuscript is that of simple iminoboronate 
formation.28 Iminoboronate chemistry was derived from simple imine formation of 
amines and ketones, which has a Kd of ~300 M, indicating that even with millimolar 
concentrations of reagents, the conjugate is formed in minimal amounts. However, by 
installing an ortho boronic acid, the reaction is accelerated and the Kd is reduced to low 
millimolar concentrations as a result of the formation of an ion-pair interaction between 
boron and nitrogen (Figure 1-6).29 This increased thermodynamic stability allows for 
facile conjugation of 2-APBA and 2-FPBA to a variety of amine-presenting biological 
targets, including lysines in proteins30, and in our case, amines on the surface of bacterial 
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cell walls via lipids (e.g. PE, Lys-PG)28 and bacterial cell surface sugar modifications 
(e.g. phosphoethanolamine modification of Lipid A). In terms of biocompatibility, 
iminoboronate formation harnesses fast and dynamic conjugation capabilities in 
biological settings. While the iminoboronate chemistry itself is less than desirable in 
terms of target specificity considering the abundance of amines in cellular contexts, we 
have been able to incorporate these 2-APBA motifs into high throughput screening 
platforms to enhance target selectivity by direct target-based screening methodologies.31 
Through these applications, we have been able to transform the boronic acid warheads 
into key chemical motifs for binding to an array of distinct biological targets, including 







Figure 1-6. Amine conjugation by (a) simple aryl ketones/aldehydes and (b) ortho 
boronic acid ketones and aldehydes displays the improvement of the thermodynamics of 
conjugation by boronic acid incorporation. 
  
Beyond iminoboronate chemistry, we have also explored applications of 
bioorthogonal boronic acid-mediated chemoselective chemistries towards reversible 
conjugation of free and N-terminal cysteines32, as well as irreversible conjugation to 



























boronic acid accelerated reactions has afforded us an arsenal of weapons with which we 
have investigated the selective labeling of bacteria to develop solutions for the current 
urgent state of the antibiotic resistant threat. 
1.3 Conclusions 
The aims of the research described throughout this manuscript exist at the 
intersection of biocompatible chemoselective chemistries and bacterial targeting, with the 
former informing our capabilities in tackling in the latter. While our application of amine-
targeting chemistries via iminoboronate formation toward bacterial targeting was inspired 
by the chemoselective targeting of amines in proteins (e.g. lysine side chains) in 
biologically relevant contexts30, we have sought to apply this reversible covalent 
approach towards selective identification of bacterial species. Through this pursuit, we 
have been able to exploit both amine-modified lipids in the cell wall of bacteria28, as well 
as amine presentation differences in bacterial cell wall composition in non-resistant and 
resistant strains of bacteria via a high throughput peptide screening approach.31 Similarly, 
this APBA assisted high throughput screening approach has been applied to the discovery 
of potent protein (e.g. human beta defensin 3) binding peptides. Moreover, we have been 
able to transform and expand our boronic acid chemistry toolbox beyond simple amines 
to selectively target naturally (e.g. cysteine)32 and exogenously installed unnatural 
chemical moieties (e.g. semicarbazide)33,34, with varying degrees of kinetic and 
thermodynamic stability.  
Thus, the research outlined herein summarizes our efforts to both 1) discover 
novel bioorthogonal chemistries to enhance our development of both protein and 
bacterial targeting molecules via conjugation to either naturally presented or 
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metabolically incorporated chemical functionalities, as well as 2) the application of those 
new chemoselective biocompatible technologies to achieve potent and selective binding 
to bacterial strains and proteins of interest, towards completion of the following aims: 
1. Modulating the reversible amine and cysteine conjugation properties of 
APBA/FPBA via synthetic analogues (Chapter 2) 
2. Detection of bacterial pathogens via stable diazaborine formation of APBA 
and semicarbazide (Chapter 3) 
3. Discovery of APBA dimer CX7C peptides selective for detection of various 
mechanisms of colistin resistance in Gram-negative bacteria (Chapter 4) 
4. Development of targeted APBA dimer CX7C peptides towards the bacterial- 
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Modulating the Reversible Amine and Cysteine Conjugation Properties of 2-
Acetylphenylboronic Acid (2-APBA) and 2-Formylphenylboronic Acid (2-FPBA) 




























2.1.1 Reversible Conjugation of Amines via Iminoboronate Formation with 2-
Formyl/Acetylphenyl Boronic Acid  
 
 Schiff base, or imine, formation plays an important catalytic role in enzymes 
throughout nature via reversible conjugation to amines. A well-known application of 
imine formation in enzyme catalysis is that of the pyridoxal phosphate (PLP) co-enzyme, 
whose aldehyde forms an imine linkage with a lysine side chain on the related enzyme; 
notably, this interaction is stabilized via several hydrogen bond linkages between the 
enzyme and ortho-phenoxide moiety in the cofactor to yield an association constant of 
1x103 M-1 (Kd~1 mM).1,2 
Without such assistance from additional bonding interactions, simple Schiff base 
formation is thermodynamically unfavorable under physiologic conditions. For example, 
the imine forming reaction of glycine with acetone yields a dissociation constant of 
nearly 300 M (Ka~3x10-3M-1), indicating that the imine conjugate is formed only at parts 
per million levels, even with millimolar concentrations of reactants.2 Yet, as observed 
with PLP, the thermodynamic stability of imine formation can be tuned by modifying the 
chemical functionalities adjacent to the reactive aldehyde/ketone (Figure 2-1). 
 In order to improve the kinetic reactivity and thermodynamic stability of the 
imine conjugation reaction, chemists have sought methods to improve the 
thermodynamic stability of imine formation via incorporation of ortho boronic acids into 
the molecular scaffold with 2-formyl/acetylphenyl boronic acid (2-FPBA/2-APBA). Both 
molecules undergo iminoboronate formation with primary amines at low millimolar 
concentrations of reactants in neutral aqueous media (Figure 2-1).3–8 While 2-APBA is 
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selective for unhindered amines, such as lysine side chains7, 2-FPBA is amenable to 
conjugation of more sterically hindered amines (e.g. α-amines of peptides).4 The 
thermodynamic stabilization provided by the boronic acid could potentially be 
rationalized by formation of an N-B dative bond; indeed, an 11B NMR study9 has shown 
that iminoboronate formation of 2-FPBA in methanol predominantly gives a solvent-
inserted zwitterionic structure.10,11 Thus, an ion-pair interaction is likely the source of the 










Figure 2-1. Evolution of thermodynamically unfavorable imine formation into the more 
stable iminoboronate conjugate. (a) PLP coenzyme catalysis employs imine formation 
with enzyme lysine residues, which are thermodynamically stabilized by hydrogen bonds. 
(b) Simple imine formation forms unstable amine conjugates only at ≥ molar 
concentrations. (c) Iminoboronate formation employs an ortho boronic acid on a 
benzaldehyde or acetophenone scaffold to achieve improved thermodynamic stability via 
an ion pair interaction. 
 
While iminoboronates experience greater thermodynamic stability than their 
imine counterparts, they maintain rapid reversibility (i.e. accelerated forward and 
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coordination or imine protonation resulting from solvent insertion.7 Both the 
thermodynamic stability and rapid reversibility make iminoboronates analogous to 
hydrogen bonds; however, iminoboronate formation is specific for primary amines and 
yields stronger transient bonds (3-4 kcal/mol energy gain versus 1-2 kcal/mol for 
hydrogen bonds).7,12,13  
 It is feasible that incorporation of the iminoboronate dynamic covalent binding 
motif in ligand design could lead to reversible covalent probes and inhibitors that bind to 
a desired target in complex biological systems. In one such instance, 2-APBA 
incorporation into a cationic peptide (H-Lys-AB1) yielded selective labeling of 
Staphylococcus aureus bacterial cells in complex mixtures of mammalian cells and blood 
serum.7 This targeted binding phenomenon is facilitated by the host defense evasion 
mechanism of S. aureus, that induces the overexpression of lysyl phosphatidylglycerol 
(Lys-PG), which can undergo facile iminoboronate formation with the APBA motifs in 
H-Lys-AB1 (Figure 2-2). Furthermore, APBA motifs can be incorporated into peptide 
libraries on phage, enabling facile selection of reversible covalent peptide probes that are 
selective binders to a wide array of bacterial species by whole cell screening, as will be 
later discussed.14  
 Other recent biological applications of iminoboronate chemistry beyond bacterial 
labeling have focused on the development of reversible covalent protein inhibitors. 
Protein modification via lysine-directed iminoboronate chemistry was first introduced by 
Gois and co-workers towards labeling of purified proteins, which was not intended to be 
site-specific.5,15 Alternatively, Su and co-workers have reported targeted covalent 
inhibition of Mcl-1 via incorporation of 2-APBA into a previously identified non-
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covalent ligand (Figure 2-2).6,16 These iminoboronate capable inhibtors displayed 20-50 
times better binding affinity in comparison to their non-covalent counterparts (IC50~3 
nM). Notably, only the protein-iminoboronate capable inhibitor adduct was observed by 
LC-MS analysis, whereas no protein-APBA adduct was detectable due to the rapid 
reversibility of iminoboronate formation, thus highlighting the importance of the non-
covalent interactions in adduct stabilization. While reversible covalent inhibitors bearing 
boronic acids have been previously reported for targeting alcohols and thiols (eg. Velcade 
and PRN1008)17–19, this contribution by Su et al.  is the first report of an iminoboronate-











Figure 2-2. Biological applications of iminoboronate formation towards conjugation of 
biological amines. (a) APBA iminoboronate formation with Lys-PG synergizes with 
electrostatic interactions of cationic peptides (H-Lys) to enable facile targeted labeling of 
bacterial cells. (b) Iminoboronate mediated inhibition of Mcl-1 via 2-APBA 
incorporation into a non-covalent ligand of Mcl-1, with ligand structure (left) and 











2.1.2 Discovery of N-Terminal Cysteine Conjugation Capabilities of 2-
Formyl/Acetylphenyl Boronic Acid 
 
 While iminoboronate formation favors unhindered amines (e.g. lysine side chains) 
over more hindered amines, such as the α-amine of alanine, 2-APBA has interestingly 
been shown to reversibly conjugate to free or N-terminal cysteine at sub-millimolar 
concentrations.20 The distinct reactivity of cysteine results from the side-chain thiol 
attacking the iminoboronate to form a thiazolidino boronate (TzB) complex. TzB 
formation with cysteine has been reported for both 2-APBA and 2-FPBA, with the former 
displaying low millimolar binding affinity, whereas the latter experiences facile 
conjugation at low micromolar concentrations (Figure 2-3).21,22 The kinetics of 
conjugation showed rates >103 M-1s-1 in comparison to cysteine conjugation with 
unsubstituted benzaldehyde, which requires several days to achieve conjugation, even 
under conjugation-favorable acidic conditions.23 The fast kinetics of TzB formation can 
be attributed to boronic acid activation of the imine intermediate, as supported by the 









Figure 2-3. Conjugation of 2-FPBA and 2-APBA to cysteine forms 
thiazolidinoboronates (TzBs). (a) 2-FPBA conjugates with cysteine at low micromolar 
concentrations, yielding a more stabilized TzB. (b) 2-APBA conjugates with cysteine at 
low millimolar concentrations to form a rapidly reversible TzB. (c) X-ray crystal 
structure (obtained by Dr. Anupam Bandyopadhyay) of the TzB complex formed with 
cysteine and 2-FPBA in 1:1 MeOH/H2O (gray=C, yellow=S, red=O, blue=N, pink=B). 
 
 
In addition to their vastly different binding affinities, 2-FPBA and 2-APBA also 
display distinct reaction profiles of TzB formation. While 2-APBA conjugates with 
cysteine at sub-millimolar concentrations in a rapidly reversible manner, 2-FPBA forms a 
more stable TzB conjugate that dissociates over the course of several hours. Importantly, 
the TzB formation of 2-FPBA has shown to be highly chemoselective, as little 
interference in N-terminal cysteine conjugation was observed from glutathione, cysteine, 
serine or lysine. Additionally, the thermodynamic stability of 2-FPBA conjugates with 
cysteine has been shown to be pH-dependent, whereby the TzB complex rapidly 
dissociates at acidic pH (Figure 2-4). These properties afford 2-FPBA with a unique N-
terminal cysteine protein labeling capacity in physiologic conditions, at low micromolar 









































conditions.21 While cysteine residue-specificity cannot afford protein or site-specific 
labeling capabilities in complex biological mixtures, the N-terminal cysteine specificity 
provided by APBA/FPBA conjugation may prove advantageous for more site-selective 
labeling. Conversely, 2-APBA conjugates dynamically with cysteine, which similar to 
iminoboronate formation, is appealing for the development of reversible covalent protein 
inhibitors. Given the wide thermodynamic range in forming TzB conjugates by 2-FPBA 
and 2-FPBA, it is feasible that the thermodynamic and kinetic properties of TzB 
conjugation should be further tunable via construction of synthetic analogues of these 
molecules.  
 
Figure 2-4. pH-triggered reversibility of the TzB conjugate of 2-FPBA and an N-
terminal cysteine-containing peptide, CAL, as shown by (a) 1H NMR analysis and (b) a 
plot of the percentage of TzB dissociated at each pH point, as determined by integration 




2.1.3 Synthesis of Analogues for Modulating the Conjugate Properties of 2-APBA 
 
 With our knowledge of the power of simple 2-FPBA/2-APBA towards binding of 
amines and cysteines, we questioned if the binding properties of these powerful chemical 
























































motifs could be altered to enhance binding affinity. Thus, we pursued optimization of the 
structure of 2-APBA, which was amenable to alterations at several positions on the 
phenyl ring, through a drug discovery inspired route. The process of drug discovery has 
traditionally followed the pathway of: 1) target discovery, 2) target validation, 3) 
screening and identification of hits, 3) lead optimization and drug development, and 5) 
clinical trials and FDA approval.25 A highly important step in this process is lead 
optimization, where potential drugs’ properties are altered to maximize their potential as 
therapeutic compounds. While synthetic compounds may display pharmacological 
activity, their other important drug properties, such as drug interactions or ADME 
(absorption, distribution, metabolism and excretion), may prohibit their transition to the 
clinic. One notable example in medicinal chemistry of the importance of lead 
optimization is that of Glivec, a notable chemotherapeutic agent.26 While a lead 
compound was initially identified by screening for inhibitors of protein kinase C, 
different alterations to the core structure enabled enhancement of activity, abolished 
undesired interaction with non-target proteins, and improved the solubility and oral 
bioavailability properties of the drug (Figure 2-5). Thus, structural optimization is a key 






Figure 2-5. Hit to lead compound development (I-IV) of the chemotherapeutic agent 
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 Inspired by the transformation of good compounds into great compounds, we 
ventured to determine if structural analogues of 2-APBA could improve the binding 
properties (eg. thermodynamic stability, kinetics) of 2-formyl/acetylphenyl boronic acids 
towards amine and cysteine conjugation.  
2.2 Modulating the Readily Reversible Amine Conjugation of 2-APBA with Synthetic 
Analogues 
 
2.2.1 Design of Panel of Synthetic 2-APBA Analogues 
 
Towards this goal of generating more thermodynamically and kinetically superior 
amine and cysteine conjugating APBA warheads, we designed a set of compounds with 
altered electronic properties to enable varied binding capabilities (Scheme 2-1). For some 
compounds, the 2-APBA scaffold was manipulated to include electron withdrawing 
functional group(s), such as fluorine (-F) or nitrogen dioxide (-NO2). In other cases, the 
scaffold was altered to incorporate an electron donating group, such as methoxy (-
OCH3).27 We hypothesized that the electron withdrawing groups would promote greater 
Lewis acidity at the electron poor boron atom to enable greater conjugate stability, and 
that electron donating analogues would have the opposite effect. Indeed, a similar 
approach was recently reported to enhance protein-ligand affinity by reversible covalent 
modification of lysine residues with a library of benzaldehyde derivatives.28 Through 
lysine binding studies, it was determined that a 2-hydroxybenzaldehyde analogue with a 
fluorine in the meta position afforded the most efficient imine formation with a binding 
dissociation constant (Kd) of about 20 mM. In comparison, simple 2-
hydroxybenzaldehyde showed no detectable imine formation at 20 mM lysine; therefore, 
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it is feasible that alteration of the substituents on 2-APBA could similarly produce 
analogues with improved binding properties to both amines and cysteines. 
 
Scheme 2-1. Panel of 2-APBA analogues for analysis of altered amine and cysteine 
kinetic and thermodynamic binding properties, with parent compounds (2-APBA and 2-
FPBA) shown for reference. Numbering of the core structure is shown on 2-APBA. 
 
 
2.2.2 Synthesis of 2-APBA Analogues 
 
 In order to synthesize the 2-APBA analogues, two different synthetic approaches 
were taken. In the first two-step route, a bromine substituted starting material was 
directly subjected to Miyaura borylation, then the purified pinacol substituted product 




































































Scheme 2-2. Two-step synthetic route to desired 2-APA analogues. Synthesis requires 1) 
Suzuki-Miyaura borylation, and 2) pinacol deprotection to yield the desired boronic acid 
substituted 2-APBA analogues. 
 
The secondary synthetic route was accessed upon initial synthesis of the majority 
of 2-APBA analogues using the first route given the high cost of the bromine substituted 
starting material in comparison to hydroxyl substituted. For the alternative route, the 
hydroxyl substituted starting material first underwent triflate protection to enable Suzuki-
Miyaura borylation of the purified triflate protected product. The purified pinacol 
substituted product was again subjected to pinacol deprotection and purified to yield the 
desired boronic acid (Scheme 2-3).  
 
Scheme 2-3. Three-step synthetic route to desired 2-APBA analogues. Synthesis requires 
1) triflate protection, 2) Suzuki-Miyaura borylation, and 3) pinacol deprotection to yield 
the desired boronic acid substituted 2-APBA analogues. 
 
 
One challenge in the synthesis of these analogues was determining the optimal 
reaction duration and temperature to achieve minimal protodeboronated side product 
during the Suzuki-Miyaura borylation step. In general, the approach taken was to start 
with a low temperature (~80oC) and allow the reaction to proceed for a short period of 






















































starting material, desired borylated product, and undesired protodeboronated product all 
stained distinctly (yellow vs. blue-green vs. orange) to afford clear reaction progress 
monitoring. After these conditions were applied, the reaction was checked and if no 
reaction was observed, the temperature was increased by 5oC and continued while 
monitoring in ~15 minute increments. The process was continued until the majority of 
starting material was consumed, or protodeboronated product was observed.  
Another challenge encountered during the synthesis of these APBA analogues 
was in determining the optimal pinacol deprotection conditions. In some cases, simple 
acidic hydrolysis with trifluoroacetic acid in a water/acetonitrile mixture was sufficient 
for deprotection of the analogues within a few hours. In other cases, an alternative 
strategy involving transesterification with diethanolamine in tetrahydrofuran stirred 
overnight, then acidified with HCl was necessary to achieve deprotection of the pinacol 
group. However, between these two methodologies, we were able to achieve efficient 
deprotection of all analogues to enable purification of the boronic acid substituted 
products.  
2.2.3 UV-Vis Analysis of 2-Methoxyethylamine (MEA) Binding Profiles of 2-APBA 
Analogues 
 
To assess the iminoboronate formation of the 2-APBA analogues with amines, we 
titrated in (0-60 mM) a model primary amine, 2-methoxyethylamine (MEA), to a fixed 
concentration of the 2-APBA analogue (50 µM). Throughout the titration, we monitored 
the shift in maximal UV-Vis absorption from ~254 nm for the boronic acid to ~280 nm 
for the iminoboronate. Simple 2-APBA and 2-FPBA were first titrated to determine the 
dissociation constants for the parent compounds, which were 15 mM and 20 mM, 
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respectively. We then carried out titrations of the synthesized 2-APBA analogues. The 
UV-Vis spectra (Figure 2-6), fitted plots (Figure 2-7), and compiled dissociation 
constants (Table 2-1) are shown.  
 
 
Figure 2-6. UV-Vis titration of (a) 2-APBA, (b) 2-FPBA, (c) 4-F-2-APBA, (d) 4,6-F-2-
APBA, (e) 4-OMe-2-APBA (f) 5-OMe-2-APBA and (g) 6-NO2-2-APHA with MEA 
displays the shift in maximal absorption wavelength from ~254 nm to ~280 nm. The 
absorbance ~280 nm at each MEA concentration point were used to determine the 

































































































































































































































































































Figure 2-7. Compiled normalized MEA titration plots for 2-APBA, 2-FPBA and 
associated analogues, which were fit to determine dissociation constants (Kd). 
 
Table 2-1. Dissociation constants (Kd) determined from the fit of the MEA titration of 2-












From these results, we observe that while the fluorine-containing 2-APBA 
analogues display a slight improvement in binding affinity, an alternative electron 
withdrawing group containing 2-APBA analogue (6-NO2) shows a significant decrease in 









binding affinity. Additionally, the 2-APBA analogues that present an electron-donating 
group also show a decrease in binding affinity. Thus, while minor improvements in the 
thermodynamics of iminoboronate formation were made with the 4-F-2-APBA and 4,6-
F-2-APBA analogues, the improvements were not as significant as anticipated. 
2.2.4 1H NMR Analysis of Boroxole Formation of 2-APBA Analogues 
 
 To assess a possible cause for the lack of improvement in binding affinity of the 
2-APBA analogues, 1H NMR analysis of the iminoboronate conjugates was carried out. 
For this experiment, 7.5 mM of each 2-APBA analogue was mixed with 60 mM 2-
methoxyethylamine in PBS pH 7.4 with 10% D2O, and was allowed to incubate for ~15 
minutes. This analysis revealed that a significant portion of several of the 2-APBA 
analogues (4,6-F-2-APBA, 6-NO2-2-APBA, 2CF3-APBA), as well as simple 2-FPBA, 
exist in the boroxole form in aqueous pH 7.4 buffer conditions (Table 2-2), which has 
previously been documented as a competing tautomeric structure by Gois and co-
workers, as well as Yatsimirsky and co-workers.3,15 The formation of boroxole is 
indicated by the significant upfield shift in the formyl/acetyl peak signal (Figure 2-8). As 
observed through the addition of MEA to these analogues (sample shown is 4,6-F-2-
APBA), the equilibrium can be shifted for some boroxole-forming APBA analogues 
towards iminoboronate formation; however, iminoboronate formation is not 100% 
complete, even with a large excess of MEA. Notably, 11B NMR analysis of 2-CF3-APBA 




Figure 2-8. Boroxole formation of (a) 2-FPBA (b) 4,6-F-2-APBA analogue and (c) 6-
NO2-2-APBA, as depicted by the upfield shift of the formyl/acetyl peak (*), which is 
observed even upon MEA conjugation. The acetyl shifts of the parent compound (*) and 












































*" *"50 mM FPBA+60 mM MEA 





7.5 mM 4,6-F-2-APBA+60 mM MEA 
7.5 mM 4,6-F-2-APBA 
10 mM 6-NO2-2-APBA +60 mM MEA 
























































Figure 2-9. 11B NMR of the 2-CF3-APBA analogue in PBS Buffer pH 7.4 exhibits 100% 
boroxole formation (chemical shift ~20 ppm corresponds to boric acid).  
 
 
Table 2-2. Summary of boroxole formation of 2-FPBA, 2-APBA, and related analogues 


























Boroxole formation is described as either 1) a nucleophilic addition of hydroxide 
anion to the carbonyl group, or 2) the shift of the equilibrium of boroxole formation by 
addition of hydroxide to the trigonal boron atom to convert the boron to a tetrahedral 
stabilized state, similar to the stabilization of boronate diol esters (Scheme 2-4). The 
second case of forming a trigonal boron atom for stabilization has been observed for 
halogen substituted 2-FPBA derivatives in organic solvents; however, such a mechanism 
has not been reported in aqueous conditions. Given the aqueous conditions of our 
experiments, it is likely that boroxoles of the 2-APBA analogues are being formed 
through the mechanism shown in Scheme 2-4a as a result of hydroxide ion in the aqueous 
buffer environment. 
 
Scheme 2-4. Mechanisms of 2-FPBA boroxole formation. Boroxole formation is 
hypothesized to proceed via either (a) the nucleophilic addition of hydroxide anion or (b) 
reversible intramolecular cyclization to form a benzoboroxole (figure modified from Ref. 
3). 
 
 Thus, it appears that the iminoboronate forming capacity of several 2-APBA 
analogues that display electron withdrawing groups is diminished as a result of the 
competing boroxole formation mechanism (Scheme 2-5). It is likely the case that the 
increased electronegativity imparted on the electron deficient boron atom promotes a 
shift in equilibrium of the 2-APBA analogues towards the tetrahedral stabilized boroxole. 



















formation in PBS pH 7.4, and whose equilibrium cannot be shifted to favor 
iminoboronate formation (Figure 2-8). Therefore, through these efforts to induce greater 
thermodynamic stability to iminoboronate conjugates of 2-APBA and 2-FPBA via 
synthetic analogues, the analogues instead favored stabilization of the non-iminoboronate 
conjugated starting material through forming a more stabilized tautomeric boroxole 
structure.  
 
Scheme 2-5. Schematic of acid-base equilibria involved in the condensation of 2-FPBA 





































































2.3 Application of 2-FPBA and 2-APBA and Their Analogues for Dynamic N-
Terminal Cysteine Conjugation  
 
2.3.1 Cysteine Binding Analysis of 2-APBA via 1H NMR  
 
Given the aforementioned unique cysteine conjugation properties of 2-FPBA, we 
set out to determine if 2-APBA and its analogues would be able to provide different TzB 
formation capabilities to enable a range of different applications in biology. First, we 
explored the conjugation of simple 2-APBA to cysteine. For this experiment, we carried 
out both a 2-APBA titration with cysteine to determine the dissociation constant, as well 
as a reversibility dilution test, both of which were studied by 1H NMR (Figure 2-10). 
From these experiments, we observed that 2-APBA has a dissociation constant of 0.5 
mM, which is two orders of magnitude greater than that of 2-FPBA (5 µM). Additionally, 
from the dilution experiment, we observed that the TzB conjugate formed with 2-APBA 
is rapidly reversible, similar to iminoboronate formation.  
With these studies of 2-APBA, we aimed to determine if the 2-APBA analogues, 
shown in Scheme 2-1, would be capable of improving the thermodynamic stability of 
APBA-Cysteine TzB conjugates, thus decreasing the 2-APBA binding dissociation 











Figure 2-10. Cysteine conjugation studies of 2-APBA. (a) 1H NMR TzB formation 
titration of 2-APBA and L-cysteine. (b) Fitting the plot of fraction of TzB formed versus 
free cysteine concentration enables determination of Kd. (c) Reversibility studies of 2-
APBA by 10x dilution displays that TzB conjugates of 2-APBA are instantaneously 
reversible. 
 
2.3.2 Cysteine Binding Titration of 2-APBA Analogues via 1H NMR Analysis 
 
 Given the greater thermodynamic reversibility afforded by the 2-APBA scaffold, 
we next sought to determine whether our 2-APBA analogues with altered electronic 
properties would modulate the binding dissociation constant towards cysteine binding. To 
do so, we mixed 200 µM of each 2-APBA analogue with increasing concentrations of L-
cysteine until TzB formation was complete (Figure 2-11). We tested the 4-F, 4,6-F, 4-

















0.2 mM 2-APBA+0.2 mM Cys 
0.2 mM 2-APBA+0.3 mM Cys 
0.2 mM 2-APBA+1 mM Cys 
0.2 mM 2-APBA+2 mM Cys 
0.2 mM 2-APBA+5 mM Cys 

























5 mM 2-APBA + 5 mM L-Cys
5 mM 2-APBA + 5 mM L-Cys – 10x Dilution 




















boroxole that 6-NO2 forms in aqueous conditions. TzB formation proceeds to form two 
species, a mixed anhydride and a hydrolyzed product. While the mixed anhydride is 
favored in acidic conditions, the hydrolyzed product predominates in basic conditions; 
however, as pH 7.4, both species exist, and thus are observed by 1H NMR. Integration of 
the TzB chemical shifts and acetyl chemical shift allowed us to quantitate the fraction of 
TzB formed at each cysteine concentration (Figure 2-12, Table 2-3). 
 From this data, it appears that the two electron-withdrawing group-containing 2-
APBA analogues (4-F and 4,6-F) both lower the binding dissociation constant by ~4x. 
The methoxy electron-donating group, however, appears to have different Kd modulating 
behavior depending on whether it is para (4-OMe) or meta (5-OMe) to the boronic acid 
functionality. This could possibly be due to the 4-OMe-2-APBA resonance structures that 
may promote cysteine binding; however, this is in contrast to the results with 
iminoboronate formation, for which both the 4-OMe and 5-OMe analogues increased the 
binding dissociation constant towards MEA.  Thus, while we can slightly improve the 
thermodynamic stability of simple 2-APBA cysteine conjugates via APBA analogues 















Figure 2-11. 1H NMR cysteine titration assays of (a) 4-F-2-APBA, (b) 4,6-F-2-APBA, 
(c) 4-OMe-2-APBA and (d) 5-OMe-2-APBA in PBS pH 7.4 (10% D2O) with increasing 
concentrations of cysteine to assess TzB formation (data collected in collaboration with 
Ik Joo Kim). 
a) b) 
c) d) 
0.2 mM 4-F-2-APBA + 0.2 mM Cys 
0.2 mM 4-F-2-APBA + 0.3 mM Cys 
0.2 mM 4-F-2-APBA + 0.5 mM Cys 
0.2 mM 4-F- 2-APBA + 1 mM Cys 
0.2 mM 4-F- 2-APBA + 2 mM Cys 


































0.2 mM 4,6-F-2-APBA + 0.2 mM Cys 
0.2 mM 4,6-F-2-APBA + 0.3 mM Cys 
0.2 mM 4,6-F-2-APBA + 0.5 mM Cys 
0.2 mM 4,6-F-2-APBA + 1 mM Cys 


































0.2 mM 4-OMe-2-APBA + 0.2 mM Cys 
0.2 mM 4-OMe-2-APBA + 0.3 mM Cys 
0.2 mM 4-OMe-2-APBA + 0.5 mM Cys 
0.2 mM 4-OMe-2-APBA + 1 mM Cys 
0.2 mM 4-OMe- 2-APBA + 5  mM Cys 


































0.2 mM 5-OMe-2-APBA + 0.2 mM Cys 
0.2 mM 5-OMe-2-APBA + 1 mM Cys 
0.2 mM 5-OMe-2-APBA + 10 mM Cys 
0.2 mM 5-OMe- 2-APBA + 30 mM Cys 
0.2 mM 5-OMe- 2-APBA + 50  mM Cys 
0.2 mM 5-OMe-2-APBA + 5 mM Cys 
0.2 mM 5-OMe-2-APBA + 0.5 mM Cys 
0.2 mM 5-OMe- 2-APBA + 20 mM Cys 












































Figure 2-12. Plots of the fraction of TzB formed versus concentration of free cysteine of 
(a) 4-F-2-APBA, (b) 4,6-F-2-APBA, (c) 4-OMe-2-APBA and (d) 5-OMe-2-APBA from 
the 1H NMR titration assays to determine dissociation constants (Kd) of cysteine binding 
for the 2-APBA analogues.  
 
Table 2-3. Summary of dissociation constants (Kd) for cysteine binding of 2-APBA 
analogues.  














2.3.3 2-APBA Coumarin Cysteine Sensing  
  
 With our knowledge of the rapid reversibility of thiazolidinoboronate conjugates 
of 2-APBA, we sought to determine if the TzB forming reaction could be transformed 
into a cysteine-sensing platform. Using APBA coumarin analogues AB21/22 (described 
in Chapter 3), we carried out a fluorescence titration experiment to assess the conjugation 
of cysteine to these molecules. While AB21 and AB22 are minimally fluorescent 
molecules, once they form conjugates, such as thiazolidinoboronates, their fluorescence 
significantly increases (Figure 2-13). From this experiment, it is clear that the 
fluorescence of AB21/22 dramatically increases when conjugated with cysteine, and the 
Kd of binding for both coumarin analogues was ~1 mM. Thus, TzB formation can be 
used as a fluorogenic method to sense cysteine at low mM concentrations. 
 
Figure 2-13. Fluorescence increase of APBA-containing coumarin analogues, AB21 (a) 
and 22 (b), upon conjugation with L-cysteine and (c,d) associated dissociation constant 


































































































































































































 While none of the 2-APBA analogues displayed significantly superior 
thermodynamic stability towards forming iminoboronate or cysteine conjugates 
compared to simple 2-APBA, the analogues did show the ability to provide greater 
exchange of TzB formation with free or N-terminal cysteine in comparison to 2-FPBA. 
This opens up the opportunities for this type of TzB forming bioorthogonal reaction for a 
wider array of applications, including the development of reversible covalent protein 
inhibitors. Indeed, the reversibility imparted by the APBA molecules makes it an 
excellent pharmacophore for these types of endeavors.17  
Recent research has explored the application of salicaldehyde coumarin 
compounds towards labeling of N-terminal cysteines, which have shown the capacity to 
form more stable conjugates with cysteine that persist even after an hour of incubation in 
PBS/acetic acid/pyridine (4:1:1).29 Considering the vast kinetic improvement on the 
simple salicaldehyde molecule afforded by our incorporation of an ortho-boronic acid in 
amine and cysteine conjugation, it may be interesting to explore the stability of 
iminoboronate and cysteine conjugates formed with our coumarin APBA analogues to 
better understand the potential thermodynamic stability of these APBA-containing 
molecules with a larger core structure.  
Indeed, similar to Su et al.’s development of a reversible covalent inhibitor for 
Mcl-16, the forging of additional interactions by a core ligand structure with a distinct 
target molecule may enable development of more stable APBA-containing binding and 
inhibiting molecules. In this case, we would be generating APBA-containing ligands for 
defined targets that experience greater target residence than either the APBA or larger 
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ligand structure alone. This is quite different from the more general APBA analogues 
pursued herein, yet the data collected thus far on simple APBA molecules shows that 
their binding dissociation constants stay in the low millimolar range despite incorporation 
of different chemical modalities. Therefore, larger structural modifications in more 
specific contexts will likely be necessary to achieve greater thermodynamic stability. 
Overall, boroxole formation, as well as oxidative deboronation30, are significant 
challenges with the application of boronic acids to biological systems. However, by 
making structural modifications to these molecules, their application in biology may be 
significantly improved towards the generation of new probes and pharmaceutical agents 
of important biological targets. 
2.5 Experimental Procedures 
 
2.5.1 General Methods 
 
2-Acetylphenyl boronic acid (2-APBA), 2-Formylphenyl boronic acid (2-FPBA), 
trifluoromethane sulfonic anhydride, triethylamine, phenol, aluminum chloride, N-
methylmorpholine and potassium acetate were purchased from Sigma Aldrich. 1-(5-
Fluoro-2-hydroxyphenl)ethan-1-one and 1-(3,5-Difluoro-2-hydroxyphenyl)ethan-1-one 
were purchased from Maybridge. Dry dioxane, dry dichloromethane, diethanolamine and 
methoxyethylamine were purchased from Acros Organics. Bispinacolato diboron 
(B2pin2) was purchased from Matrix Scientific. 1,1’-
Bis(Diphenylphosphino)ferrocenepalladium(II) dichloride and 2-hydroxy-3-
nitroacetophenone were purchased from Oakwood chemical. 2’Bromo-4’ 
Methoxyacetophenone was purchased from Combi Blocks. Trifluoroacetic anhydride and 
2’-hydroxy-4’-methoxyacetophenone were purchased from Alfa Aessar. Trifluoroacetic 
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acid was purchased from Protein Technologies. Deuterated chloroform, deuterated 
DMSO, and D2O were purchased from Cambridge Isotopes. 1H, 13C and 11B NMR data 
were collected on a VNMRS 600MHz NMR spectrometer. Mass spectrometry data was 
generated using an Agilent 6230 LC TOF mass spectrometer with a 1.8 µm Agilent 
Extend C18 column. All RP-HPLC purifications were carried out on a Waters Prep LC 
with a Jupiter 10 µm C4 300A column with water/acetonitrile/0.1% TFA as eluent 
(Buffer A= 95% water, 5% acetonitrile, 0.1% TFA, Buffer B= 95% acetonitrile, 5% 
water, 0.1% TFA) with a gradient from 100% Buffer A to 60% Buffer B. UV-Vis data 
was collected on a Nanodrop 2000c UV/Vis spectrometer by cuvette. Fluorescence data 
were collected on a Cary Eclipse fluorescence spectrophotometer with slit width set to 5 
nm. 
2.5.2 Synthesis of 2-APBA Analogues 
 
The nomenclature for labeling 2-APBA analogues throughout the synthetic 
methods is shown in Scheme 2-6. Methods are described for each individual analogue 
below with associated 1H NMR, 13C NMR and mass spectrometry analysis. 
 












































(a) Synthesis of 2-I-b: 2-I-a (1.00 mmol) was combined in a dry round bottom flask 
with 8 mol % Pd(dppf)Cl2DCM (0.08 mmol), 2.5 equivalents 
bis(pinacolato)diboron (2.5 mmol), 3 equivalents KOAc (3.0 mmol) and 4.5 mL 
dry dioxane. The solution was flushed with argon for 15 minutes, and stirred at 
95oC for 30 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated. The dried product was purified by silica gel 
chromatography with a hexane/diethyl ether mixture to yield the pure produce, 
which was dried to a yellow oil (190 mg, 65%).  
1H NMR (CDCl3): δ 1.43 (s, 12H), 2.59 (s, 3H), 7.25 (d, J=2.5 Hz, 1H), 7.49 
(ddd, J=11.6, 8.7, 4.2 Hz, 2H). 
13C NMR (CDCl3): δ 21.34, 28.61, 92.42, 110.29, 122.41, 133.66, 136.78, 
141.02, 172.41, 201.41.  
MS-ESI+ (m/z): Calculated for C14H18BFO3 [M-H2O+H]+ 247.21, observed 
247.10.  
(b) Synthesis of 2-I: 2-I-b (0.1 mmol) was stirred with 10 equivalents (1 mmol) 













for 30 minutes, then evaporated and dissolved in 4 mL 2:1 water/acetonitrile 
mixture. The crude material was purified by RP-HPLC with a water/acetonitrile 
mixture to yield a white powder after lyophilization (7 mg, 38%). 
1H NMR (10% D2O in 1X PBS pH 7.4): δ 2.58 (s, 3H), 7.35 (d, J=8.8 Hz, 1H), 
7.43 (t, J=6.9 Hz, 1H), 7.70 (d, J=9.8 Hz, 1H). 
13C NMR (10% D2O in 1X PBS pH 7.4): δ 23.72, 24.83, 113.74, 121.40, 132.75, 
141.44, 161.87, 203.25. 
MS-ESI+ (m/z): Calculated for C8H8BFO3 [M-H2O+H]+ 165.10, observed 165.06.  




(a) Synthesis of 2-II-b: 2-II-a (2.9 mmol) was combined with 4 equivalents (11.6 
mmol) triethylamine and 10 mL dry dichloromethane, and cooled to -80oC under 
argon. To this stirring cooled mixture, 2.2 equivalents (6.40 mmol) 
trifluoromethanesulfonic anhydride was added dropwise. The mixture was stirred 
for 5 minutes at -80oC, then brought to room temperature, and stirred 30 minutes. 
100 mL sodium bicarbonate was added to the stirring mixture, and allowed to mix 
for 30 minutes. The organic layer was extracted with dichloromethane (3x100 
mL), and the combined organic layers were washed with brine and dried over 
sodium sulfate. The mixture was then evaporated and purified via silica gel 
chromatography with a hexane/ethyl acetate mixture. The pure product was dried 
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1H NMR (CDCl3): δ 2.63 (s, 3H), 7.15 (s, 1H), 7.28 (s, 1H). 
13C NMR (CDCl3): δ 29.44, 108.59, 109.28, 112.28, 117.21, 153.33, 155.50, 
161.74, 194.02. 
MS-ESI+ (m/z): Calculated for C9H5F5O4S [M+H]+ 305.19, observed 304.99.  
(b) Synthesis of 2-II-c: 2-II-b (1.32 mmol) was combined in a dry round bottom 
flask with 8 mol % Pd(dppf)Cl2DCM (0.11 mmol), 2.5 equivalents 
bis(pinacolato)diboron (3.3 mmol), 3 equivalents KOAc (4.95 mmol) and 6.0 mL 
dry dioxane. The solution was flushed with argon for 15 minutes, and stirred at 
80oC for 30 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100 mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated to yield. The dried product was purified by silica 
gel chromatography with a hexane/diethyl ether mixture to yield the pure product, 
which was dried to a yellow oil (169 mg, 46%). 
1H NMR (CDCl3): δ 1.43 (d, J=1.9 Hz, 12H), 2.57 (s, 3H), 6.96 (s, 1H), 7.34 (s, 
1H).  
13C NMR (CDCl3): δ 22.31, 92.86, 114.73, 117.42, 125.45, 141.13, 164.54, 
167.61, 189.76, 204.55. 
MS-ESI+ (m/z): Calculated for C14H17BF2O3 [M+H]+ 283.09, observed 283.16. 
(c) Synthesis of 2-II: 2-II-c (0.35 mmol) was stirred in 1 mL of 2:1 acetonitrile/water 
with 1% TFA for 1 hour. The mixture was evaporated and dissolved in 4 mL 2:1 
water/acetonitrile mixture. The crude material was purified by RP-HPLC with a 
water/acetonitrile mixture to yield a white powder after lyophilization (5 mg, 7%). 
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1H NMR (10% D2O in 1X PBS pH 7.4): δ 1.52 (s, 3H), 2.58 (s, 3H), 6.65 (s, 1H), 
6.80 (s, 1H), 7.16 (s, 1H), 7.61 (s, 1H). (*Boroxole and boronic acid structures co-
exist). 
13C NMR (DMSO-d6): δ 27.91, 113.23, 115.35, 117.28, 119.22, 162.78, 163.02, 
200.09. 
MS-ESI+ (m/z): Calculated for C8H8BF2O3 [M-H2O+H]+ 182.95, observed 
183.04.  




(a) Synthesis of 2-III-b: 2-III-a (2.76 mmol) was combined with 4 equivalents (11.1 
mmol) triethylamine and 10 mL dry dichloromethane, and cooled to -80oC under 
argon. To this stirring cooled mixture, 2.2 equivalents (5.5 mmol) 
trifluoromethanesulfonic anhydride was added dropwise. The mixture was stirred 
for 5 minutes at -80oC, then brought to room temperature, and stirred 30 minutes. 
100 mL sodium bicarbonate was added to the stirring mixture, and allowed to mix 
for 30 minutes. The organic layer was extracted with dichloromethane (3x100 
mL), and the combined organic layers were washed with brine and dried over 
sodium sulfate. The mixture was then evaporated and purified via silica gel 
chromatography with a hexane/ethyl acetate mixture. The pure product was dried 
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1H NMR (CDCl3): δ 2.68 (s, 3H), 7.75-7.61 (m, 1H), 7.98 (dd, J=1.8, 1.3 Hz, 
1H), 8.20 (d, J=8.2 Hz, 1H). 
13C NMR (CDCl3): δ 29.73, 114.48, 117.04, 119.59, 129.01, 134.36, 135.75, 
138.02, 195.13. 
MS-ESI+ (m/z): Calculated for C9H6F3NO6S [M+H]+ 314.20, observed 313.98.  
(b) Synthesis of 2-III-c: 2-III-b (0.639 mmol) was combined in a dry round bottom 
flask with 8 mol % Pd(dppf)Cl2DCM (0.051 mmol), 2.5 equivalents 
bis(pinacolato)diboron (1.60 mmol), 3 equivalents KOAc (1.92 mmol) and 4.0 
mL dry dioxane. The solution was flushed with argon for 15 minutes, and stirred 
at 97oC for 30 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100 mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated to yield. The dried product was directly used in 
step c without purification (171 mg, 92%). 
(c) Synthesis of 2-III: 2-III-c (0.34 mmol) was stirred in 2 mL of 2:1 
acetonitrile/water with 1% TFA for 2 hours at room temperature. The mixture was 
evaporated and dissolved in 4 mL 2:1 water/acetonitrile mixture. The crude 
material was purified by RP-HPLC with a water/acetonitrile mixture to yield a 
white powder after lyophilization (5 mg, 7% over 2 steps). 
1H NMR (10% D2O in 1X PBS pH 7.4): δ 1.53 (s, 3H), 2.62 (s, 3H), 7.34-7.40 
(m, 1H), 7.54 (d, J=7.4 Hz, 1H), 7.69 (t, J=7.9 Hz, 1H), 7.97 (d, J=7.81 Hz, 1H), 
8.40, (d, J=8.3 Hz, 1H). (*Boroxole and boronic acid structures co-exist). 
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13C NMR (DMSO-d6): δ 28.17, 123.21, 128.26, 130.81, 136.27, 140.50, 150.63, 
202.41. 
MS-ESI+ (m/z): Calculated for C8H8NO5 [M-H2O+H]+ 191.96, observed 192.04. 





(a) Synthesis of 2-IV-b: 2-IV-a (21.25 mmol) was stirred with 3 equivalents 
aluminum chloride (63.76 mmol) and 25 mL 1,2-Dichloroethane for 30 minutes. 
To this stirring mixture, 2 equivalents (42.5 mmol) of trifluoroacetic anhydride 
was added drop-wise over 30 minutes. The reaction mixture was stirred for 4 
hours at room temperature. The mixture was slowly poured over 10 grams of ice, 
after which the organic layer was extracted with DCM (3x250 mL). The 
combined organic layers were washed with brine and dried over sodium sulfate 
and evaporated. The dried product was purified by silica gel chromatography with 
a hexane/diethyl ether mixture to yield the pure product, which was dried to a 
yellow oil (526 mg, 13%). 
1H NMR (CDCl3): δ 7.00 (ddd, J=8.3 Hz, 7.2 Hz, 1.2 Hz, 1H), 7.09 (ddd, J=8.5 
Hz, 1.2 Hz, 0.5 Hz, 1H), 7.63 (dddd, J=8.7 Hz, 7.2 Hz, 1.6 Hz, 0.5 Hz, 1H), 7.78-






























13C NMR (CDCl3): δ 115.22, 117.52, 119.30, 120.14, 130.65, 138.79, 164.58, 
184.25. 
MS-ESI+ (m/z): Calculated for C8H5F3O2 [M+H]+ 191.12, observed 191.03. 
(b) Synthesis of 2-IV-c: 2-IV-b (2.77 mmol) was combined with 4 equivalents (11.1 
mmol) N-methylmorpholine and 10 mL dry dichloromethane, and cooled to -80oC 
under argon. To this stirring cooled mixture, 2.2 equivalents (6.10 mmol) 
trifluoromethanesulfonic anhydride was added dropwise. The mixture was stirred 
for 5 minutes at -80oC, then brought to room temperature, and stirred 30 minutes. 
100 mL sodium bicarbonate was added to the stirring mixture, and allowed to mix 
for 30 minutes. The organic layer was extracted with dichloromethane (3x100 
mL), and the combined organic layers were washed with brine and dried over 
sodium sulfate. The mixture was then evaporated and purified via silica gel 
chromatography with a hexane/ethyl acetate mixture. The pure product was dried 
to a yellow oil (300 mg, 34% yield).  
1H NMR (CDCl3): δ 7.48 (dd, J=8.3, 1.0 Hz, 1H), 7.60 (td, J=7.7 Hz, 1.0 Hz, 
1H), 7.79 (ddd, J=8.4 Hz, 7.5 Hz, 1.7 Hz, 1H), 7.98 (dt, J=7.9 Hz, 1.6 Hz, 1H).  
13C NMR (CDCl3): δ 109.81, 114.28, 119.84, 123.72, 128.60, 131.23, 136.10, 
148.10, 178.82. 
MS-ESI+ (m/z): Calculated for C9H5F6O4S [M+H]+ 323.18, observed 322.98.  
(c) Synthesis of 2-IV-d: 2-III-c (0.93 mmol) was combined in a dry round bottom 
flask with 8 mol % Pd(dppf)Cl2DCM (0.075 mmol), 2.5 equivalents 
bis(pinacolato)diboron (2.33 mmol), 3 equivalents KOAc (2.79 mmol) and 8.0 
mL dry dioxane. The solution was flushed with argon for 15 minutes, and stirred 
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at 97oC for 30 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100 mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated to yield a yellow oil, which was directly used for 
step d. 
(d) Synthesis of 2-IV-e: 2-IV-d (0.13 mmol) was stirred with 10 equivalents (1.33 
mmol) diethanolamine in 1 mL THF for 3 hours. The mixture was treated with 1N 
HCl for 30 minutes, then evaporated and dissolved in 4 mL 2:1 water/acetonitrile 
mixture. The crude material was purified by RP-HPLC with a water/acetonitrile 
mixture to yield a white powder after lyophilization (3 mg, 10% over 2 steps). 
1H NMR (CDCl3): δ 7.25 (td, J=7.4 Hz, 1.3 Hz, 1H), 7.32 (dd, J=7.2 Hz, 1.1 Hz, 
1H), 7.34-7.37 (m, 1H), 7.41 (dt, J=7.2 Hz, 1.1 Hz, 1H). 
13C NMR (DMSO-d6): δ 115.37, 117.30, 122.63, 127.22, 128.49, 129.53, 143.01, 
163.01. 
MS-ESI+ (m/z): Calculated for C8H6BF3O3 [M+H]+ 200.94, observed 201.03. 




(a) Synthesis of 2-V-b: 2-V-a (3 mmol) was combined with 4 equivalents (12 mmol) 
triethylamine and 10 mL dry dichloromethane, and cooled to -80oC under argon. 
To this stirring cooled mixture, 2.2 equivalents (6.6 mmol) 
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continued to stir for 5 minutes at -80oC, then brought to room temperature, and 
stirred 30 minutes. 100 mL sodium bicarbonate was added to the stirring mixture, 
and allowed to mix for 30 minutes. The organic layer was extracted with 
dichloromethane (3 x 100 mL), and the combined organic layers were washed 
with brine and dried over sodium sulfate. The mixture was then evaporated and 
purified via silica gel chromatography with a hexane/ethyl acetate mixture. The 
pure product was dried to a yellow oil (890 mg, 99% yield).  
1H NMR (CDCl3): δ 2.61 (s, 3H), 3.86 (s, 3H), 7.05 (dd, J=9.0 Hz, 3.2 Hz, 1H), 
7.22-7.27 (m, 2H).  
13C NMR (CDCl3): δ 27.45, 48.76, 98.75, 99.19, 101.32, 119.22, 122.81, 147.66, 
165.34, 210.86.  
MS-ESI+ (m/z): Calculated for C10H9F3O5S [M+H]+ 299.23, observed 299.02.  
(b) Synthesis of 2-V-c: 2-V-b (1.34 mmol) was combined in a dry round bottom flask 
with 8 mol % Pd(dppf)Cl2DCM (0.107 mmol), 2.5 equivalents 
bis(pinacolato)diboron (3.36 mmol), 3 equivalents KOAc (4.03 mmol) and 6.0 
mL dry dioxane. The solution was flushed with argon for 15 minutes, and stirred 
at 97oC for 30 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100 mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated to yield. The dried product was purified by silica 
gel chromatography with a hexane/diethyl ether mixture to yield the pure product, 
which was dried to a yellow oil (169 mg, 46%). 
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1H NMR (CDCl3): δ 1.41 (s, 12H), 2.57 (s, 3H), 7.04 (dd, J=8,1 Hz, 2.4 Hz, 1H), 
7.28 (d, J=2.4 Hz, 1H), 7.44 (d, J=7.91 Hz, 1H). 
13C NMR (CDCl3): δ 22.47, 27.91, 56.58, 91.88, 114.56, 121.86, 129.76, 138.22, 
146.02, 210.08. 
MS-ESI+ (m/z): Calculated for C15H21BO4 [M+H]+ 277.14, observed 277.08. 
(c) Synthesis of 2-V: 2-V-c (0.18 mmol) was stirred with 10 equivalents (1.8 mmol) 
diethanolamine in 0.3 mL THF for 10 hours. The mixture was treated with 1N 
HCl for 30 minutes, then evaporated and dissolved in 4 mL 2:1 water/acetonitrile 
mixture. The crude material was purified by RP-HPLC with a water/acetonitrile 
mixture to yield a yellow powder after lyophilization (10.5 mg, 30%). 
1H NMR (10% D2O in 1X PBS pH 7.4): δ 2.57 (s, 3H), 3.84 (s, 3H), 7.05 (ddd, 
J=8.1 Hz, 2.4 Hz, 0.9 Hz, 1H), 7.28 (dd, J=2.4 Hz, 0.8 Hz, 1H), 7.45 (dd, J=8.1 
Hz, 0.8 Hz, 1H). 
13C NMR (10% D2O in 1X PBS pH 7.4): δ 25.10, 55.70, 113.21, 115.34, 119.31, 
132.10, 140.50, 159.23, 204.40. 




















(a) Synthesis of 2-VI-b: 2-VI-a (0.90 mmol) was combined in a dry round bottom 
flask with 3 mol % Pd(dppf)Cl2DCM (0.0027 mmol), 2 equivalents 
bis(pinacolato)diboron (1.8 mmol), 3 equivalents KOAc (2.7 mmol) and 4.5 mL 
dry dioxane. The solution was flushed with argon for 15 minutes, and stirred at 
75oC for 75 minutes under argon. Upon completion, the reaction mixture was 
cooled to room temperature and diluted in 100 mL ethyl acetate. The solution was 
washed with water (3x100 mL) and brine (1x100mL) before being dried over 
sodium sulfate and evaporated to yield. The dried product was purified by silica 
gel chromatography with a hexane/diethyl ether mixture to yield the pure produce, 
which was dried to a yellow oil (177 mg, 71%).  
1H NMR (CD3Cl3): δ 1.97 (s, 12H), 2.55 (s, 3H), 3.86 (s, 3H), 6.85-6.88 (dd, 
J=7.8 Hz, 1.8 Hz, 1H), 6.97 (d, J=7.4 Hz, 1H), 7.76-7.78 (d, J=8.2 Hz, 1H).  
13C NMR (CDCl3): δ 21.34, 28.61, 92.42, 110.29, 122.41, 133.66, 136.78, 
141.02, 172.41, 201.41.  
MS-ESI+ (m/z): Calculated for C15H21BO4 [M+H]+ 277.14, observed 277.15. 
(b) Synthesis of 2-I: 2-I-b (0.1 mmol) was stirred with 10 equivalents (1 mmol) 













for 30 minutes, then evaporated and dissolved in 4 mL 2:1 water/acetonitrile 
mixture. The crude material was purified by RP-HPLC with a water/acetonitrile 
mixture to yield a white powder after lyophilization (3 mg, 15%). 
1H NMR (10% D2O in 1X PBS pH 7.4): δ 1.42 (s, 12H), 2.58 (s, 3H), 3.85 (s, 
3H), 7.05 (dd, J=8.1 Hz, 2.4 Hz, 1H), 7.29 (d, J=2.3 Hz, 1H), 7.45 (d, J=8.1 Hz, 
1H). 
13C NMR (CDCl3): δ 22.73, 29.68, 55.65, 114.64, 114.91, 129.62, 132.40, 
165.34, 204.51. 
MS-ESI+ (m/z): Calculated for C9H11BO4 [M-H2O+H]+ 176.99, observed 177.07.  
2.5.3 UV-Vis Binding Titration Studies with 2-Methoxyethylamine 
 
 50 µM of each APBA analogue (1X PBS pH 7.4 stock) was mixed in 1X PBS pH 
7.4 with increasing concentrations of 2- methoxyethylamine (1X PBS pH 7.4 stock, 0-60 
mM) in a UV-Vis cuvette. After each addition of MEA, the cuvette was inverted several 
times before an absorbance reading was taken. The titration was determined to be 
complete when the absorbance at the shifted absorbance maximum wavelength no longer 
increased. 
2.5.4 1H NMR Iminoboronate Conjugate Analysis 
 
 Each APBA analogue was diluted to 7.5 mM in 1X PBS pH 7.4 with 10% D2O. 
1H NMR was obtained with water suppression and 64 scans. To this mixture, 60 mM 
methoxyethylamine in 1X PBS pH 7.4 was added. The mixture was incubated for 10 
minutes at room temperature, before a 1H NMR was again obtained with water 
suppression and 64 scans. 
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2.5.5 1H NMR Cysteine Titration to Determine Dissociation Constants (Kd) 
 
 Each APBA analogue was diluted to 0.2 mM in 1X PBS pH 7.4, to which 
increasing concentrations of L-cysteine was added in 1X PBS pH 7.4. 10% D2O was 
added to the mixture, and 1H NMR spectra were immediately obtained with water 
suppression and 64 scans. The titration cysteine concentration increased until complete 
disappearance of the acetyl APBA chemical shift.  
2.5.6 Reversibility of TzB Formation  
 
2-APBA in 1X PBS pH 7.4 was diluted to 5 mM in 1X PBS pH 7.4, and 5 mM L-
cysteine in 1X PBS pH 7.4 was added. An aliquot of this mixture was taken, to which 
10% D2O was added. The mixture was directly analyzed by 1H NMR with water 
suppression and 64 scans. Another aliquot of same mixture was then diluted 10x in 1X 
PBS pH 7.4, to which 10% D2O was added, and another 1H NMR with water suppression 
and 64 scans was obtained. Additionally, a mixture of 0.5 mM 2-APBA and 0.5 mM L-
cysteine was made in 1X PBS pH 7.4 with 10% D2O, and a 1H NMR was directly 
obtained with water suppression and 64 scans. 
2.5.7 Fluorogenic Cysteine Sensing by 2-APBA Coumarin Analogues 
 The syntheses of AB21 and AB22 are summarized in 3.6.15. 50 µM of each 
analogue (from DMSO stock) was combined in a fluorescence cuvette with increasing 
concentrations of L-cysteine (1X PBS stock) in 1X PBS pH 7.4. The fluorescence cuvette 
was inverted several times to mix after each cysteine addition, and the fluorescence 
readings were obtained at a voltage of 700. The titration was complete when the 
fluorescence no longer increased.  
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Stable Diazaborine Formation of APBA and Semicarbazide Enables Facile 






























 In our continued search for bioorthogonal reactions that would enable our 
discovery of solutions to the antibiotic resistance crisis, we turned our attention to a series 
of published chemistries involving α-nucleophiles that enable reactivity between non-
natural chemical moieties. Similar to the discovery of iminoboronate formation, the 
addition of ortho-boronic acids to these chemistries has improved their bioothogonality 
(eg. fast kinetics in physiologic conditions), which has enabled their application to 
bacterial labeling via metabolic unnatural amino acid incorporation into the bacterial 
peptidoglycan component of the cell wall.  
3.1.1 Bioorthogonal Conjugation of APBA with Non-Natural Nucleophiles 
  
Mechanistically similar to imine formation, α-nucleophiles are known to 
conjugate with carbonyls, yielding oximes and hydrazones, which are among the earliest 
documented bioorthogonal reactions. Also similar to imine formation, oxime and 
hydrazone formation with carbonyls suffers from slow kinetics, even with high 
concentrations of aniline catalysts or acidic conditions.1,2 Incorporation of an ortho-
boronyl substituent, however, greatly accelerates the conjugation of 2-APBA/2-FPBA to 
α-nucleophiles through carbonyl activation and assisted dehydration to yield the carbon 
nitrogen double bond (Figure 3-1). These conjugation reactions give second order rate 
constants of ~103-104 M-1s-1, making them some of the fastest documented bioorthogonal 
reactions. Notably, the fast conjugation enabled by the reactions affords the use of α-
nucleophiles at low concentrations, thus minimizing their potential cytotoxicity and 




Figure 3-1. Mechanistic illustration of the boronic acid-accelerated conjugation of 2-
FPBA/APBA with α-nucleophiles.  
 
 
Although both 2-APBA and 2-FPBA conjugate with alkoxyamines and 
hydrazines with fast kinetics, the reaction profiles of these two molecules conjugating to 
α-nucleophiles can vary dramatically in terms of reversibility and product stability. The 
conjugation of 2-FPBA to benzylhydroxylamine (Figure 3-2) gives fast kinetics (~1x104 
M-1s-1), and proceeds with minimal yield reduction in blood serum, indicating high 
bioorthogonality.4 Moreover, this conjugation reaction gives a dissociation rate constant 
of ~1x10-5 s-1, indicating a half-life of ~6.6 hours. 2-APBA conjugation to alkoxyamines, 
however, is instantaneously reversible, with a Kd of 1.4x10-5 M, which is 3 orders of 
magnitude larger than that of 2-FPBA (Kd~10-8 M).5 The distinct reactivity profiles of 2-
FPBA and 2-APBA towards oxyamines enable different applications given the stabilities 
of the conjugates formed, with the former finding utility in biomolecular labeling, while 
the latter may be useful for combinatorial chemistry applications that require facile 





























Figure 3-2. Oxime formation of 2-FPBA and 2-APBA yields conjugates with varying 
stabilities. ND= not determined; NA= not applicable. 
 
 
2-APBA and 2-FPBA have also been shown to readily conjugate with hydrazines, 
such as phenylhydrazine, at rate constants >103 M-1s-1, yielding highly stable products 
that do not exhibit dissociation.5 Kinetic stability experiments have confirmed the slow, 
minimal dissociation of 2-APBA-Phz conjugates (k-1<10-4 s-1). The conjugation of 2-
FPBA and phenylhydrazine has also been reported, and these contributions have 
elucidated a diazaborine structure of these conjugates (Figure 3-3).6,7 The capacity to 
form diazaborines likely underlies the stability of APBA-phenylhydrazine conjugates; 
however, structural confirmation of this conjugate has been elusive due to both a lack of 
crystal structure, as well as the water loss problem of boronic acid analysis by mass 
spectrometry.8  
 
Figure 3-3. Stable diazaborine formation of 2-FPBA/APBA upon conjugation with 
phenylhydrazine. ND= not determined 
 
Phenylhydrazine conjugation with 2-FPBA/APBA has been applied for the 
labeling of proteins under physiological conditions.5,6 While this conjugation chemistry 
readily proceeds without interference by endogenous small molecules or serum proteins, 













R Kd (µM) Dissociation (t1/2) Exchange (t1/2) 
H 0.004 ND Yes (6.6 hours) 












R Kd (µM) Dissociation (t1/2) Exchange (t1/2) 
H ND ND ND 
CH3 ND ND Yes (4-6 hours) 
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cytotoxicity, as described herein. Therefore, we investigated the structurally similar 
molecule, semicarbazide, which enables the same fast formation of stable diazaborine 
conjugates in complex biological conditions, but with minimal cellular toxicity.9,10 
3.1.2 Bacterial Metabolic Incorporation of Unnatural Amino Acids into Peptidoglycan 
 
Recently, a series of manuscripts have shown that bacterial peptidoglycan (PG) 
undergoes dynamic remodeling, which enables the incorporation of synthetic amino 
acids/dipeptides into the cell wall network (Figure 3-4). Peptidoglycan is an essential 
component of the bacterial cell wall that is highly conserved across bacterial species. This 
mesh-like polymer consists of linear glycan strands of repeating N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) dissacharides that are cross-linked by 
short peptides.11 While the general structure is conserved, the composition of the cross-
linking peptide, as well as the thickness of PG, varies slightly between bacterial species.12 
A key contribution on PG structure and remodeling from the Waldor group described the 
importance of D-amino acids in the modulation of bacterial cell walls, which are 
produced at millimolar concentrations and assist in the morphology of cell walls 
throughout bacterial growth.13  
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Figure 3-4. Structure of the bacterial peptidoglycan component of the cell wall showing 
the (a) disaccharide/peptide cross-link as well as (b) possible crosslinking structures 
(image from Ref. 12).  
 
Many groups have taken advantage of the importance of D-amino acids to 
bacterial cell morphology throughout cell growth to incorporate a wide array of unnatural 
D-amino acids into the peptidoglycan.14–22 The mechanism by which these unnatural 
amino acids incorporate into the cell wall is through the transpeptidase activity of 
penicillin binding proteins (PBPs), which is responsible for cross-linking PG (Figure 3-
5).14 Transpeptidases activate the donor PG cross-linking peptide via formation of an 
acyl-enzyme intermediate, which releases the terminal D-Ala. The activated donor then 
reacts with an amino group on an acceptor peptide or D-amino acid residue. While the 
donor peptide must be a polymeric fragment of PG, the acceptor molecule can be a single 

























Figure 3-5. Transpeptidase activity of PBPs enables incorporation of unnatural D-amino 
acids into bacterial peptidoglycan (adapted from Ref. 14). 
 
Through this promiscuous transpeptidase mechanism, several groups have 
achieved incorporation of a wide array of unnatural amino acids (Figure 3-6). These 
amino acids, which generally fall into either the clickable or fluorescent derivatives 
categories, often lack one or more ideal criterion for achieving bioorthogonality towards 
labeling of bacterial cells. The clickable derivatives incorporate CuAAC or SPAAC 
clickable handles, which suffer from slow kinetics or high toxicity of catalysts required to 
make the reactions faster. The fluorescent derivatives, on the other hand, are quite large, 
which makes them challenging to both penetrate through the cell wall, as well as to 
achieve efficient cell wall incorporation via the transpeptidase enzyme. Therefore, we 





























































































provide a better substitute to these aforementioned unnatural D-amino acids given the 
superior biocompatiblity qualities of semicarbazides and 2-FPBA/APBA towards the 
labeling of bacterial cells.  
 
Figure 3-6. Published unnatural D-amino acids for bacterial peptidoglycan labeling. 
These unnatural amino acids fall into either (a) clickable or (b) fluorescent derivative 
categories.  
 
3.1.3 Fluorogenic Reactions Enable No Wash Labeling of Bacteria 
  
 While fluorescent reactive handles are useful tools for assessing the incorporation 
of our unnatural amino acids, molecular probes that turn on fluorescence in response to a 
target are of great utility for biological applications.23–28 Probes belonging to this 
category have been successfully developed for a variety of metal ions and small molecule 
messengers, which function by eliciting a fluorescence increase through coordination or 
conjugation with a reactive partner probe. Additionally, fluorogenic substrates have been 
used to study enzymes that can catalyze the formation of fluorescent products.29 
Alternatively, development of fluorogenic probes for biomolecules with no 












































































chemistry. As previously mentioned, bioorthogonal conjugation chemistry enables the 
fluorescent labeling of non-enzymatic biomolecules through conjugation of a reactive 
handle to a reactive partner labeled fluorophore.30–33 These types of chemistries have 
been applied for the labeling of proteins, as well as for tracing carbohydrate metabolism 
in live cells; however, these applications are limited by the need for excess labeling 
reagents, which often result in high background fluorescence. Thus, bioorthogonal 
conjugation reactions that are fluorogenic, would help us to overcome this limitation.34 
Towards this end, we envisioned that by generating a non-fluorescent APBA-coumarin 
analogue, we would be able to elicit turn-on fluorescence via conjugation to 
semicarbazide (Figure 3-7). The capacity for biological applications of this fluorogenic 
reaction is highlighted by the fast and targeted visualization of semicarbazide-presenting 
bacterial cells generated through metabolic PG incorporation of a D-Dap-semicarbazide 
unnatural amino acid. 
 
Figure 3-7. Conjugation of a non-fluorescent APBA coumarin derivative with 




























3.2 Fast Diazaborine Formation of Semicarbazide Yields Stable Conjugates of 2-
FPBA/APBA 
 
 Although the rapid conjugation of phenylhydrazine to form stable diazaborines is 
attractive as a bioorthogonal reaction, we determined that phenylhydrazine is prone to 
oxidation, which results in a short half life of only a few hours in physiologically relevant 
aqueous buffer (Figure 3-8a). Moreover, phenylhydrazine that is subjected to neutral 
aqueous conditions for several hours no longer forms diazaborines with 2-APBA (Figure 
3-8b). Other possible α-nucleophile surrogates that are stable in aqueous physiologic 
conditions, including acethydrazide and benzhydrazide, have previously been shown to 
reversibly conjugate with 2-APBA to form iminoboronates instead of stable 
diazaborines.35 In search of alternatives to phenylhydrazine that generate stable 








Figure 3-8. Stability test of semicarbazide and phenylhydrazine in 1X PBS buffer (pH 
7.4). (a) Stacked HPLC chromatograms over time are shown for 100 µM Phzn-FITC 
(left) and 100 µM Scz-FITC (right). (b) 1H NMR analysis of non-fluorescently labeled 
phenylhydrazine and semicarbazide (both 1 mM) incubated in 1× PBS buffer (pH 7.4) 
over time, then subjected to diazaborine formation with 2-APBA (1 mM) in 1X PBS 






3.2.1 Semicarbazide Conjugates with 2-FPBA and 2-APBA to Form Diazaborines 
 The α-nucleophile semicarbazide is superior to phenylhydrazine in terms of its 
stability in aqueous physiologic buffer, which remains intact even after several weeks of 
incubation (Figure 3-8a, right). Importantly, semicarbazide conjugates with 2-
FPBA/APBA to form stable diazaborines (2-FPBA conjugate = DAB1, 2-APBA 
conjugate = DAB2, Figure 3-9a). Mixing semicarbazide with 2-FPBA in neutral buffer 
resulted in a clean 1H NMR spectrum corresponding to a single conjugation product 
(Figure 3-9b). The crystal structures of the diazaborine conjugate of 2-FPBA and 
semicarbazide (Figure 3-9c), as well as that of a 2-APBA bearing amino acid, L-AB3, 
and semicarbazide (Figure 3-9d) were obtained. These X-ray structures confirmed that 
















Figure 3-9. Diazaborine formation of semicarbazide. (a) Schematic illustration of 
diazaborine formation of semicarbazide in comparison to that of phenylhydrazine. (b) 1H 
NMR spectra of semicarbazide mixed with equimolar 2-FPBA (top) and 2-APBA 
(bottom). (c) Crystal structure of DAB1, the diazaborine conjugate of semicarbazide and 
2-FPBA. (d) Crystal structure of DAB3, a diazaborine conjugate of semicarbazide and 
the synthetic APBA-presenting amino acid L-AB3. (1H NMR and X-Ray crystal data 


























































R = H (DAB1)








3.2.2 Diazaborine Formation of Semicarbazide is Fast and Irreversible 
Similar to phenylhydrazine, semicarbazide conjugation with 2-FPBA/APBA 
yields stable diazaborine conjugates in aqueous physiologic buffer, as observed by LC-
MS and 1H NMR analysis. In the former case, DAB1 and DAB2 remained intact during 
LC analysis and purification performed with acidic eluents (Figure 3-10). Conversely, 
the 2-APBA conjugates of acethydrazide previously could not be identified in LC-MS 
analysis due to complete hydrolysis.35  
 
 
Figure 3-10. ESI-MS analysis of diazaborine conjugates. Diazaborine conjugates (a) 
DAB1 and (b) DAB2 were identified by MS. (Data collected by Dr. Anupam 
Bandyopadhyay) 
 
In the case of 1H NMR analysis, 100 µM samples of DAB1 and DAB2 exhibited 
no degradation over 3 days at room temperature (Figure 3-11). To assess whether the 
stability was a result of kinetic or thermodynamic origin, control samples of 100 µM 
semicarbazide with equimolar 2-FPBA/APBA were prepared. While 2-FPBA conjugated 
completely with semicarbazide, 2-APBA reached a maximum yield of 80% with 20% of 
reactants remaining, as shown by LC-MS analysis (Figure 3-12). This incomplete 
a) b) 
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conjugation of 2-APBA is in contrast to the lack of degradation of DAB2, which 
indicates that the diazaborines of semicarbazide are kinetically stable, which is highly 
desirable for bioorthogonal reactions.  
Figure 3-11. 1H NMR analysis of the stability of diazaborine conjugates. Diazaborine 
conjugates (a) DAB1 and (b) DAB2 were prepared with 100 µM 2-APBA/FPBA and 100 




Figure 3-12. LC-MS analysis of the conjugation of 10 µM 2-FPBA/APBA conjugating 





























































2-APBA (0.1 mM) + 
semicarbazide (0.1 mM) 
Purified DAB2 24h 




The conjugation efficiency of semicarbazide was examined by both 1H NMR and 
LC-MS analysis (Table 3-1). 1H NMR results show that while DAB1 formation proceeds 
quantitatively, even with reactants at low micromolar concentrations, DAB2 formation 
only yields 60% diazaborine conjugate at 50 µM 2-APBA and semicarbazide (Figure 3-
13b). The LC-MS analysis yielded consistent results.  
 
 Table 3-1. Yields of diazaborine formation for various combinations of 2-FPBA/APBA 





















Figure 3-13. Assessing the efficiency of semicarbazide conjugation to APBA by 1H 
NMR. Yields are calculated by integrating the 2-APBA (*) and diazaborine (*) CH3 
chemical shifts. (Data collected by Dr. Anupam Bandyopadhyay) 



































To investigate the source of the lack of completion observed for DAB2 formation 
despite no evidence of side product formation, we probed the possibility of product 
inhibition by analyzing the 1H NMR spectra of a DAB2 derivative mixed with each 
reactant at equimolar concentrations (Figure 3-14). As a result of low water solubility of 
DAB2, the diazaborine conjugate of semicarbazide and the unnatural amino acid L-AB3 
was used for the experiment. The NMR spectrum revealed a distinct shift of the aromatic 
peaks of the diazaborine conjugate when mixed with either reactant. This peak is believed 
to originate from interactions of the product with the reactants, which indicates a 










Figure 3-14. 1H NMR analysis of potential sequestration of the reactants by the 
diazaborine product. Equimolar excess L-AB3 or semicarbazide (1 mM excess each) was 
added to the pre-formed diazaborine (1 mM) in 1X PBS pH 7.4, and the 1H NMR spectra 
were obtained in 10% D2O. The spectra were aligned on by the acetyl peak of free L-
AB2 (gray dashed line) and observed shifts in the diazaborine peaks (blue dashed line) 
indicate interactions between the diazaborine products and reactants. 
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The kinetics of diazaborine formation of DAB1 and DAB2 were determined via a 
UV-Vis experiment, which enabled the reaction to be monitored at low concentrations 
(Figure 3-15). Both 2-FPBA and 2-APBA exhibit an absorption maximum at ~254 nm, 
which shifts to ~290 nm upon diazaborine formation. The kinetics of DAB1 formation 
was determined upon mixing 10 µM 2-FPBA and semicarbazide by monitoring the 
absorption increase at 290 nm, which afforded a kinetic plot of the reaction that was fit to 
a second order reaction mechanism, yielding a rate constant of >103 M-1s-1 (Figure 3-16). 
A similar rate constant was obtained for the conjugation of 2-APBA and semicarbazide, 
which shows that the diazaborine formation of semicarbazide is equally fast to that of 
phenylhydrazine, and is also comparable to the fastest conjugation reactions documented 
in literature.  
Figure 3-15. UV-Vis assessment of the kinetics of diazaborine formation. Kinetic rate 
constants of (a) DAB1 and (b) DAB2 were determined by UV-Vis absorption. (Data 


















Figure 3-16. Kinetic profiles of diazaborine formation. Kinetic fits of (a) DAB1 and (b)  
DAB2 formation as monitored by UV-Vis absorption. Measurements were carried out in 
triplicate to generate error values. (Data collected by Dr. Anupam Bandyopadhyay) 
 
 
3.3 Diazaborine Formation of Semicarbazide Enables Facile Labeling of Bacterial 
Pathogens via D-AB3 Peptidoglycan Incorporation 
  
With the knowledge that diazaborine formation of semicarbazide with 2-
FPBA/APBA yields stable conjugates, we aimed to further investigate the 
bioorthogonality of this chemistry. To do so, we explored the stability of the reagents and 
products in biological conditions, as well as the toxicity of the reagents towards bacterial 
and mammalian cells.  
3.3.1 Assessing the Bioorthogonality of Diazaborine Formation of Semicarbazide 
 Given our reports on the slowly reversible conjugation of 2-FPBA and cysteine at 
low micromolar concentrations36, we postulated that this thiazolidinoboronate (TzB) 
formation with 2-FPBA may interfere with the conjugation of 2-FPBA to semicarbazide. 
To test this hypothesis, we pre-incubated 2-FPBA with equimolar L-cysteine (0.2 mM), 
and then examined the diazaborine formation of 2-FPBA with semicarbazide, which 
yielded only 40% diazaborine after 40 minutes (Figure 3-17a).  2-APBA, which also 
conjugates with free cysteine in a rapidly reversible manner, was also pre-incubated with 
a) b) 
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equimolar L-cysteine (0.2 mM), which showed no interference with diazaborine 
formation of 2-APBA (Figure 3-17b), suggesting superior bioorthogonality of the 2-










Figure 3-17. Orthogonality of diazaborine chemistry of DAB1 and DAB2 formation to 
cysteine-containing biological environments.1H NMR analysis of diazaborine formation 
of 0.2 mM (a) 2-FPBA or (b) 2-APBA after pre-incubation with 0.2 mM L-cysteine in 
PBS pH 7.4 (data collected by Dr. Anupam Bandyopadhyay). 
 
 
 Diazaborine formation of semicarbazide was further analyzed for 
bioorthogonality in the presence of fetal bovine serum (FBS), as well as bacterial and 
mammalian cell lysates. The presence of FBS (20%) in the reaction mixture yielded 
minimal interference to diazaborine formation of both 2-FPBA and 2-APBA (Figure 3-
18), which may result from the oxidative environment of blood serum, which contains 
low levels of free cysteine.37 The diazaborine formation of 2-FPBA and 2-APBA was 

































18). This phenomenon could be due to minimal free cysteine in the lysate as a result of 
dilution and oxidation during lysate preparation. Staphylococcus aureus lysates, however, 
did inhibit the conjugation of 2-FPBA to semicarbazide, which yielded only 12% 
diazaborine after 30 minutes (Figure 3-18). Beyond free cysteine, S. aureus is known to 
express high concentrations of bacillithiol, which displays an N-terminal cysteine, and 
thus is likely responsible for the inhibition of 2-FPBA diazaborine formation. The 
diazaborine product of 2-FPBA in the S. aureus lysate mixture was observed to increase 
over the course of several hours (data not shown), highlighting the reversibility of the 
interfering TzB reaction. In contrast to 2-FPBA, 2-APBA was observed to rapidly 




















Figure 3-18. Compatibility of diazaborine chemistry to mammalian and bacterial 
biological systems. (a) LC-MS confirmation of the diazaborine formation of 2-
FPBA/APBA with semicarbazide-NBD. (b) DAB1 and (c) DAB2 formation of 25 µM 2-
FPBA/APBA and 50 µM semicarbazide-NBD in PBS buffer (pH 7.4) alone, or in the 
presence of FBS (20% v/v), HEK cell lysate (5 mg/mL), and S. aureus (5 mg/mL). (Data 
























































3.3.2 Assessing the Stability and Toxicity of Diazaborine Conjugation Reagents  
To test the stability of the diazaborine-forming reagents in biological conditions, 
we incubated 2-FPBA, 2-APBA and a FITC labeled semicarbazide (Scz-FITC) with 20% 
FBS or HEK cell lysates for 24 hours before subjecting them to diazaborine conjugation 
reactions. HPLC analysis of these reactions (Figure 3-19) showed essentially the same 
yields regardless of the length of incubation (0 or 24 hours). Notably, the reactive 
semicarbazide molecule is quite stable in comparison to the fast degradation observed 
with phenylhydrazine (Figure 3-8). Moreover, PAGE analysis of the HEK cell lysates 
treated with Scz-FITC showed no significant protein labeling (Figure 3-20). Altogether 


























































Figure 3-19. Stability of diazaborine reactants in biological conditions. (a) Analytical 
HPLC traces and mass spectrometry data of the conjugation of 2-FPBA (left) and 2-
APBA (right) (100 µM each) with Scz-FITC (50 µM). (b) 2-FPBA (left), 2-APBA 
(center) and Scz-FITC (right) incubated in the presence of 20% FBS (w/v), then 
conjugated to either Scz-FITC or 2-APBA as in part a. (c) 2-FPBA (left), 2-APBA 
(center) and Scz-FITC (right) incubated in the presence of 3 mg/mL HEK 293T lysate, 
then conjugated to either semicarbazide-FITC or 2-APBA as in part a. Chromatograms 


























































 We also examined the potential cytotoxicity of semicarbazide alongside 
phenylhydrazine for comparison. Two strains of bacteria (Escherichia coli and S. aureus) 
and a model mammalian cell line (HEK 293T) were treated with both semicarbazide and 
phenylhydrazine (Figure 3-21). The percentage of surviving cells was determined by 
colony counting for the bacteria, and by MTT assay for the HEK cells. The results 
showed little toxicity for all three cell lines for semicarbaizde, whereas phenylhydrazine 
elicited 10-25% cell death for bacteria, and ~50% cell death for the HEK cells after 24 
hours of incubation. We also examined the toxicity of a 2-APBA amino acid derivative, 
D-AB3, which elicited no measureable death for any of the cell lines. Thus, the reagents 








Figure 3-21. Cytotoxicity studies of the reactants for diazaborine conjugation.               
(a) Percentage of cell survival determined by colony counting for E. coli and S. aureus. 
(b) Percentage of cell survival determined by MTT assay for HEK293T cells. 
Phenylhydrazine (Phz) was included as a direct comparison to semicarbazide. 
Camptothecin (Camp) was included as a positive control in the HEK293T MTT assay. 
All compounds were tested at 50 µM. 
 
 
3.3.3 Semicarbazide Conjugation Allows Facile Labeling of Bacterial Pathogens 
 
Given the observed high biocompatibility of diazaborine chemistry, we applied 
semicarbazide conjugation chemistry to the facile detection of bacterial pathogens via 
peptidoglycan incorporation. Towards this end, we synthesized the amino acid D-AB3, 
which is a 2-APBA analogue, and analyzed its incorporation into an array of bacterial 
species including S. aureus (Figure 3-24), E. coli (Figure 3-23), Klebsiella pneumonia 
(K. pneumoniae, Figure 3-25), and Pseudomonas aeruginosa (P. aeruginosa, Figure 3-
26) at varying concentrations. While E. coli was brightly labeled, S. aureus and K. 
pneumoniae were stained with lower efficiency, and P. aeruginosa was not significantly 
stained. To measure this D-AB3 incorporation, excess amino acid was washed away and 
the cells were subsequently stained with Scz-FITC. The semicarbazide ligation was 
performed with 50 µM Scz-FITC for 30 minutes, which was expected to yield 60% 
diazaborine. After washing, the cells were analyzed by fluorescence microscopy and flow 
a) b) 
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cytometry (Figure 3-22). As previously mentioned, E. coli exhibited bright staining in 
comparison to minimally fluorescent S. aureus. This higher efficiency of D-AB3 
incorporation into E. coli was further validated by flow cytometry, which exhibited a 
median fluorescence intensity ~10X higher for E. coli than that for S. aureus and K. 
pneumoniae (Figure 3-22c). Importantly, the bacterial cell staining via diazaborine 
formation showed little interference by the presence of blood serum or cell lysates 
(Figure 3-22d). Specifically, E. coli cells were labeled with D-AB3, then labeled with 
Scz-FITC in the presence of 5 mg/mL HEK293T cell lysate or 10% (v/v) FBS. The 
samples were then analyzed by flow cytometry, which yielded comparable histograms of 







Figure 3-22. Semicarbazide conjugation to form stable diazaborines enables facile 
labeling of bacterial pathogens. (a) Schematic illustration of the two-step protocol for 
bacterial cell labeling. (b) Microscopic images and (c) flow cytometry analysis show that 
D-AB3 incorporation varies across bacterial species. (d) Flow cytometry histograms 
show that semicarbazide-enabled bacterial labeling is unaffected by blood serum or 

















































Figure 3-24. E. coli labeling with D-AB3 and Scz-FITC. (a) Time course of D-AB3 
incubation (125 µM) at 0.5, 2, 4 and 6 hours followed by Scz-FITC incubation for 30 













Figure 3-24. S. aureus labeling with D-AB3 and Scz-FITC. (a) Time course of D-AB3 
incubation (125 µM) at 0.5, 2, 4 and 6 hours followed by Scz-FITC incubation for 30 






























Figure 3-25. K. pneumoniae labeling with D-AB3 and Scz-FITC. (a) Time course of D-
AB3 incubation (125 µM) at 0.5, 2, 4 and 6 hours followed by Scz-FITC incubation for 
















Figure 3-26. P. aeruginosa labeling with D-AB3 and Scz-FITC. (a) Time course of D-
AB3 incubation (125 µM) at 0.5, 2, 4 and 6 hours followed by Scz-FITC incubation for 

















The preferential labeling of E. coli by D-AB3 was further validated by a co-
culture experiment, for which the D-AB3 treated E. coli and S. aureus cells were mixed 
and then labeled with Scz-FITC (Figure 3-27). Microscopy of the co-culture 
demonstrates the selective labeling of E. coli, which displays strong fluorescence while S. 
aureus cells appear dimly fluorescent. This more efficient incorporation of D-AB3 into E. 
coli was further validated by flow cytometry analysis, which displays a mean cell 




Figure 3-27. Fluorescence microscopy image of an E. coli and S. aureus co-culture 
showing preferential staining of E. coli  by D-AB3. 
 
Treating the bacterial cells with L-AB3 through the same protocol yielded 
minimal fluorescence staining regardless of the strain of bacteria used (Figure 3-28), 
indicating that D-AB3 can be incorporated into the PG whereas L-AB3 cannot be 
accepted by the transpeptidases responsible for PG remodeling as expected.15 Confocal 
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microscopy images also confirmed the cellular envelope localization of fluorescence 
(Figure 3-29). Given the high specificity of Scz-FITC for D-AB3, the fluorescence of the 
labeled cells should directly reflect the amount of D-AB3 incorporated into 
peptidoglycan. Quantitative analysis of D-AB3 uptake by E. coli was carried out by 
plotting the cell mean fluorescence against D-AB3 concentration, which displays a 
saturating profile, as expected for an enzyme catalyzed reaction (Figure 3-30). Fitting the 
data according to a Michaelis-Menten mechanism yields a KM value of 23 µM. This KM 
value is about an order of magnitude lower than that of a D-Lysine derivative used for S. 
aureus labeling, suggesting that D-AB3 uptake by E. coli is highly efficient. 
Alternatively, the concentration profile of D-AB3 for S. aureus staining data displays a 
linear relationship (Figure 3-31), suggesting the KM value is well above the highest 
concentration tested (125 µM). While a precise KM value cannot be obtained for S. 
aureus, the slope of the linear fit should be roughly proportional to the catalytic 
efficiency of the relevant enzyme (Vmax/KM). Comparison of the catalytic efficiencies 
shows that D-AB3 is more efficiently incorporated into E. coli by 26 folds.  
	 102 
 
Figure 3-28. Comparison of D-AB3, L-AB3 and no treatment (Scz-FITC) in bacterial 
cell staining. (a) S. aureus, (b) E. coli, (c) K. pneumoniae and (d) P. aeruginosa were all 
incubated with 125 µM D-AB3, L-AB3 or neither for 6 hours, followed by 30 minutes of 








Figure 3-29. D-AB3-Scz-FITC labels the bacterial membrane. Confocal microscope 
images of E. coli display the specific bacterial cell envelope location of fluorescence 
(scale bar, 2.5 µm). 
 
 
Figure 3-30. Concentration profiles of D-AB3 incorporation into E. coli (top) S. aureus 
(bottom left) and K. pneumoniae (bottom right). The flow cytometry data were fit to a 
hyperbolic curve for E. coli and a linear fit for S. aureus and K. pneumoniae according to 
Michaelis-Menten kinetics. 
E. coli 
S. aureus K. pneumoniae 
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The preferential incorporation of D-AB3 into E. coli is interesting given the 
documented favorability of Gram-positive bacteria incorporation over Gram-negative 
bacteria incorporation of many published amino acids, likely due to outer membrane 
impermeability.16,20,21 To confirm this phenomenon, we synthesized a previously reported 
amino acid, D-Lys-FITC, which showed 50x better staining of S. aureus in comparison to 

















Figure 3-31. Flow cytometry analysis of S. aureus and E. coli stained with D-Lys-FITC 
(125 µM) reveals that D-Lys-FITC stains S. aureus much greater than it does E. coli. 
 
 Overall, the D-AB3 conjugation chemistry enables facile labeling of E. coli cell 
walls in complex biological settings via diazaborine formation with semicarbazide. While 
D-AB3 does not exhibit complete selectivity for E. coli detection, the clear saturation of 
incorporation is in stark contrast to that of S. aureus and K. pneumoniae, which exhibit no 
saturation at any concentration tested. 
 



























3.4 Turn-On Fluorescent APBA Diazaborine Formation Facilitates “No Wash” 
Labeling of Bacterial Pathogens 
 
 Towards our goal of achieving bioorthogonal, no wash labeling of biomolceules, 
we expanded the diazaborine chemistry with turn-on fluorescent APBA-presenting 
molecules that become fluorescent upon conjugation to semicarbazide. 
3.4.1 Synthesis of APBA Coumarin Analogues  
 
 To create fluorogenic, diazaborine-forming probes, we synthesized several 
coumarin derivatives (AB21-24) that present either a 2-APBA motif, or one of its 
structural analogues at the C3 position (Scheme 3-1). While AB21 and AB22 are 
expected to conjugate with semicarbazide to form diazaborines, AB23 and AB24 are 
designed to serve as negative controls. The coumarin core structure has been widely used 
in the design of fluorescent molecules as its fluorescence can be easily tuned with 
electron donating and withdrawing groups.38–41 
Scheme 3-1. Structures of the coumarin derivatives AB21, AB22, AB23 and AB24 
 
 We first characterized the absorption and fluorescence properties of the coumarin 
analogues (Figure 3-32). All four coumarin derivatives display similar absorption 
profiles, with absorption maxima around 395 nm; the fluorescence properties, however, 






































































dramatically differ. While AB24 exhibits strong fluorescence, AB21 and AB22 give 
minimal fluorescence, whereas AB23 displays slightly higher fluorescence than 
AB21/22.  The varying fluorescence intensities correlate well with the electron 
withdrawing capabilities of the C3 substituents: the 2-APBA motif of AB21 and AB22 is 
the most electron deficient, and the phenol substituent of AB24 is the most electron rich.  
Figure 3-32. Absorption and fluorescence properties of the coumarin analogues.            
(a) Coumarin derivatives exhibit similar absorption properties (50 µM, 1 cm cuvette, PBS 
buffer pH 7.4). (b) Fluorescence emission of the coumarin derivatives show quenched 
fluorescence of AB21/22 (10 µM, PBS buffer pH 7.4, λex=392 nm (AB22/24), 397 nm 
(AB21) and 402 nm (AB23). 
 
 
3.4.2 Analysis of Diazaborine Formation of APBA Courmarin Analogues  
 
 The quenching effect of 2-APBA suggests that AB21 and AB22 are capable of 
exhibiting turn-on fluorescence upon conjugation, such as diazaborine formation with 
semicarbazide. To test this hypothesis, the APBA coumarin analogs were first examined 
for their ability to conjugate with semicarbazide. As shown by LC-MS, AB21 or AB22 
(200 µM) mixed with semicarbazide (200 µM) for 30 minutes yielded quantitative 
conversion to the corresponding diazaborine (Figure 3-33a). Additionally, the 
conjugation of AB21/22 to semicarbazide is minimally inhibited in the presence of 20% 








































































blood serum (Figure 3-34). To assess the possible turn-on fluorogenic property of 
AB21/22, the conjugation products were diluted to 10 µM for fluorescence measurement 
(Figure 3-33b). Both coumarin derivatives displayed significant fluorescence increase; 
while semicarbazide conjugation to AB21 elicited a 5-fold increase in fluorescence 
emission, AB22 gave a 7-fold enhancement. Comparatively, AB23 and AB24 showed no 
change in fluorescence emission when mixed with semicarbazide, which is consistent 

















Figure 3-33. Diazaborine formation of AB21/22 with semicarbazide induces an increase 
in fluorescence. (a) LC traces showing clean and complete conjugation of AB21/22 (200 
µM) to semicarbazide (200 µM) in 30 minutes. The identities of the peaks were 
confirmed with MS data. (b) Conjugation to semicarbazide leading to much enhanced 
fluorescence of AB21 and AB22 (10 µM, 1x PBS Buffer, pH 7.4, λex= 392 nm (AB22) 
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Figure 3-34. Analytical HPLC analysis of AB21 and AB22 conjugation to semicarbazide 
in the presence of 20% fetal bovine serum. 
 
 
Figure 3-35. Addition of semicarbazide to AB23 and 24 generates no increase in 




 The fluorogenic properties of AB21 and AB22 enabled facile quantification of the 
conjugation kinetics, yielding rate constants of 144 M-1s-1 and 177 M-1s-1 for AB21 and 
AB22, respectively (Figure 3-36). Although the kinetics of AB21/22 are slower than that 
of simple 2-APBA, the diazaborine formation of AB21/22 is still remarkably fast, with 
the reaction reaching completion in just a few minutes with low micromolar 
concentrations of reactants.  
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Figure 3-36. Kinetics of AB21 (left) and AB22 (right) conjugation to semicarbazide as 
determined by fluorescence titration. 
 
 
 We also obtained quantum yield data for the coumarin analogues themselves, as 
well as when conjugated to semicarbazide (Table 3-2).42 From this data, we observed a 
dramatic increase in quantum yield of AB21/22 upon semicarbazide conjugation, 
whereas the control compounds (AB23/24) displayed no such increase, as expected, due 
to lack of conjugation. 
Table 3-2. Summary of AB21-24 quantum yield data obtained from comparison to the 
quantum yield of the standard, fluorescein.1 
  Voltage Integrated 
Area 
Absorbance Quantum Yield  
AB21 700 V 4,032 0.066 0.014 
AB21+Scz 700 V 16,862 0.066 0.060 
AB22 700 V 8,311 0.096 0.020 
AB22+Scz 700 V 41,877 0.096 0.102 
AB23 700 V 20,518 0.033 0.145 
AB23+Scz 700 V 14,524 0.033 0.103 
AB24 600 V 28,737 0.063 0.455 
AB24+Scz 600 V 19,932 0.063 0.315 
Fluorescein 600 V 6,768 0.071 0.950 
Fluorescein 700 V 28,905 0.071 0.950 
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k2=144 ± 28 M-1s-1  k2=177 ± 44 M-1s-1  
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3.4.3 No Wash Labeling of Bacterial Pathogens via D-Dap-Scz Peptidoglycan 
Incorporation  
 
 The fast and fluorogenic conjugation of AB21/22 with semicarbazide makes these 
molecules appealing for biological applications. With our interest in developing novel 
solutions to the antibiotic crisis and our success in PG remodeling incorporation of 
unnatural amino acids, we envisioned that fluorogenic diazaborine formation of 
AB21/AB22 could be implemented for bacterial cell labeling via a semicarbazide-
presenting D-amino acid (Figure 3-37). Towards this end, we synthesized the unnatural 
amino acid D-Dap-Scz, which was obtained by conjugating a semicarbazide derivative to 
Boc-D-Dap-OH through amide bond formation (Figure 3-38). With the amino acid in 
hand, we tested the conjugation of D-Dap-Scz to AB21 and AB22, as well as the 
fluorescence upon conjugation, both of which agreed with the results obtained for simple 
semicarbazide (Figure 3-39).  
 
Figure 3-37. Schematic two-step labeling process involving D-Dap-Scz incorporation 
into peptidoglycan followed by APBA coumarin conjugation to form a stable 
diazaborine. 
 







































































Figure 3-39. Conjugation of D-Dap-Scz to AB21 and AB22. (a) LC-MS analysis of the 
conjugation of AB21 and AB22 (indicated by gray dashed lines) to D-Dap-Scz. (b) 
Fluorescence change of AB21-24 when conjugated to D-Dap-Scz (Voltage= 700 
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 We then examined the ability of D-Dap-Scz to incorporate into the cell wall of S. 
aureus, which is a prevalent bacterial pathogen. Specifically, we incubated the bacteria 
with various concentrations of D-Dap-Scz (5-500 µM) for various times (0.5-4 hours). 
The amount of D-Dap-Scz incorporated into peptidoglycan was assessed via a 
fluorophore-labeled 2-formylphenylboronic acid (FPBA-FITC, Figure 3-40), which is 
expected to give quantitative diazaborine yield. The FPBA-FITC treated cells were then 
analyzed by flow cytometry, which showed that the extent of bacterial incorporation of 
D-Dap-Scz depends on both the concentration and incubation time. Efficient D-Dap-Scz 
incorporation was observed after 4 hours of incubation with D-Dap-Scz at 100 µM 
concentration or higher (Figure 3-41). Specifically, with 4 hours of incubation, FPBA-
FITC afforded proportionally strong fluorescence staining of the cells treated with D-






























































Figure 3-41. Flow cytometry of S. aureus metabolically labeled with D-Dap-Scz and 




 These conditions were then adopted to examine the fluorogenic conjugation of the 
coumarin derivatives on live bacterial cell surfaces. Towards this end, S. aureus cells 
were treated with 0, 100 and 500 µM of D-Dap-Scz in LB media for 4 hours, then the 
cells were washed to eliminate any excess D-Dap-Scz, and finally directly stained with 
AB21 and AB22. FPBA-FITC and AB24 were examined in parallel as non-fluorogenic 
controls (Figure 3-42). While washing after FPBA-FITC enabled facile visualization of 
D-Dap-Scz treated cells (Figure 3-41), strong background fluorescence was observed 
without the washing step. Importantly, FPBA-FITC afforded significant straining of the 
cells without D-Dap-Scz treatment. Similarly, background fluorescence and non-specific 
cell staining was observed for AB24 under no-wash conditions, although AB24 is not as 
bright as FPBA-FITC. In sharp contrast, little background fluorescence was observed 
with the AB21/22 stained cells under the same settings. Comparing S. aureus incubated 
[D#Dap#Scz],+μM+































with no D-Dap-Scz (0 µM) versus 100 µM and 500 µM D-Dap-Scz, it is apparent that 
AB21 and AB22 elicited bright fluorescence staining only in the presence of D-Dap-Scz. 
The D-Dap-Scz-dependent bacterial staining by AB21 and AB22 is presumably due to 
their fluorogenic conjugation with D-Dap-Scz to form diazaborines. Although it is 
difficult to determine whether AB21 and AB22 afford non-specific bacterial binding, 
their quenched fluorescence allows them to only fluorescently reveal bacterial cells that 










Figure 3-42. No wash S. aureus cell labeling by AB21/AB22 conjugation to PG-
incorporated D-Dap-Scz. S. aureus was incubated with 0 µM, 100 µM or 500 µM D-Dap-
Scz for four hours followed by 100 µM AB21, AB22, AB24 or FPBA-FITC incubation 











3.4.4 Development of D-Phe-Scz for E. coli Incorporation 
 
 After examining the application of D-Dap-Scz in S. aureus labeling experiments, 
we were interested in developing an unnatural amino acid with an aromatic structure (D-
Phe-Scz), which, based on our results with D-AB3, we hypothesized would experience 
facile incorporation into E. coli. After synthesizing D-Phe-Scz, we applied it for bacterial 
labeling by incubating S. aureus and E. coli with D-Phe-Scz at 5-500 µM for 0.5-4 hours, 
washing the bacteria, then incubating with 50 µM FPBA-FITC for 30 minutes, again 
washing the bacteria, and subjecting to both fluorescence imaging and flow cytometry. 
These experiments were conducted alongside D-Dap-Scz for comparison, and showed 
that while D-Dap-Scz more efficiently incorporated into the S. aureus cell walls, D-Phe-
Scz did not incorporate more efficiently into the E. coli cell wall as we had anticipated 
(Figure 3-43). While the origin of this difference in the anticipated and observed results 
is not certain, it is possible that the semicarbazide moiety has some effect on either 




Figure 3-43. Analysis of D-Phe-Scz peptidoglycan incorporation into bacterial cell walls. 
(a) S. aureus and (b) E. coli were analyzed for D-Phe-Scz incorporation via FPBA-FITC 




 Through these efforts we have discovered that semicarbazide conjugation to 
boronic acid substituted aryl ketones and aldehydes enables stable diazaborine formation 
in a bioorthogonal manner. These conjugation reactions proceed with rate constants over 
103 M-1s-1 in aqueous physiologic buffer, with no need for catalysts. Notably, the reaction 
rate of diazaborine formation is 2-3 orders of magnitude greater than the widely used 
azide-alkyne chemistry.43 Given the degradation and toxicity observed with 
phenylhydrazine, as well as the lack of stability of conjugates for acethydrazide, 
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semicarbazide appears to reside in the “sweet spot” of reactivity, being high enough to 
afford diazaborines and low enough to avoid degradation. Other than the cysteine adduct 
formation with 2-FPBA, this diazaborine forming chemistry exhibited little interference 
from biological media with blood serum and cell lysates, thus indicating the high level of 
biocompatibility afforded by diazarborine chemistry. 
 To demonstrate the utility of the conjugation chemistry, we have explored the 
facile labeling of bacterial pathogens by diazaborine formation of semicarbazide. A 
synthetic amino acid, D-AB3, which displays a 2-APBA moiety, was shown to be taken 
up by bacterial cells through metabolic peptidoglycan remodeling. The cells with D-AB3 
incorporated were visualized though conjugation with a fluorophore labeled 
semicarbazide. While a number of synthetic D-amino acids have been shown to 
covalently modify bacterial peptidoglycans with a variety of bioorthogonal reactive 
partners (eg. azide-alkyne click chemistry, tetrazine ligation, alkyne-nitrone 
cycloaddition motifs), the diazaborine formation chemistry is much faster than most of 
these alternative chemistries.  
 We observed that D-AB3 preferentially labeled E. coli over several other bacterial 
species including S. aureus, a Gram-positive bacterium. This is interesting given that 
several amino acids, including D-Lys-FITC, have been shown to preferentially label 
Gram-positive bacteria over Gram-negative strains, likely due to the outer membrane of 
Gram-negative bacteria acting as a barrier. Since D-AB3 incorporates into the E. coli 
peptidoglycan with high efficiency, it must also display high penetration of the cell wall. 
Work from the Kahne and Walker labs shows that the E. coli transpeptidase preferentially 
incorporates aromatic amino acids over aliphatic ones.44 Given that nearly all synthetic 
	 118 
amino acids known to modify peptidoglycans are aliphatic, the aromatic structure of D-
AB3 might be the underlying reason for its efficient uptake. Conversely, D-Phe-Scz was 
shown to give similar incorporation into E. coli in comparison to a similar aliphatic 
amino acid. Thus, there may be some caveats underlying this hypothesis. 
 In addition to D-AB3 incorporation, we also explored the incorporation of a 
semicarbazide presenting unnatural amino acid, D-Dap-Scz, to use for turn-on fluorescent 
detection of bacterial pathogens via diazaborine formation with the APBA coumarin 
analogues AB21/22. Specifically, the D-Dap-Scz amino acid was incorporated into S. 
aureus peptidoglycan, and subsequently detected with the turn-on fluorescence elicited 
by diazaborine formation of AB21/22 with minimal background fluorescence. 
Altogether, these bioorthogonal probes enable efficient bacterial pathogen detection to 
further our efforts towards developing solutions to the antibiotic resistance crisis. 
3.6 Experimental Procedures  
 
3.6.1 General Methods 
Triflic anhydride, tert-Butyl 2,2,2-trichloroacetimidate, 1,1′-
Bis(diphenylphosphino)ferrocene (dppf), sodium chloride (NaCl), tyrosine, fluorescein 
isothiocyanate isomer I (FITC), N-Boc-Bromoethylamine, potassium carbonate, 2-bromo 
hydroxybenzaldehyde, potassium acetate and triethylamine were purchased from Sigma 
Aldrich Trifluoroacetic acid, dry DCM, dry dioxane, DMF, tetrahydrofuran, N-
hydroxysuccinimide, ethyl isocyanoacetate, tert-butyl carbazate, N-boc-ethylenediamine, 
2-acetylphenyl boronic acid, 2-formylphenyl boronic acid, 4-chloro 7-nitrobenzofurazan 
(NBD-Cl), semicarbazide, fetal bovine serum (FBS) and B-per were purchased from 
Fischer Scientific. Pd(dppf)Cl2 was purchased from Strem Chemicals. B2pin2 was 
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purchased from Frontier Scientific. Boc-D-Dap-OH and dicyclohexylcarboiimide were 
purchased from Chem Impex International. Diethanolamine was purchased from Alfa 
Aesar. D-AB3 was synthesized according to a published procedure.45 Klebsiella 
pneumoniae (ATCC 4352), Pseudomonas aeruginosa (ATCC 27853), and 
Staphylococcus aureus (ATCC 6538) were purchased from ATCC as a lyophilized cell 
pellet. Escherichia coli (BL 21) was a gift from the lab of Professor Mary F. Roberts at 
Boston College. HEK293T cells were a gift from the lab of Professor Eranthie 
Weerapana at Boston College. All the ligation experiments were performed in PBS (1X, 
7.4) buffer unless noted otherwise. 
 UV-vis spectra were collected on a Nanodrop UV-Vis spectrometer (Thermo 
Scientific, Waltham, MA, USA). NMR data were collected on a Varian 600 MHz NMR 
spectrometer. LC-MS data were generated using an Agilent 6230 LC-TOF mass 
spectrometer with an Agilent Extend C18 column with acetonitrile/water (0.1% formic 
acid) eluent. HPLC purification and analysis was performed using a Waters Alliance 
2695 system with a Jupiter C18 column (Phenomenex) with acetonitrile/water (0.1% 
TFA) eluent. Analytical HPLC data was obtained on a Waters Alliance 2695 HPLC with 
a Phenomenex C18 column with acetonitrile/water (0.1% TFA) eluent. Fluorescence 
images were taken on a Zeiss Axio Observer A1 inverted microscope. Confocal images 
were taken on the Leixa SP5 confocal fluorescence microscope housed in the Biology 
Department at Boston College. Flow cytometry analyses were carried out on a BD 
FACSAria cell sorter also housed in the Biology Department of Boston College. NMR 
spectra were recorded in the presence of 10% D2O using the water suppression PRESAT 
parameter, 160 scans, and a line broadening value of 0.5 on a Varian 600 MHz NMR 
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spectrometer. All NMR data processing was performed in MestReNova 10. Fluorescence 
data were collected on a Cary Eclipse fluorescence spectrophotometer with slit width set 
to 5 nm. Voltages varied, as noted in the designated fluorescence sections. 96 well plate 
absorbances were obtained with a SpectraMax M5 plate reader (Molecular Devices). The 
concentration of all fluorescently labeled samples was determined by measuring their 
absorbance at 495 nm (ε=72,000 M-1cm-1) for FITC or 493 nm (ε=24,000 M-1cm-1) for 
NBD with a Nanodrop 2000c UV-Vis spectrometer. 
3.6.2 Synthesis of Semicarbazide-FITC, Semicarbazide-NBD, and Phenylhydrazine-FITC 
Synthesis of Semicarbazide-FITC (3-I-f) 
 
(a)  Synthesis of 3-I-b: 3-I-b was synthesized following a previously reported 
protocol.46 Ethyl isocyanatoacetate (0.56 mL, 5 mmol) was dissolved in dry 
dichloromethane (5 mL) by stirring. Tert-butyl carbazate (650 mg, 5 mmol) was 
dissolved in dichloromethane (5 mL) and added into the stirring mixture, followed 
by the addition of N-Methylmorpholine (800 µL, 5.5 mmol). The reaction mixture 
was then refluxed at 50 oC for 2 hours. Upon completion, the reaction mixture 
was cooled to room temperature and diluted into 250 mL ethyl acetate. The 
resulting solution was then washed with sodium carbonate (1x150 mL), 1N HCl 
(1x150 mL), and brine (1x150 mL). The organic layer was then dried over sodium 
sulfate and evaporated to yield a thick solid (1.3g ,73%). The compound identity 
was confirmed by 1H-NMR, which agrees with the earlier reported spectrum. 

























Compound 3-I-b was directly used for the next step without purification. 
(b) Synthesis of 3-I-c: 3-I-b (500 mg, 1.92 mmol) was dissolved in 5 mL methanol 
and the solution was treated with 2.5 mL of 2N NaOH with stirring condition for 
0.5 hours. The solvent was then evaporated and the resulting residue was acidified 
with 1N HCl (~5 mL) and subsequently extracted with ethyl acetate (3x25 mL). 
The combined organic layer was dried over sodium sulfate and concentrated to 
afford a white solid pure product (323 mg, 72%).  
1H NMR (MeOH d4) δ: 3.88 (s, 2H), 1.47 (s, 9H). 
13C NMR (MeOH d4) δ: 172.29, 159.88, 156.84, 80.41, 40.85, 27.20. 







(c) Synthesis of 3-I-d: N-Boc-ethylenediamine (6 mg, 0.0375 mmol) was stirred with 
fluorescein isothiocyanate (FITC) (15 mg, 0.0375 mmol) and triethylamine (10 
µL, 0.0075 mmol) in DMF (1.5 mL). The reaction was allowed to proceed for 1 
hour and the product formation was confirmed by LC-MS. The reaction mixture 
was then purified using reverse phase HPLC using semi-prep column to obtain the 
Boc protected intermediate as an orange powder after lyophilization. Further, the 






















































dichloromethane:trifluoroacetic Acid (DCM/TFA: 400 µL/ 200 µL) on ice for 0.5 
hours. The solvent was then evaporated from the reaction mixture, and the 
product was purified via reverse phase HPLC using a semi-prep column to yield 
an orange powder after lyophilization. The product identity was confirmed by LC-
MS and NMR, which agrees with the data previously reported.47 
(d) Synthesis of 3-I-e: 3-I-c (6 mg, 0.024 mmol), 3-I-d (11 mg, 0.024 mmol) and 
HBTU (9 mg, 0.024 mmol) were dissolved together in DMF (500 µL). Then, N-
methylmorpholine (11 µL, 0.096 mmol) was added to the reaction mixture and 
stirred at room temperature for 3 hours. The reaction mixture was then acidified 
with 1N HCl (20 mL) and extracted with ethyl acetate (3 × 20 mL). The combined 
organic layers were dried over sodium sulfate and concentrated. Then, the crude 
product was purified via reverse phase HPLC to yield an orange powder after 
lyophilization. The identity and purity of FITC labeled Boc-semicarbazide (3-I-e) 
was confirmed by LC-MS analysis. 
MS-ESI+ (m/z): Calculated for C31H32N6O9S [M+H]
+ 665.20, observed 665.2044. 
(e) Synthesis of 3-I-f: 3-I-e (2 mg, 0.0030 mmol) was Boc-deprotected in 2:1 
Dichloromethane:Trifluoroacetic acid (200 µL/100 µL) on ice for 0.5 hours. The 
resulting crude mixture was then purified via reverse phase HPLC to yield an 
orange powder after lyophilization. The product purity and identity was 
confirmed by LC-MS.  
MS-ESI+ (m/z): Calculated for C26H24N6O7S [M+H]





Synthesis of Semicarbazide-NBD (3-II-c) 
 
(a) Synthesis of 3-II-a: Synthesis of 3-II-a was carried out following the previously 
reported protocol by Palomo et al.48 The method was slightly changed due to 
reagent availability and synthetic convenience. NBD-Cl (1 mmol, 200 mg) was 
dissolved in DCM (5 mL) and the solution was cooled in an ice bath under argon. 
Then, a solution of N-Boc ethylenediamine (1.1 mmol, 176 mg) and NMM (1.1 
mmol, 0.2 mL) in DCM (2 mL) was added slowly using a syringe. The reaction 
mixture was stirred for 2 hours at room temperature. The reaction progress was 
monitored by TLC. DCM was evaporated from the reaction mixture after 
completion and the residue was dissolved in ethyl acetate (100 mL). The organic 
layer was washed with 0.1 N HCl (2 × 70 mL). The organic layer was then 
washed with brine and dried over Na2SO4. The organic layer was evaporated 
under vacuum and the product was purified through silica gel using hexane/EOAc 
as eluent to yield an orange solid product. The product formation was confirmed 
by LC-MS. The intermediate compound was then subjected for Boc-deprotection 
using 4N HCl in dioxane (2 mL) for 1 hour at room temperature. Dioxane was 
evaporated from the reaction mixture and the oily residue was dissolved in 
EtOAC (1 mL) and 9 mL ether was added into the solution to precipitate out the 













































and mass spectrum suggested that the product was pure enough to use for the next 
step.    
1H NMR (Acetone-d6) δ 2.54 – 2.60 (quin, J = 6.2 Hz, 2H), 4.92 (b, 4H), 6.67– 
6.68 (d, J = 7.2 Hz, 1H), 8.54 – 8.56 (d, J = 8.4 Hz, 1H).  
13C NMR (DMSO-d6) δ: 150.02, 143.83, 132.95, 130.95, 129.23, 66.78, 37.69. 
MS-ESI+ (m/z): Calculated for C8H10N5O3 [M+H]+ 224.0784, observed 224.0786. 
(b) Synthesis of 3-II-b: 3-I-c (0.02 mmol, 6.2 mg), 3-II-a (0.021 mmol, 2.5 mg) and 
HBTU (0.02 mmol, 8 mg) were dissolved together in DMF (0.1 mL). NMM (0.1 
mmol, 9 µL) was the added to the reaction mixture, which was stirred for 3 hours 
at room temperature. The reaction mixture was then diluted with 30 mL ethyl 
acetate and washed with 1N HCl (2x20 mL), followed by 10% sodium carbonate 
solution in water (1x20 mL). The organic layer was then washed with brine (20 
mL) and dried over anhydrous Na2SO4. The organic layer was evaporated under 
reduced pressure to give a dark orange solid product, which was purified through 
silica gel using ethyl acetate/hexane to yield an orange solid product. The product 
identity was confirmed by LC-MS. 
MS-ESI+ (m/z): Calculated for C16H22N8O7 [M+H]
+ 461.15, observed 461.1491. 
(c) Synthesis of 3-II-c: 3-II-b (5mg) was dissolved in 0.5 mL of DCM:trifluoroacetic 
acid (1:1) and stirred for 30 minutes. Finally, the mixture was evaporated under 
reduced pressure, dissolved in 1 mL deionized water, and the product was purified 
via reverse phase HPLC using acetonitrile/water (1% TFA) mixture as eluent to 
get an orange yellow powder after lyophilization. The compound identity and 
purity were confirmed by LC-MS. 
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MS-ESI+ (m/z): Calculated for C11H14N8O5 [M+H]
+ 339.12, observed 339.1169. 
Synthesis of Phenylhydrazine-FITC (3-III-b) 
 
(a) Synthesis of 3-III-a: 4-(2'-N-Boc-hydrazino)benzoic acid (6 mg, 0.024 mmol), 3-
I-d (11 mg, 0.024 mmol) and HBTU (9 mg, 0.024 mmol) were dissolved together 
in DMF (500 µL). Then, N-Methylmorpholine (11 µL, 0.096 mmol) was added to 
the reaction mixture and stirred at room temperature for 3 hours. The reaction 
mixture was then acidified with 1N HCl (20 mL) and extracted with ethyl acetate 
(3 × 20 mL). The combined organic layers were dried over sodium sulfate and 
concentrated. Then the crude product was purified via reverse phase HPLC to 
yield an orange powder after lyophilization. The identity and purity of FITC 
labeled Boc-phenylhydrazine (3-III-a) was confirmed by LC-MS analysis. 
MS-ESI+ (m/z): Calculated for C35H33N5O8S [M+H]
+ 684.20, observed 684.2076. 
(b) Synthesis of 3-III-b: 3-III-a (2 mg, 0.0030 mmol) was Boc-deprotected in 2:1 
Dichloromethane:Trifluoroacetic Acid (200 µL/100 µL) on ice for 0.5 hours. The 
resulting crude mixture was then purified via reverse phase HPLC to yield an 
orange powder after lyohpilization. The product purity and identity was 
confirmed by LC-MS. 
MS-ESI+ (m/z): Calculated for C30H25N5O6S [M+H]
































3.6.3 Stability of Phenylhydrazine and Semicarbazide in Neutral Buffer 
100 µM solutions of the FITC derivatives of phenylhydrazine and semicarbazide 
were prepared in PBS (1X, pH 7.4). The stability of the reagents was monitored by 
analytical HPLC over time. Additionally, the stability of unlabeled phenylhydrazine and 
semicarbazide were examined via 1H NMR.  A 1 mM solution of each was prepared in 
PBS (1X, pH 7.4). Aliquots were taken at 0, 24, 48 and 240 hours, and conjugated to an 
equimolar concentration of 2-APBA for 10 minutes at room temperature. Then the NMR 
spectra were recorded in the presence of 10% D2O 
3.6.4 NMR and LC-MS Analysis of DAB1 and DAB2 Formation 
NMR analysis of the conjugation reactions was performed in PBS buffer (1X, pH 
7.4) in the presence of 10% D2O. 300 µM of 2-FPBA or 2-APBA was mixed with 300 
µM of semicarbazide and incubated at room temperature for 10 min. NMR analysis 
revealed complete conjugation with 2-FPBA and ~90% product formation with 2-APBA. 
The reaction mixtures were further analyzed with LC-MS, which confirmed clean 
conversion without any formation of side product. 
3.6.5 Assessing the Hydrolytic Stability of DAB1 and DAB2 
Semicarbazide (6 mg, 0.5 mmol) was dissolved in 1 mL PBS buffer (1X, pH 7.4) and 
then mixed with 2-FPBA (7.5 mg, 0.5 mmol) or 2-APBA (8.2 mg, 0.5 mmol) dissolved 
in 1 mL PBS:MeOH (1:4). The reaction mixture was vortexed for 2 min, during which 
the product precipitated out as a white solid. The product was isolated after centrifugation 
and then washed with water (2 × 0.5 mL) to yield essentially pure DAB1 and DAB2. The 
product identity was confirmed by LC-MS and NMR: 
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• DAB1: Isolated yield (91%), 1H-NMR (1 ×PBS pH 7.4, 10% D2O): 7.56-7.55 (d, 
J = 8.3, 1H), 7.40 (s, 1H), 7.35-7.32 (t, J = 7.9), 7.28-7.23 (m, 2H).   
• DAB2: Isolated yield (90%), 1H-NMR (1 ×PBS pH 7.4, 10% D2O): 7.60-7.59 (d, 
J = 7.6, 1H), 7.49-7.48 (d, J = 7.8, 1H), 7.38-7.35 (t, J = 8.2, 1H), 7.32-7.29 (t, J 
= 8.0, 1H).   
100 µM DAB1 and DAB2 solutions were prepared in PBS (2X, pH 7.4) with 50% D2O. 
The final pH was again tuned to 7.4 using 0.1N HCl and 0.1 N NaOH. NMR spectra were 
recorded over time (160 scans with line broadening value of 0.3) to assess their 
hydrolytic stability. The aromatic signatures of DAB1 and DAB2 were compared to their 
parent compounds, 2-FPBA and 2-APBA, to assess the stability. 
3.6.6 Assessing the Efficiency of Semicarbazide Ligation 
The efficiency of semicarbazide in diazaborine formation was initially determined 
through LC-MS analysis. 2-FPBA and semicarbazide were mixed in PBS buffer (2X, pH 
7.4, 10 µM final concentration for both reactants). LC-MS analysis was performed after 
10 minutes of incubation. The efficiency of 2-APBA conjugation with semicarbazide was 
analyzed through both LC-MS and NMR. For NMR analysis, mixtures of 2-APBA (50 
µM) and semicarbazide (50, 100, 150, 250, 400 µM) in PBS (2X, 7.4) with 50% D2O 
were incubated for 10 minutes. Then, the NMR spectra were. Percentage of product 
formation was calculated using the ratio of the integrated area between the acetyl -CH3 
peak of 2-APBA and the acetyl –CH3 peak of the ligated product (diazaborine). For LC-




3.6.7 Probing the Source of Sub-Quantitative DAB2 Formation 
To examine the origin of the sub-quantitative yield of DAB2 formation, 1 mM of 
L-AB3, an unnatural amino acid bearing a 2-APBA motif on its side chain, was 
conjugated to an equimolar concentration of semicarbazide in 1X PBS buffer (pH 7.4). 
After incubating for 5 minutes, either 1 mM excess of L-AB3 or semicarbazide was 
added to the conjugate in 1X PBS buffer (pH 7.4). 1H NMR spectra were obtained in 
10% D2O using water suppression PRESAT parameter, 160 scans, and line broadening 
value of 0.5. 
3.6.8 Kinetics of DAB1 and DAB2 Formation 
The kinetics of the conjugation reaction between semicarbazide and 2-FPBA were 
studied by recording UV-vis absorption with a Nanodrop UV-vis spectrometer. The data 
were collected after blank subtraction using PBS buffer (1X, 7.4). The reaction was 
performed in a quartz cuvette (10 mm path length; total volume ~ 2 mL) at room 
temperature. 1 mL PBS buffer was pipetted into the cuvette, followed by addition of 1 µL 
of 2-FPBA stock (10 mM in PBS), and then the spectrum of 2-FPBA was recorded. 
Subsequently, 1 µL of the semicarbazide stock (10 mM in PBS) was added into the 2-
FPBA solution in the cuvette. After quick mixing (~ 5 sec), UV-vis spectra of the 
reaction mixture were collected on 10 second intervals. A quick shift of the absorption 
maxima from ~254 nm to ~ 290 nm was observed upon DAB1 formation. The 
experiment was repeated three times and consistent results were obtained. The kinetic 
data were fitted according to a second order mechanism with the two reactants at equal 
concentrations. Kinetics of DAB2 formation were examined via UV-vis by mixing 20 
µM of 2-APBA and 50 µM of semicarbazide, which gave 60% product formation 
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according to NMR results. The change of the absorption maxima at ~290 nm was 
collected on 4 second intervals. The experiment was repeated three times and consistent 
results were obtained. The kinetic data were fitted according to the equations shown 
below to obtain the rate constant. All kinetic data were plotted with Origin 8.  
Kinetics of DAB1 Formation 
!"
!"
= 𝑘!(𝐶! − 𝑃)(𝐶! − 𝑃) (1) 
in which P is the product concentration, C0 is the starting material concentration, which is 
10 µM for both reactants, and k2 is the rate constant. 
!(!!!!)
!"
= −𝑘!(𝐶! − 𝑃)! (2) 
!(!!!!)
(!!!!)!
= −𝑘!𝑑𝑡  (3) 





 = 𝑘!𝑡  (4) 
Solving the equation for P gives: 
𝑃 =  !!!
!! !!!!!
    (5) 
Fitting the Kinetic Data to a Hyperbolic Equation: 
𝑦 = !!!
!!!!
    (6) 







  (7) 
Kinetics of DAB2 Formation 
!"
!"
= 𝑘!(𝐶! − 𝑃)(𝐶! − 𝑃)  (1) 
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in which P is the product concentration and C1 and C2 are the initial starting materials’ 
concentration respectively (C1=20 µM and C2=50 µM). Given that C2 is significantly 
larger than C1, to simplify kinetics fitting, the reaction is treated as a pseudo-first order 
reaction. C2 is set to 40 µM (C2*), which falls in between the initial and ending 
concentrations of semicarbazde. We acknowledge this treatment may introduce some 
error; however, if we do not carry out the approximation, the order of magnitude of the 
rate constant will be affected. 
!"
!"
= 𝑘!𝐶!∗(𝐶! − 𝑃)   (2) 
!"
!!!!
= 𝑘!𝐶!∗𝑑𝑡   (3) 
!(!!!!)
!!!!
= −𝑘!𝐶!∗𝑑𝑡   (4) 
𝑙𝑛 !!!!
!!!
= −𝑘!𝐶!∗𝑡   (5) 
𝑃 = 𝐶! − 𝐶!exp (−𝑘!𝐶!∗𝑡) (6) 
Fitting the kinetic data according to the equation gives the k2 value. 
3.6.9 Assessing the Biocompatibility of Semicarbazide Ligation 
Reversibility of 2-APBA and Cysteine Conjugation 
2-APBA and L-cysteine were mixed in 1 mL PBS (1X, pH 7.4, 1 mL) in 10% 
D2O at a final concentration of 2 mM each and the mixture was incubated for 30 min at 
room temperature. Formation of thiozolidinoboronate (~ 80% completion) was analyzed 
using NMR by identifying the chemical shift of the acetyl –CH3 group. Then the mixture 
was diluted 10x and the NMR spectrum was taken immediately. The results showed 20% 
of the product remaining and the rest of product was hydrolyzed back to the starting 
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material. The experiment clearly establishes the quick equilibrium between the 
thiazolidinoboronate conjugate and reactants (2-APBA and cysteine).  
Inhibitory Effect of Cysteine to Semicarbazide Ligation 
A mixture of 2-FPBA (or 2-APBA) and L-cysteine was prepared at 200 µM (1 
mL) in PBS (1X, pH 7.4) in 10% D2O. The mixture was incubated for 30 min at room 
temperature. Then, 10 µL semicarbazide stock (20 mM in 1X PBS, pH 7.4) was added to 
the mixture, which was monitored by LC-MS analysis.  
Inhibitory Effect of Bacterial Cell Lysate to Semicarbazide Ligation 
The inhibitory effect of cell lysate in semicarbazide ligation was examined using 
HPLC analysis. To assess the extent of inhibition, control experiments were first 
performed in 1X PBS buffer (pH 7.4).  25 µM 2-FPBA and 2-APBA were separately 
incubated with 50 µM semicarbazide-NBD (Scz-NBD) in 1X PBS buffer (pH 7.4) for 30 
min, and then the mixtures were analyzed using HPLC. Product formation was confirmed 
by LC-MS.  
For S. aureus cell lysate, 5 mL of S. aureus culture in LB-broth was spun down 
and the pellet was washed with 5 mL PBS buffer (1X, pH 7.4). The pellet (~ 50 mg) was 
then lysed by the addition of 1 mL of B-per (Thermo Scientific) following the suggested 
protocol (https://www.thermofisher.com/order/catalog/product/78248). Then the clear 
supernatant was collected to give a 5 mg/mL cell lysate, as determined by standard 
Bradford assay. Then 475 µL cell lysate was mixed with 1.25 µL 2-FPBA or 2-APBA 
stock (10 mM in 1X PBS, pH 7.4). The mixture was incubated for 10 min at room 
temperature, and then mixed with 25 µL of Scz-NBD stock (1 mM in 1X PBS, pH 7.4). 
The final mixture was incubated for 30 min at room temperature and analyzed using 
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HPLC. Scz-NBD ligation to 2-FPBA in the presence of cell lysate was further analyzed 
over time by incubation at room temperature. The chromatograms were blank subtracted 
and plotted with Origin 8. 
Inhibitory Effect of FBS to Semicarbazide Ligation 
The inhibitory effect of FBS on semicarbazide ligation was studied using HPLC 
analysis. To assess the extent of inhibition, a mixture of 20% FBS and 25 µM 2-FPBA or 
2-APBA was prepared in PBS (1X, pH 7.4). Then the mixture was incubated with 50 µM 
Scz-NBD for 30 min at room temperature. The mixtures were analyzed using HPLC. The 
chromatograms were blank subtracted and plotted with Origin 8.  
Inhibitory Effect of HEK293T Cell Lysate to Semicarbazide Ligation 
The inhibitory effect of HEK 293T lysate on semicarbazide ligation was studied 
using HPLC analysis. To assess the extent of inhibition, a mixture of 5 mg/mL HEK 
293T lysate and 25 µM 2-FPBA or 2-APBA was prepared in PBS (1X, pH 7.4). Then the 
mixture was incubated with 50 µM Scz-NBD for 30 min at room temperature. The 
mixtures were analyzed using HPLC. The chromatograms were blank subtracted and 
plotted with Origin 8.  
Stability of semicarbazide ligation reagents in FBS and HEK 293T cell lysate 
To assess the stability of 2-APBA, 2-FPBA and Scz-FITC in the presence of FBS 
and HEK 293T cell lysates, 100 µM 2-APBA or 2-FPBA (500 µM stock in 1X PBS, pH 
7.4), or 50 µM Scz-FITC (4.87 mM stock in 1X PBS (pH 7.4, 1% DMSO) were 
incubated in either 20% (w/v) FBS (200µL) or 5% (w/v) HEK 293T cell lysate (200 µL, 
5 mg/mL) prepared in PBS for 0 or 17 hours at RT. Then, each was mixed with either 50 
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µM Scz-FITC or 100 µM 2-APBA. The conjugation reaction was first confirmed by LC-
MS analysis, then monitored by analytical HPLC. 
HEK 293T cell lysate labeling via in gel fluorescence 
HEK 293T soluble protein lysates (50 µL, 2 mg/mL) were treated with Scz-FITC 
(50 µM, 3 mM stock in 1X PBS Buffer (pH  7.4, 1% DMSO) or fluorescein (50 µM, 3 
mM stock in 1X PBS Buffer, pH  7.4, 1% DMSO) at room temperature for 0.5 hr. A 
sample containing 50 µM Scz-FITC (3 mM stock in 1X PBS Buffer, pH  7.4, 1% DMSO) 
incubated at room temperature for 0.5 hr was included as a control for non-specific 
interactions with the SDS-PAGE gel. SDS-PAGE loading buffer (2X, reducing, 50 µL) 
was added to the samples, and 25 µL of each sample was separated by SDS-PAGE at 
100V for 120 minutes on a 10% polyacrylamide gel. Gels were visualized on a Hitachi 
FMBO II multiview flatbed laser-induced fluorescent scanner. HEK 293T protein lysates 
were then visualized by standard Coomassie staining and destaining protocols via a 
Stratgene Eagle Eye apparatus by COHU high performance CCD camera.  
Evaluating bacteria cell killing by semicarbazide, phenylhydrazine and D-AB3 
S. aureus and E. coli were grown from a single colony overnight in LB broth via 
incubation at 37oC with agitation. A small aliquot was then taken and diluted (1:100) in 
fresh broth and cultured for another ~2.5 hours until the cells reached the beginning of 
logarithmic phase (OD600~0.3). Then, the bacteria were serially diluted to a pre-
determined factor (105 for S. aureus and 3x106 for E. coli) to allow for accurate colony 
counting. Semicarbazide (1 mM stock), phenylhydrazine (1 mM stock) and D-AB3 (12.5 
mM stock) were then added to triplicate aliquots of the bacteria dilution to reach a final 
concentration of 50 µM, 50 µM and 125 µM, respectively. The aliquots were incubated at 
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37oC for 1 hour with agitation. Then, 100 µL of the aliquots were spread on LB agar 
plates, and the plates were allowed to incubate at 37oC overnight. Individual colonies 
were counted on each plate and the average and standard deviation for triplicate plating 
were obtained. 
MTT cytotoxicity assay  
HEK 293T cells (grown in complete DMEM media with 10% fetal bovine serum, 
2 mM glutamine, and 1% Pen/Strep) were grown to about 80% confluency before 
removal from the surface of a 20 cm petri-dish with 25% Trypsin with EDTA (5 minutes, 
37oC, 5% CO2). Cells were pelleted (3,500 rpm, 5 minutes, 4oC), diluted in 10 mL fresh 
complete DMEM media to generate aliquots of 30,000 cells per well (100 µL), then 
incubated for 24 hours before addition of semicarbazide (50 µM), phenylhydrazine (50 
µM), D-AB3 (125 µM) or camptothecin (50 µM). Stock solutions of semicarbazide and 
phenylhydrazine were prepared fresh in DMSO, and diluted to the working concentration 
as listed above in DMEM so that the total volume of DMSO added was kept constant at 
1% (v/v). For each reagent, samples were set up as three replicates with two timepoints (6 
and 24 hours). Control wells were loaded with 1 µL DMSO or 1 µL of camptothecin (5 
mM stock in DMSO for a final concentration of 50 µM, used as positive control for 
cytotoxicity). After incubation for 6 or 24 hours, cells were washed once with 1X PBS 
(pH 7.4) before being incubated for 4 hours with 110 µL of 12 mM 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dissolved in RPMI 
media. The MTT assay was quenched with 100 µL of 10% SDS in 0.01 M HCl and 
allowed to incubate overnight before absorbance at 570 nm was recorded with a 
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SpectraMax M5 plate reader (Molecular Devices). The results of the averages and 
standard deviations of the wells determined after normalization to the DMSO control. 
3.6.10 Bacterial Cell Culture and Labeling Experiments for D-AB3 
For each strain, bacterial cells from a single colony were grown overnight in LB 
broth at 37 oC with agitation. An aliquot was taken and diluted (1:100) in fresh broth and 
cultured for another ~ 2.5 hours until the cells reached the beginning of logarithmic phase 
(OD600 ~ 0.3). Then, the unnatural D-amino acids (4 mM stock in 1X PBS, 7.4) were 
added to the bacterial cell cultures (final concentration 0-125 µM) and the cultures were 
allowed to continue growth before 1 mL aliquots were taken at 0.5, 2, 4 and 6 hour time 
points. The aliquots were spun down at 5000 rcf, washed once with 1 mL PBS (1X, pH 
7.4), spun down again, and the cell pellet was then incubated with 100 µL of 50 µM 
semicarbazide-FITC (Scz-FITC) at 37 oC for 30 minutes. The cells were then spun down 
and washed twice with PBS (1X, pH 7.4) before the final dilution of the cells in PBS for 
microscopic or flow cytometry analysis (~1 × 106 cells).  
  For bacteria labeling in the presence of 10% FBS and mammalian cell lysate, 
overnight cultured bacteria were diluted (1:100) and grown to OD600 ~ 0.3 in LB broth. 
60 µM D-AB3 was added to the cultures which were continued to grow until OD600 ~ 1. 
Then cells were spun down at 5000 rcf, washed once with 1 mL PBS (1X, pH 7.4) and 
resuspended in either 10% FBS (95 µL) or 5 mg/mL HEK 293T cell lysate (95 µL) for 10 
min. Additionally, 5 µL (1 mM stock) of Scz-FITC solution in PBS (1X, pH 7.4) was 
added to the mixture, which was then incubated at 37 oC for 30 minutes. The cells were 
spun down and washed twice with 1X PBS (pH 7.4) before a final dilution in phosphate 
buffer for microscopic or flow cytometry analysis (~1 × 106 cells). 
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3.6.11 Bacterial Co-Culture Preparation for D-AB3 
For the co-culture staining experiment, E. coli (500 µL) and S. aureus (500 µL) 
were separately diluted (1:100) from overnight culture, and then treated with D-AB3 (25 
µM).  The cultures were then grown until OD600 ~1.0, spun down at 5000 rcf, washed 
once with PBS buffer (1X, pH 7.4, 1 mL), and resuspended in PBS (1X, pH 7.4, 1 mL). 
Then the bacteria were mixed together in a new microcentrifuge tube, combining 500 µL 
of each of the resuspended cells, which was then spun down at 5000 rcf. The combined 
cell pellet was treated with 100 µL semicarbazide-FITC (50 µM), and was incubated at 
37 oC for 30 minutes. Cells were then spun down and washed twice with PBS buffer (1X, 
pH 7.4), before a final dilution of the cells in 100 µL PBS buffer (1X, pH 7.4) for 
microscopic analysis. 
3.6.12 Microscopic Analysis of D-AB3 Labeled Bacteria  
For epi-fluorescence microscopy, 2 µL of the bacterial cell suspension was placed 
on a glass slide (Fisherfinest premium, 75 × 25 × 1 mm3). A coverslip (Fisherbrand, 22 × 
22 × 0.15 mm3) was pressed down on the cell droplet to give a single layer of cells on the 
glass slides. White light and fluorescence images were taken on a Zeiss Axio Observer 
A1 inverted microscope equipped with a filter cube (488 nm excitation, 515-520 nm 
emission) suitable for detection of FITC fluorescence. A Plan-NeoFluar × 100 oil 
objective from Zeiss was used to visualize the bacterial cells. All images were captured 
with the exposure time of 1000 ms for all D-AB3 concentrations and time points. All 
fluorescence images were processed following a fixed protocol with the software Fiji 
ImageJ. 
	 137 
For confocal analysis, 2 µL of cells were placed on a glass slide and a coverslip 
was placed on top. Images were taken on a Leica SP5 confocal fluorescence microscope 
with filters that allowed the detection of FITC (492 nm excitation, 518 emission). A × 63 
oil objective was used with an Argon laser at 10% laser power. Gain was adjusted to 
between 900 HV and 1,100 HV with an offset of -0.5%. The images were captured with 
the software LAS 2.6 and then processed with Fiji ImageJ. 
3.6.13 Bacterial Flow Cytometry Analysis for D-AB3 Labeled Bacteria 
The samples were prepared and stained following the same protocol described for 
microscopy. 300 µL aliquots were filtered through a 35 µm filter (Nalgene) before 
analysis. The samples were analyzed on a BD FACSAria cell sorter (BS Biosciences). 
Data analysis was performed with FlowJo (Tree Star, Inc.), from which the median 
fluorescence intensities of the stained cells were extracted. 
3.6.14 Extraction of HEK293T Cell Lysates 
HEK 293T cells were grown at 37°C under 5% CO2 atmosphere in DMEM media 
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine and 1% Pen/Strep. 
The plates were allowed to grow to ~100% confluency, then the cells were harvested by 
scraping. The cells were washed 3 times with PBS and resuspended in PBS (1X, pH 7.4, 
600 µL). Cells were then sonicated for lysis to form whole cell lysates, which were 
centrifuged at 4°C for 30 minutes (45,000 rpm). The supernatant was collected as the 
soluble fraction and the pellet was discarded. The protein concentration of the 




3.6.15 X-Ray Crystallographic Data for DAB1 and DAB3 
DAB1: DAB1 (5 mg) was dissolved in 2 mL of EtOH:water (1:1) mixture. The solution 
was then subjected to slow evaporation in a 5 mL glass test tube. After a week, very thin 
fiber shaped crystal growth was observed. The crystals were carefully taken out by 
spatula, and placed on glass slide in a drop of glycerol and a single crystal was selected 
under a Leica MDG-30 microscope. The details of structure analysis and parameters are 
shown below in Table S1 and CIF can be found in The Cambridge Crystallographic Data 
Centre (CCDC, 1478626).   
Table S1.  Crystal data and structure refinement for C8H8BN3O2. 
Identification code  C8H8BN3O2 
Empirical formula  C8H8BN3O2                                                                                               
Formula weight  188.98 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 6.7872(3) Å a= 90°. 
 b = 11.6855(5) Å b= 102.759(2)°. 
 c = 10.8557(5) Å g = 90°. 
Volume 839.73(6) Å3 
Z 4 
Density (calculated) 1.495 Mg/m3 
Absorption coefficient 0.902 mm-1 
F(000) 392 
Crystal size 0.370 x 0.080 x 0.060 mm3 
Theta range for data collection 5.638 to 69.967°. 
Index ranges -8<=h<=8, -14<=k<=14, -13<=l<=12 
Reflections collected 7508 
Independent reflections 1570 [R(int) = 0.0236] 
Completeness to theta = 67.679° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7533 and 0.6605 
Refinement method Full-matrix least-squares on F2 
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Data / restraints / parameters 1570 / 3 / 136 
Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.0328, wR2 = 0.0930 
R indices (all data) R1 = 0.0337, wR2 = 0.0943 
Extinction coefficient na 
Largest diff. peak and hole 0.267 and -0.202 e.Å-3 
 
Boc-AB3-OtBu-semicarbazide (DAB3): Boc-AB3(pin)-OtBu (25 mg) was dissolved in 
ethanol (1 mL) and was mixed with semicarbazide solution (5 mg in 1 mL PBS, pH 7.4). 
Immediate white precipitation was observed from the reaction mixture, which was 
isolated by centrifugation. The product was washed twice with water (2 × 1 mL) and 
finally with 1:1 MeOH/Water mixture (1 mL). The white powder product was lyophilized 
to dryness and then 5 mg of the product was dissolved in 2 mL of MeOH:water (1:1) 
mixture. The solution was then subjected to slow evaporation in a 5 mL glass test tube. 
After a week, very thin fiber shaped crystal growth was observed. The crystals were 
carefully taken out by spatula and placed on glass slide in a drop of glycerol, and a single 
crystal was selected under a Leica MDG-30 microscope. The details of structure analysis 
and parameters are shown below in Table S2 and CIF can be found in The Cambridge 
Crystallographic Data Centre (CCDC, 1478627).  
  
 
Table S2.  Crystal data and structure refinement for C21H31BN4O6 
Identification code  C21H31BN4O6 
Empirical formula  C21.38 H32.50 B N4 O6.38 
Formula weight  458.32 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 11.1773(5) Å a= 100.992(4)°. 
 b = 12.6727(6) Å b= 97.611(4)°. 
 c = 18.2164(11) Å g = 91.693(3)°. 
Volume 2506.7(2) Å3 
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Z 4 
Density (calculated) 1.214 Mg/m3 
Absorption coefficient 0.736 mm-1 
F(000) 979 
Crystal size 0.300 x 0.050 x 0.030 mm3 
Theta range for data collection 2.496 to 67.150°. 
Index ranges -13<=h<=13, -12<=k<=14, -21<=l<=21 
Reflections collected 8844 
Independent reflections 8844 [R(int) = 0.0836] 
Completeness to theta = 67.150° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5078 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8844 / 1005 / 1222 
Goodness-of-fit on F2 0.976 
Final R indices [I>2sigma(I)] R1 = 0.0905, wR2 = 0.2294 
R indices (all data) R1 = 0.1250, wR2 = 0.2604 
Absolute structure parameter 0.1(4) 
Extinction coefficient n/a 









3.6.16 Synthesis of APBA Coumarin Analogues 
Synthesis of AB21 (3-VI-c) 
 
(a) Synthesis of 3-VI-a: 3-VI-b (100 mg, 0.274 mmol) was dissolved in anhydrous 
dichloromethane (1 mL) and triethylamine (160 µL, 1.15 mmol) was added while 
stirring. The reaction mixture was cooled to -78 oC and trifluoromethane sulfonic 
anhydride (102 µL, 0.6 mmol) was added slowly. The reaction mixture was 
allowed to stir at room temperature for 0.5 hr under an argon environment. After 
that, the reaction was quenched with saturated sodium bicarbonate (1 mL) and the 
mixture was allowed to stir for 5 min. The product was extracted with 
dichloromethane (3x20 mL). The combined organic layer was washed with brine 
(30 mL) and dried over Na2SO4. After removing the solvent, the crude product 
was purified on silica gel column using ethyl acetate:hexane (1:4) as eluent to 
yield a dark red gummy product (126 mg, 93%). 
1H NMR (CDCl3): δ, 7.87-7.86, (d, J = 7.1, 1H), 7.49-7.47 (m, 2H), 7.29 (d, J = 
4.2, 1H), 6.63 (d, J = 7.2, 1H), 6.53 (d, J = 3.8, 1H) 3.46-3.42 (q, J = 6.8, 4H), 
2.67 (s, 3H), 2.27 (s, 3H), 1.23-1.21 (t, J = 6.5, 6H). 
13C NMR (CDCl3): δ 196.28, 161.14, 155.36, 150.93, 149.76, 146.42, 141.71, 
131.07, 130.52, 126.43, 125.20, 117.66, 108.98, 97.33, 60.36, 44.81, 29.47, 16.30, 
12.43. 





















(b) Synthesis of 3-IV-b: 3-IV-a (100 mg, 0.2 mmol), B2Pin2 (126 mg, 0.5 mmol), 
Pd(dppf)Cl2 (18 mg, 0. 020 mmol, 10 mol %),  and potassium acetate (60 mg, 0.6 
mmol) were was dissolved in anhydrous dioxane (1.2 mL). The reaction mixture 
was bubbled with argon for 10 minutes and it was allowed to stir at 95 oC for 50 
minutes. Completion of the reaction was monitored by LC-MS. Then water (30 
mL) was added to the reaction and the product was extracted with ethyl acetate (3 
× 30 mL). The combined organic layer was washed with brine (100 mL) and dried 
over Na2SO4. The solvent was removed under vacuum and the crude product was 
purified on silica gel using hexane:diethylether (11:9) as eluent. The desired 
product was obtained as a yellow gummy (68 mg, 72%). 
1H NMR (CDCl3): δ 7.88-7.86 (d, J = 7.2, 1H), 7.43-7.41 (d, J = 6.5, 1H), 7.41-
7.40 (m, 2H), 6.62-6.60 (dd, J = 7.1, J = 3.9, 1H), 6.53 (d, J = 3.8, 1H), 3.45-3.42 
(q, J = 6.7, 4H), 2.61 (s, 3H), 2.20 (s, 3H), 1.46 (s, 12H), 1.22-1.20 (t, J = 6.4, 
6H). 
13C NMR (CDCl3): δ 199.52, 161.36, 155.23, 150.42, 148.73, 139.83, 134.59, 
131.26, 128.24, 126.13, 120.11, 109.29, 108.61, 97.44, 83.67, 77.00, 44.74, 30.30, 
25.70, 24.86, 16.38, 12.45. 
MS-ESI+ (m/z): Calculated for C28H33BNO4 [M-H2O]+ 457.2424, found 
457.2443. 
(c) Synthesis of 3-IV-c: 3-IV-b (60 mg, 0.126 mmol) was dissolved in anhydrous 
THF (500 µL) and diethanolamine (150 mg, 1.25 mmol) was added into the 
solution at room temperature. The reaction was allowed to stir for 3 hours and 
then quenched with 1N HCl (30 mL). The solution was then neutralized using 
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NaHCO3 (5%) solution in water. Then the product solution was directly purified 
by HPLC. The HPLC purification with acetonitrile/water (0.1% TFA) eluent, 
which yielded the pure product as a yellow powder after lyophilization (72%, 35 
mg). 
1H NMR (Methanol-d4): δ 8.11-8.10 (d, J = 6.2, 1H), 7.63-7.61 (d, J = 7.2, 1H), 
7.46-7.45 (d, J = 6.4, 1H), 7.33 (s, 1H), 6.80 (dd, J = 5.7, J = 3.4, 1H), 6.58-6.57 
(d, J = 4.9, 1H), 3.51-3.48 (q, J = 7.1, 4H), 2.68 (s, 3H), 2.25 (s, 3H), 1.23-1.21 (t, 
J = 6.3, 6H). 
13C NMR (Methanol-d4): δ 200.98, 162.27, 155.07, 150.72, 150.20, 140.66, 
138.60, 132.75, 130.77, 128.66, 119.16, 109.21, 96.70, 84.64, 78.76, 44.36, 23.68, 
15.13, 11.30. 
MS-ESI+ (m/z): Calculated for C22H25BNO5 [M+H]+ 394.1826, found 394.1843. 
 
Synthesis of AB22 (3-V-d) 
 
(a) Synthesis of 3-V-a: 5-bromo-2-hydroxy acetophenone (215 mg, 1 mmol), B2Pin2 
(280 mg, 1.1 mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol, 3 mol %) and potassium 





























reaction mixture was bubbled with argon for 10 minutes and it was allowed to stir 
at 90 oC for 90 minutes. Completion of the reaction was monitored by LC-MS. 
The reaction mixture was cooled to room temperature, and then 3-VI-a (216 mg, 
0.7 mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol, 3 mol %), K3PO4 (445 mg, 2.1 
mmol) and water (1mL) were added subsequently in the same pot. Further, 
reaction mixture was heated to 85 oC for overnight. The reaction mixture was 
filtered through sintered funnel and digested in water (100 mL). The product was 
extracted with ethyl acetate (3x100 mL). The combined organic layer was washed 
with brine (100 mL) and dried over Na2SO4. The solvent was removed under 
vacuum and the crude product was purified on silica gel using hexane:ethyl 
acetate (4:1) as eluent. The desired product was obtained as a yellow solid (182 
mg, 67%). 
1H NMR (CDCl3): δ 12.31 (s, 1H), 7.71 (b, 1H), 7.46-7.45 (d, J = 6.9, 1H), 7.40-
7.39 (d, J = 7, 1H), 7.04-7.03 (d, J = 6.9, 1H), 6.63-6.62 (dd, J = 7.0, J = 4, 1H), 
6.55 (d, J = 4, 1H), 3.45-3.42 (q, J = 6.8, 4H), 2.63 (s, 3H), 2.26 (s, 3H), 1.24-
1.21 (t, J = 7.5, 6H). 
13C NMR (CDCl3): δ 204.51, 162.19, 161.77, 155.07, 150.38, 148.68, 138.80, 
132.88, 126.12, 125.91, 119.53, 118.30, 109.32, 108.70, 97.44, 77.21, 77.00, 
76.79, 44.76, 26.69, 16.39, 15.26, 12.45. 
MS-ESI+: m/z calculated for C22H23NO4 [M+H]+ 366.1707, found 366.1723. 
(b) Synthesis of 3-V-b: 3-V-a (100 mg, 0.274 mmol) was dissolved in anhydrous 
dichloromethane (1 mL) and triethylamine (160 µL, 1.15 mmol) was added while 
stirring. The reaction mixture was cooled to -78 oC and trifluoromethane sulfonic 
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anhydride (102 µL, 0.6 mmol) was added slowly during 5 min. The reaction 
mixture was allowed to stir at room temperature for 0.5 hr under an argon 
environment. After that, the reaction was quenched with saturated sodium 
bicarbonate (1 mL) and the mixture was allowed to stir for 5 min. The product 
was extracted with dichloromethane (3x20 mL). The combined organic layer was 
washed with brine (30 mL) and dried over Na2SO4. After removing the solvent, 
the crude product was purified on silica gel column using ethyl acetate:hexane 
(1:4) as eluent to yield a dark red gummy product (120 mg, 91%). 
1H NMR (CDCl3): δ, 7.76, (d, J = 5.9, 1H), 7.55-7.53 (dd, J = 6.4, J = 3.7, 1H), 
7.48-7.47 (d, J = 6.5, 1H), 6.65-6.63 (dd, J = 6.7, J = 3.8, 1H), 6.55-6.54 (d, J = 
6.3, 1H), 3.46-3.42 (q, J = 6.8, 4H), 2.65 (s, 3H), 2.25 (s, 3H), 1.24-1.22 (t, J = 
6.3, 6H). 
13C NMR (CDCl3): δ 196.50, 155.28, 150.80, 149.52, 145.89, 133.25, 126.35, 
122.48, 119.67, 117.95, 117.54, 108.91, 97.36, 44.80, 29.55, 16.47, 12.43. 
MS-ESI+ (m/z): Calculated for C23H22F3NO6S [M+H]+ 498.1196, found 497.1182. 
(c) Synthesis of 3-V-c: 3-V-b (100 mg, 0.2 mmol), B2Pin2 (126 mg, 0.5 mmol), 
Pd(dppf)Cl2 (18 mg, 0. 020 mmol, 10 mol %),  and potassium acetate (60 mg, 0.6 
mmol) were was dissolved in anhydrous dioxane (1.2 mL). The reaction mixture 
was bubbled with argon for 10 minutes and it was allowed to stir at 95 oC for 50 
minutes. Completion of the reaction was monitored by LC-MS. Then water (30 
mL) was added to the reaction and the product was extracted with ethyl acetate 
(3x30 mL). The combined organic layer was washed with brine (100 mL) and 
dried over Na2SO4. The solvent was removed under vacuum and the crude 
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product was purified on silica gel using hexane:diethylether (11:9) as eluent. The 
desired product was obtained as a yellow gummy (62 mg, 70%). 
1H NMR (CDCl3): δ 7.78 (b, 1H), 7.58-7.57 (d, J = 6.8, 1H), 7.47-7.43 (m, 2H), 
6.63-6.61 (dd, J = 7.3, J = 3.7, 1H), 6.54 (d, J = 3.5, 1H), 3.45-3.41 (q, J = 6.6, 
4H), 2.60 (s, 3H), 2.18 (s, 3H), 1.44 (s, 12H), 1.22-1.21 (t, J = 5.9, 6H). 
13C NMR (CDCl3): δ 199.72, 161.64, 155.20, 150.42, 148.76, 140.82, 136.24, 
134.56, 132.18, 130.73, 126.13, 125.48, 119.94, 109.27, 108.65, 97.43, 44.74, 
30.30, 24.87, 16.21, 12.46. 
MS-ESI+ (m/z): Calculated for C26H34BNO5 [M-H2O]+ 457.2424, found 457.2415. 
(d) Synthesis of 3-V-d: 3-V-c (50 mg, 0.105 mmol) was dissolved in anhydrous THF 
(500 µL) and diethanolamine (150 mg, 1.25 mmol) was added into the solution at 
room temperature. The reaction was allowed to stir for 3 hours and then quenched 
with 1N HCl (30 mL). Further, the solution was neutralized using NaHCO3 (5%) 
solution in water. Then the product solution was directly purified through HPLC. 
The HPLC purification with acetonitrile/water (0.1% TFA) (Gradient: 5% ACN 
to 95% ACN during 50 min) mixture yielded the pure product as a yellow powder 
after lyophilization (74%, 28 mg). 
1H NMR (Methanol-d4): δ 7.98 (b, 1H), 7.66-7.64 (d, J = 7.8, 1H), 7.56-7.55 (d, J 
= 6.7, 1H), 7.50-7.49 (d, J = 6.9, 1H),  6.84-6.82 (d, J = 7.8, 1H), 6.63 (b, 1H), 
3.53-3.50 (q, J =7, 4H), 2.65 (s, 3H), 2.28 (s, 3H), 1.24-1.21 (t, J = 6.9, 6H). 
13C NMR (Methanol-d4): δ 203.88, 165.25, 161.81, 161.55, 157.64, 152.97, 
142.37, 138.50, 137.87, 133.78, 132.94, 129.16, 121.94, 112.26, 99.89, 47.35, 
26.39, 17.84, 13.91. 
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MS-ESI+ (m/z): Calculated for C22H25BNO5 [M+H]+ 394.1826, found 394.1838. 
Synthesis of AB23 (3-IV-b) 
(a) Synthesis of 3-IV-a: A mixture of 7-(diethylamino)-4-methyl-2H-chromen-2-one 
(1) (2.5 g, 13.5 mmol) and N-bromosuccinimide (3.75 g, 19.5 mmol, 1.5 eq) was 
added in chloroform (150 mL). Then, a catalytic amount of benzoyl peroxide 
(175 mg, 0.67 mmol, 0.05 eq) was added to the reaction mixture and refluxed for 
12 h. The solvent was removed under a vacuum and the residue was digested in 
water and ethyl acetate (1:1; total volume 400 mL). Product was extracted in 
ethyl acetate (200 mL × 2). The combined organic layer was washed with brine 
(200 mL) and dried over sodium sulfate. After removing the solvent, the crude 
product was purified on silica gel column using ethyl acetate:hexane (1:9) as 
eluent to yield a yellow solid product (3.09 g, 74%). The product formation was 
confirmed by NMR and LC-MS. 
1H NMR (CDCl3): δ 7.57 (d, 1H, J = 8.8 Hz), 6.92 (dd, 1 H, J = 2.5, J = 8.9 Hz), 
6.85(d, 1 H, J = 2.5 Hz), 3.91 (s, 3 H), 2.63 (s, 3 H). 
13C NMR (CDCl3): δ 158.08, 154.41, 151.45, 150.61, 128.20, 126.03, 
108.99, 105.58, 97.22, 44.77, 19.08, 12.42. 
MS-ESI+ (m/z): Calculated for C14H16BrNO2 [M+H]+ 310.0443, found 310.0425. 
(b) Synthesis of 3-IV-b: 4-bromo-2-hydroxy acetophenone (215 mg, 1 mmol), 















potassium acetate (294 mg, 3 mmol) were dissolved in anhydrous dioxane (5 
mL). The reaction mixture was bubbled with argon for 10 minutes and it was 
allowed to stir at 90 oC for 90 minutes. Completion of the reaction was monitored 
by LC-MS. The reaction mixture was cooled to room temperature, and then 2 
(216 mg, 0.7 mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol, 3 mol %), K3PO4 (445 mg, 
2.1 mmol) and water (1mL) were added subsequently in the same pot. Further, 
reaction mixture was heated to 85 oC for overnight. The reaction mixture was 
filtered through sintered funnel and digested in water (100 mL). The product was 
extracted with ethyl acetate (3x100 mL). The combined organic layer was 
washed with brine (100 mL) and dried over Na2SO4. The solvent was removed 
under vacuum and the crude product was purified on silica gel using hexane:ethyl 
acetate (4:1) as eluent. The desired product was obtained as a yellow solid (170 
mg, 62%). 
1H NMR (CDCl3): δ 12.30 (s, 1H), 7.80-7.78 (d, J = 7, 1H), 7.47-7.45 (d, J = 7.4, 
1H), 6.91-6.89 (m, 2H), 6.64-6.62 (dd, J = 7.2, J = 4, 1H), 6.54 (d, J = 3.8, 1H), 
3.46-3.41 (q, J = 6.8, 4H), 2.65 (s, 3H), 2.26 (s, 3H), 1.24-1.21 (t, J = 6.1, 6H). 
13C NMR (CDCl3): δ 204.13, 162.13, 161.24, 155.22, 150.57, 148.87, 144.17, 
130.53, 126.25, 121.51, 120.44, 118.79, 108.77, 97.37, 44.77, 26.65, 24.83, 
16.25, 12.44. 





Synthesis of AB24 (3-VII-a) 
 
(a) Synthesis of 3-VII-a: 3-bromophenol (173 mg, 1 mmol), B2Pin2 (280 mg, 1.1 
mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol, 3 mol %) and potassium acetate (294 
mg, 3 mmol) were was dissolved in anhydrous dioxane (5 mL). The reaction 
mixture was bubbled with argon for 10 minutes and it was allowed to stir at 90 oC 
for 90 minutes. Completion of the reaction was monitored by LC-MS. The 
reaction mixture was cooled to room temperature, and then 3-VI-a (216 mg, 0.7 
mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol, 3 mol %), K3PO4 (445 mg, 2.1 mmol) 
and water (1mL) were added subsequently in the same pot. Further, reaction 
mixture was heated to 85 oC for overnight. The reaction mixture was filtered 
through sintered funnel and digested in water (100 mL). The product was 
extracted with ethyl acetate (3x100 mL). The combined organic layer was washed 
with brine (100 mL) and dried over Na2SO4. The solvent was removed under 
vacuum and the crude product was purified on silica gel using hexane:ethyl 
acetate (4:1) as eluent. The desired product was obtained as a yellow solid (163 
mg, 67%). 
1H NMR (CDCl3): δ 7.45-7.44, (d, J = 7.9, 1H), 7.26-7.22 (m, 1H), 6.77-6.74 (m, 
2H), 6.72 (m, 1H), 6.63-6.61(dd, J = 8.1, J = 4,1H) , 6.53 (d, J = 7.4, 1H), 6.34 













13C NMR (CDCl3): δ 162.79, 156.33, 154.95, 150.29, 149.30, 136.11, 129.40, 
126.14, 122.02, 120.83, 117.58, 115.12, 109.51, 108.81, 97.41, 44.74, 16.28, 
12.45. 
MS-ESI+ (m/z): Calculated for C20H21NO3 [M+H]+ 324.1597, found 324.1587. 
3.6.17 UV-Vis Analysis of the Coumarin Analogues 
The UV-Vis profiles of the coumarin analogues were obtained by diluting a 
DMSO stock of each analog (AB21= 1 mM, AB22=2 mM, AB23=3 mM, AB24= 2.6 
mM) to 50 µM in PBS (1x, pH 7.4). 
3.6.18 Fluorescence Analysis of the Coumarin Analogues 
Fluorescence profiles of the coumarin analogues were obtained by diluting a 
DMSO stock of each analog (AB21= 1 mM, AB22=2 mM, AB23=3 mM, AB24= 2.6 
mM) to 10 µM in PBS (1X, pH 7.4). Voltages applied to obtain a spectrum for each 
analog varied (AB21/22=800, AB23=700, AB24/25=600). 
3.6.19 LC-MS Analysis of the Conjugation of Coumarin Analogues to Semicarbazide 
DMSO stocks of the coumarin analogues (AB21= 1 mM, AB22=2 mM) were 
diluted to 200 µM in PBS (1x, pH 7.4) and incubated with 200 µM semicarbazide (18 
mM stock in PBS) for 30 minutes, then analyzed by LC-MS. 
3.6.20 Conjugation of the Coumarin Analogues to Semicarbazide in the Presence of 
Serum 
DMSO stocks of the coumarin analogues (AB21= 1 mM, AB22=2 mM, AB23=3 
mM, AB24= 2.6 mM) were diluted to 100 µM in 1X PBS buffer with or without 20% 
fetal bovine serum (FBS).  Then semicarbazide was added to these solutions from a stock 
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solution to a final concentration of 100 µM. The reactions were incubated for 30 minutes 
before analysis via analytical HPLC. 
3.6.21 Fluorescence Analysis of the Conjugation of Coumarin Analogues to 
Semicarbazide 
Fluorescence profiles of the coumarin analogues conjugated to semicarbazide 
were obtained by diluting a DMSO stock of each analogue (AB21= 1 mM, AB22=2 mM, 
AB23=3 mM, AB24= 2.6 mM, AB25=5.3 mM) to 200 µM in PBS (1X, pH 7.4), adding 
200 µM semicarbazide (18 mM stock in PBS), and incubating for 30 minutes. 
Fluorescence spectra were then obtained immediately after diluting the conjugation 
mixture 20X in PBS (1X, pH 7.4). Voltages applied to obtain a spectrum for each analog 
varied. 
3.6.22 Quantum Yield of Coumarin Analogs and Diazaborine Conjugates42 
To measure the quantum yield, the UV-Vis spectra of 10 µM AB21-24 were 
obtained (all around absorbance of 0.1). The concentration of fluorescein necessary to 
obtain the same absorbance was estimated to be 2 µM (ε=50,358 M-1cm-1 in 1M NaOH). 
The UV-Vis spectrum of this concentration of fluorescein was obtained in 0.1M NaOH. 
Fluorescence readings were then obtained for AB21-24, as well as for diazaborine 
conjugates as outlined. The integrations of the fluorescence peak areas were then 
obtained. For fluorescein, a 10x dilution of the estimated concentration to produce the 
same absorbance as AB21-24 was necessary to obtain a readable fluorescence peak area 
within the range of fluorescence detection. The fluorescence readings for fluorescein 
were obtained in 0.1M NaOH at 0.2 µM. Integration of the fluorescence peak area was 
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also obtained. To account for this dilution factor, the integrated area of fluorescein was 
multiplied by 10 for the quantum yield calculation.  
3.6.23 Kinetics of AB21 and AB22 Conjugation to Semicarbazide  
The kinetics of conjugation of AB21 and AB22 conjugating to semicarbazide 
were measured at 50 µM AB21/22 and 50 µM semicarbazide. Measurements were taken 
at 30 second intervals at a voltage of 600V until no further increase in fluorescence was 





= 𝑘!(𝐶! − 𝑃)(𝐶! − 𝑃) (1) 
in which P is the product concentration, C0 is the starting material concentration, which is 
50 µM for both reactants, and k2 is the rate constant. 
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Solving the equation for P gives: 
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Fitting the kinetic data of Figure S3 to a hyperbolic equation: 
𝑦 = !!!
!!!!
    (6) 














3.6.24 Synthesis of D-Dap-Scz (3-VIII-c) 
 
(a) Synthesis of 3-VIII-b: 3-VIII-a (0.11 mmol) was dissolved in 
dimethylformamide (200 µL) on ice for 5 minutes to dissolve. N-
Hydroxysuccinimide (NHS, 0.16 mmol) and dicyclohexylcarboiimide (0.10 
mmol) were added, and the mixture was allowed to stir on ice for an additional 5 
minutes. The reaction mixture was then stirred at room temperature for 2 hours 
after which all of the starting material was consumed (note: the reaction mixture 
turns opaque due to the formation of dicyclohexyl urea). Boc-D-Dap-OH (0.16 
mmol) was then dissolved in 1:1 10% sodium carbonate: tetrahydrofuran (400 
µL) and added to the stirring reaction mixture, which was then stirred for 14 hours 
at room temperature. The reaction mixture was then acidified with 6N HCl and 
extracted with ethyl acetate (3x30 mL). The combined organic layers were 
washed with brine and dried over sodium sulfate. The solvent was then 
evaporated from the reaction mixture, and the product was purified via reverse 
phase HPLC using a semiprep column to yield a white powder after lyophilization 
(24 mg, 52%).  
1H NMR (DMSO-d6) δ: 1.37 (18H), 3.55-3.62 (3H), 4.00 (2H), 6.36 (1H), 6.95 
(1H), 7.85 (1H), 8.54 (1H), 12.61 (1H).  
MS-ESI (m/z): Calculated for C16H29N5O8 [M+H]


































(b) Synthesis of 3-VIII-c: 3-VIII-b (24 mg, 0.057 mmol) was treated with 50% TFA 
in DCM (2 mL) for 1 hour. The solvent was evaporated, and the product was 
washed with DCM (3x10 mL). The product was then dissolved in 5 mL water and 
lyophilized to yield a white powder (12 mg, 100%).  
1H NMR (DMSO-d6) δ: 3.45 (1H), 3.60 (1H), 2.69 (2H), 3.90-3.97 (1H), 6.55 
(2H), 6.91 (2H), 7.41 (1H), 8.18 (1H), 9.13 (1H).  
MS-ESI (m/z): Calculated for C11H21N5O6 [M+H]
+ 220.10, Observed 220.10.   
3.6.25 Synthesis of D-Dap-Phe (3-IX-a) 
 
(a) Synthesis of 3-IX-b: 3-VIII-a (0.11 mmol) was dissolved in dimethylformamide 
(200 µL) on ice for 5 minutes to dissolve. N-Hydroxysuccinimide (NHS, 0.16 
mmol) and dicyclohexylcarboiimide (0.10 mmol) were added, and the mixture 
was allowed to stir on ice for an additional 5 minutes. The reaction mixture was 
then stirred at room temperature for 2 hours after which all of the starting material 
was consumed (note: the reaction mixture turns opaque due to the formation of 
dicyclohexyl urea). Boc-D-Phe-OH (0.16 mmol) was then dissolved in 1:1 10% 
sodium carbonate: tetrahydrofuran (400 µL) and added to the stirring reaction 
mixture, which was then stirred for 14 hours at room temperature. The reaction 
mixture was then acidified with 6N HCl and extracted with ethyl acetate (3x30 
mL). The combined organic layers were washed with brine and dried over sodium 






















product was directly treated with 50% TFA in DCM (2 mL) for 1 hour. The 
solvent was evaporated, and the product was washed with DCM (3x10 mL). The 
product was then dissolved in 5 mL water and purified by reverse phase HPLC 
with water/acetonitrile (1% TFA) as eluent 
MS-ESI (m/z): Calculated for C12H17N5O4 [M+H]
+ 296.13, Observed 296.10.   
3.6.26 LC-MS Analysis of D-Dap-Scz for Conjugation with AB21/22 
DMSO stocks of the coumarin analogs (AB21= 1 mM, AB22=2 mM, AB23=3 
mM, AB24= 2.6 mM) were diluted to 50 µM in PBS (1X, pH 7.4) and incubated with 
100 µM D-Dap-Scz (9 mM stock in PBS) for 30 minutes, then analyzed by LC-MS. 
3.6.27 Fluorescence of Coumarin Analogues Conjugating to D-Dap-Scz 
Fluorescence profiles of the coumarin analogs conjugated to D-Dap-
semicarbazide were obtained by diluting a DMSO stock of each analog (AB21= 1 mM, 
AB22=2 mM, AB23=3 mM, AB24= 2.6 mM, AB25=5.3 mM) to 50 µM in PBS (1X, pH 
7.4), adding 100 µM D-Dap-semicarbazide (9 mM stock in PBS), and incubating for 30 
minutes. Fluorescence spectra were then obtained immediately after diluting the 
conjugation mixture 5x in PBS (1X, pH 7.4). Voltages applied to obtain a spectrum for 








3.6.28 Synthesis of FPBA-FITC (3-X-d) 
 
(a) Synthesis of 3-X-b: 3-X-a (1.00 g, 0.0050 mol) was refluxed with N-Boc-
bromoethylamine (1.30 g, 0.0055 mol) and potassium carbonate (2.10g, 0.015 
mol) in DMF (5 mL) at 80oC for 15 hours. The crude product was dissolved in 50 
mL water, and extracted with ethyl acetate (3x50 mL). The combined organic 
layers were washed with brine, then dried over sodium sulfate and concentrated 
under reduced pressure. The crude material was then purified by silica gel 
chromatorgraphy with 1:10 ethyl acetate:hexane (550 mg, 32% yield). 
1H NMR (Chloroform-d6) δ : 1.44 (s, 9H), 3.54 (q,  J=5.5 Hz, 2H) 4.03-4.05 (q, 
J=5.3 Hz, 2H), 4.97 (s, 1H), 7.01-7.03 (dd, J=8.8, 3.2 Hz, 1H), 7.38 (d, J=3.2 Hz, 
1H), 7.52 (d, J=8.8 Hz, 1H), 10.28 (s, 1H). 
13C NMR (Chloroform-d6) δ: 31.02, 42.53, 63.04, 82.37, 116.38, 120.82, 125.65, 
136.65, 137.30, 158.47, 160.86, 194.24. 
MS-ESI (m/z): Calculated for C14H18BrNO4 [M+H-Boc]
+ 244.21, Observed 






























(b) Synthesis of 3-X-c: 3-X-b (550 mg, 0.0016 mol), B2pin2 (1.02g, 0.0040 mol), 
Pd(dppf)Cl2 (65 mg, 0.000080 mol) and potassium acetate (490 mg, 0.0048 mol) 
were combined in dry dioxane (10 mL), and purged with argon for 15 minutes. 
The reaction was then allowed to stir under argon at 85oC for 1 hour. The crude 
product was dissolved in 50 mL water, then extracted with ethyl acetate (3x50 
mL). The combined organic layers were washed with brine and dried over sodium 
sulfate before being concentrated under reduced pressure. The crude mixture was 
purified via silica gel chromatography with 3:20 ethyl acetate:hexane (439 mg, 
70% yield). 
1H NMR (Chloroform-d6) δ: 1.35 (s, 12H), 1.43 (s, 9H), 3.54 (q, J=5.4 Hz, 2H), 
4.07 (q, J=5.7 Hz, 2H), 5.00 (s, 1H), 7.09-7.11 (d, J=8.3 Hz, 1H), 7.36 (s, 1H), 
7.84-7.86 (d, J=8.3 Hz, 1H), 10.64 (s, 1H). 
13C NMR (Chloroform-d6) δ:  24.83, 28.35, 39.93, 60.35, 67.30, 84.16, 111.25, 
119.86, 130.11, 138.00, 143.54, 155.80, 160.86, 194.60. 
MS-ESI (m/z): Calculated for C20H30BNO6 [M+H-Boc-4xCH3]
+ 391.27, 
Observed 236.07.   
(c) Synthesis of 3-X-d: 3-X-c (100 mg, 0.26 mmol) was stirred with diethanolamine 
(270 mg, 2.6 mmol) in tetrahydrofuran (1 mL) overnight at room temperature. 
The mixture was then acidified with 1 N HCl, and stirred in 5 mL ethyl acetate for 
30 minutes. The crude product was then extracted with ethyl acetate (3x10 mL), 
and the combined organic layers were washed with brine, dried over sodium 
sulfate, and concentrated under reduced pressure. The crude product was then 
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directly dissolved in 2 mL dry dichloromethane and 2 mL TFA (50% TFA in 
DCM), and stirred for 30 minutes. The mixture was then evaporated under 
reduced pressure, and crude 3-VII-d (10 mg, 0.062 mmol) was directly stirred 
with fluorescein isothiocyanate (24 mg, 0.062 mmol) for 1 hour in triethylamine 
(18 µL, 0.124 mmol) and 2 mL DMF. The reaction mixture was then diluted in 10 
mL 2:1 Water:Acetonitrile and purified via reverse phase HPLC using a semiprep 
column to yield a orange powder after lyophilization (9 mg, 25%).  
MS-ESI (m/z): Calculated for C30H23BN2O9S [M+H]
+ 599.39, Observed 599.13 
3.6.29 Flow Cytometry Analysis of S. aureus Labeling with D-Dap-Scz/D-Phe-Scz and 
FPBA-FITC 
S. aureus or E. coli from a single colony was grown overnight in LB broth at 37 
oC with agitation. An aliquot was taken and diluted (1:100) in fresh broth and cultured for 
another 2 hours until the cells reached the beginning of logarithmic phase (OD600 ~ 0.2). 
Then, D-Dap-Scz or D-Phe-Scz(9 mM stock in 1X PBS, 7.4) was added to the bacterial 
cell culture (final concentration 0 µM, 5 µM, 25 µM, 50 µM, 100 µM, or 500 µM) and the 
cultures were allowed to continue to grow before 400 µL/200 µL aliquots were taken at 
0.5, 1, 2 and 4 hours. The aliquots were spun down at 5000 rcf, washed once with 1 mL 
PBS (1X, pH 7.4), spun down again, and the cell pellet was then incubated with 50 µL of 
50 µM FPBA-FITC at 37oC for 30 minutes. The cells were spun down and washed two 
additional times, then diluted in 1 mL PBS (1X, pH 7.4). The cells were further diluted in 
PBS (1X, pH 7.4) to reach a cell density of ~3x106 cells/mL, and 300 µL aliquots were 
filtered through a 35 µm filter (Nalgene) before analysis on a BD FACSAria cell sorter 
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(BS Biosciences). Data analysis was performed with FlowJo (Tree Star, Inc.), from which 
the median fluorescence intensities of the stained cells were extracted. 
3.6.30 Microscopy Analysis of S. aureus Cell Labeling via Fluorogenic Conjugation 
S. aureus from a single colony was grown overnight in LB broth at 37 oC with 
agitation. An aliquot was taken and diluted (1:100) in fresh broth and cultured for another 
2 hours until the cells reached the beginning of logarithmic phase (OD600 ~ 0.2). Then, D-
Dap-Scz or D-Phe-Scz (9 mM stock in 1× PBS, 7.4) was added to the bacterial cell 
culture (final concentration 0 µM, 100 µM, or 500 µM) and the cultures were allowed to 
continue growth before 500 µL aliquots were taken at 4 hours. The aliquots were spun 
down at 5000 rcf, washed once with 1 mL PBS (1X, pH 7.4), spun down again, and the 
cell pellet was then incubated with 100 µL of 100 µM AB21/22 at 37oC for 30 minutes. 
Parallel experiments were performed with AB24 and FPBA-FITC as controls. 
For epi-fluorescence microscopy, 2 µL of the bacterial cell suspension was placed on a 
glass slide (Fisherfinest premium, 75 × 25 × 1 mm3). A coverslip (Fisherbrand, 22 × 22 × 
0.15 mm3) was pressed down on the cell droplet to give a single layer of cells on the glass 
slides. White light and fluorescence images were taken on a Zeiss Axio Observer A1 
inverted microscope equipped with a filter cube (358 nm excitation, 417-477 nm 
emission) suitable for detection of DAPI fluorescence. A Plan-NeoFluar × 100 oil 
objective from Zeiss was used to visualize the bacterial cells. All images were captured 
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4.1 Introduction 
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Psuedomonas aeruginosa, 
Enterobacter) represent bacterial species with high levels of antibiotic resistance in 
clinical settings.1 The gram-negative pathogens on this list have recently begun to exhibit 
wide ranging resistance to multiple antibiotics, making treatment of these infections 
extremely challenging, and causing physicians to turn to previously rejected antibiotics 
that show high levels of toxicity for treatment.2 
5.1.1 Polymyxin Antibiotics 
 Given the current challenges associated with widespread antibiotic resistance, 
bacterial membranes are an attractive target for development of novel therapeutics due to 
their conserved structures, as well as the lack of permeability needed for these drugs 
since their targets reside on the exterior of the cell wall. While only a few notable 
membrane-targeting antibiotics exist in the clinic (eg. vancomycin, daptomycin), nature 
widely utilizes cationic antimicrobial peptides (CAMPs), such as the aforementioned 
defensins, to combat bacterial infections.3 CAMPs generally consist of 20-50 amino acids 
with a net positive charge of +2 to +7 in physiological conditions, and are oftentimes 
amphiphilic, with over 50% of amino acids usually containing hydrophobic side chains.4 
This amphiphilic characteristic of CAMPs allows them to make crucial interactions with 
bacterial membranes.5 
 Cationic lipopeptide antibiotics are one subset of CAMPs that exert their 
bactericidal activity by selectively binding to lipopolysaccharides (LPS), which is a major 
lipid component of the outer membrane of Gram-negative bacteria.6 The lipopeptides 
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polymyxin B and polymyxin E (eg. colistin) were isolated from the Gram-positive 
bacteria Bacillus polymyxa, and consist of a hepta-peptide ring and a tripeptide side chain 
with a fatty acid tail (Figure 4-1).2 These polymyxins exert their bactericidal activity by 
specifically binding to the lipid A core of LPS with >3 times higher affinity than the 
natural calcium and magnesium cations that normally stabilize the LPS molecules.7 
Specifically, the short fatty acid side chain of the polymyxins interacts with the lipid 
region of LPS to anchor these antibiotics to the outer membrane lipid bilayer 
Additionally, the positively charged diaminobutyric acid (Dab) side chains of polymyxins 
interact with the two phosphate groups of lipid A via ionic interactions.8,9 By binding to 
these LPS molecules, polymyxins are able to disrupt LPS assembly in the outer 







Figure 4-1. Structure of polymyxin cationic antimicrobial peptides. 
  
Despite the effectiveness of these CAMPs, bacteria have developed mechanisms 
of resistance to evade killing by these membrane targeting peptide antibiotics. Since the 
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binding and activity, Gram-negative bacteria have evolved cell surface modification 
strategies to increase electrostatic repulsion by enabling the addition of cationic primary 
amines to LPS (Figure 4-2 and Figure 4-3).6 These modifications include the addition of 
phosphatidylethanolamine (PE) and/or 4-aminoarabinose (Ara4N), both of which are LPS 
modifications implicated in the resistance of Acinetobacter baumannii (A. baumannii), as 
well as several other Gram-negative bacterial species, to colistin.10 As an alternative 
resistance mechanism, Gram-negative colistin resistant bacteria can shut down their LOS 
biosynthesis and replace the outer leaflet of the outer bacterial membrane with amine-
presenting lipoproteins, which eliminates the capacity for polymyxins to bind Lipid A 
altogether (Figure 4-3).11,12  
Importantly, polymyxin antibiotics are used as antibiotics of last resort due to 
high levels of neuro- and renal toxicity.13 However, the recent discovery of widespread 
resistance indicates that these therapeutics are not immune to development of resistance, 
which demands development of novel diagnostics and further identification of novel 
therapeutics to avoid complications as a result of the continued spread of resistance.  
4.1.2 Mechanisms of Colistin Resistance  
 As noted, Gram-negative bacteria are capable of acquiring resistance to 
polymyxin antibiotics, and colistin specifically, through several different mechanisms: 
addition of PE to LPS, addition of Ara4N to LPS, or LOS depletion. The PE and Ara4N 
modifications can originate from either a plasmid-mediated mechanism via mobilized 
colistin resistance determinant (mcr-1), or via mutations in the PmrAB two-component 
regulatory system.  
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The mcr-1 plasmid-borne gene has been detected in nearly 40 countries 
worldwide, with over 11 species of Enterobacteriaceae carrying this gene (eg. E. coli, K. 
pneumoniae, Salmonella enterica).13,14 The mcr-1 gene enables colistin resistance by 
encoding PE-Lipid A transferases that specifically append PE to the 1(4’)-phosphate 
position of glucosamine on Lipid A (Figure 4-2). Based on the widespread nature of the 
gene across various bacterial species, mcr-1 appears to be highly transferrable. 
Additionally, several genetic variants (eg. mcr-2, mcr-3, cr-4), have been recently 
identified, which further highlights the threat posed by this highly transferrable 
mechanism of colistin resistance.  
Amine-presenting modifications to LPS can also occur as a result of mutations in 
the PmrAB regulatory system, which lead to its constitutive activation and subsequent 
expression of PmrC.15 In A. baumannii specifically, polymyxin resistance is controlled at 
the chromosomal level by the PmrA/B two-component regulatory system, in which PmrB 
is a membrane-localized sensor kinase that phosphorylates and activates PmrA, the 
cytosolic DNA-binding response regulator. Importantly, PmrA/B regulates the enzyme 
PmrC, which encodes the PE/Ara4N transferases that are responsible for attaching the PE 
group to the 4’-phosphate of Lipid A, as well as Ara4N to the 1’-phosphate. Thus, 
mutations that up-regulate the expression of PmrA/B also influence the expression of 
PmrC. Reports have elucidated that A baumannii with PmrB gene mutations contain 
Lipid A modified with both PE and Ara4N (Figure 4-2).16,17 Bacterial species in which 
the locations of the Ara4N and PE groups (1’ and 4’ phosphate), are reversed, or in which 
both phosphates are modified with the same substituent also exist at low occurence. 
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Additionally, depending on the species of colistin resistant A. baumannii, either the PE 










Figure 4-2. Amine presenting PE (blue) and Ara4N (red) modifications on Lipid A 
resulting from PmrAB mutants and mcr-1. 
 
Unlike mc-r1 and pmrAB mediated amine-presenting modifications, LOS 
depleted colistin resistant Gram-negative bacterial variants entirely inactivate the lipid A 
biosynthetic pathway to mediate resistance to polymyxins (Figure 4-3).18 A. baumannii 
are one of only three (Neisseria meningitides and Moraxella catarrhalis) known Gram-
negative bacteria that survive after inactivation of lipid A biosynthesis.19 Importantly, 
LOS-deficient A. baumannii have been isolated following colistin treatment of a patient 
in South Korea, highlighting the potential clinical relevance of this type of bacterial cell 
wall modification.20 Examination of LOS deficient A. baumannii strains indicates that the 
lack of LOS in the cell wall is compensated for by increasing the transcription of genes 
that encode cell-envelope biogenesis of lipoproteins and their associated transport 
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proteins (eg. mla retrograde phospholipid transporter, lol lipoprotein transport) to 
maintain an outer membrane barrier. Interestingly, the expression of PBP1 in A. baumnnii 
mitigated the development of colistin resistance in LOS deficient strains. Although 
LipidA biogenesis and peptidoglycan synthesis are not linked, previous analysis has 
shown that mutations can result in convergence of the two distinct pathways.  
 
Figure 4-3. LOS deficient Gram-negative bacteria upregulate lipoprotein expression to 
maintain an outer membrane barrier (image from Ref.18). 
 
 
These three different pathways to achieve colistin resistance that involve 
variations in alterations made to the outer membrane of Gram-negative bacterial species, 
and especially A. baumannii, were of interest to our group in our efforts to develop 























Figure 4-4. Schematic of APBA dimer peptide binding of amine-modified Gram-
negative bacterial cell surfaces via pmrB and mcr-1 mediated pathways. 
 
4.1.3 Whole Cell Phage Screening Approach to Identify Targeted Peptide Probes of 
Colistin Resistance 
 
 Our group has applied an APBA dimer phage library screening approach to 
identify species-, as well as strain-specific peptide binders to S. aureus and LOS- A. 
baumannii, respectively.21 The bacterial species A. baumannii is of particular interest to 
our research efforts as it has become increasingly more common in hospital settings, 
concurrent with new reported cases of colistin resistance, making it particularly relevant 
to clinical applications.22 Previous work carried out by Dr. Kelly A. McCarthy led to the 
discovery of novel peptides (KAM20 and KAM21, Table 4-1) that specifically detect a 
strain of A. baumannii carrying a pmrB mutation (EGA-408) in relation to its wild type 
counterpart (Figure 4-5). Further investigation of these peptides revealed that while they 
efficiently differentiate between EGA-408 and the non-mutant A. baumannii (17978), 
these peptides also bind to LOS deficient A. baumannii (LOS-), indicating that they are 
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aimed to identify peptides that would act as resistance mechanism-specific probes to 
provide facile identification of the mechanism of colistin resistance for any bacterial 
sample in question.  
Table 4-1. Sequences of KAM20 and KAM21 EGA-408 peptides (peptides synthesized 
by Dr. Kelly A. McCarthy). 
 
Name Peptide Sequence 
KAM20 ACmTNANHYFCmGGGDap* 
KAM21 ACmYSSPSHFCmGGGDap* 
Cm= APBA-IA modified Cys; Dap*= fluorophore (FAM/TAMRA) modified Dap 
 
 
Figure 4-5. KAM20 and KAM21 are selective peptide probes for EGA-408 compared to 
the 17978 WT strain. Fluorescence microscopy (left) and flow cytometry (right) analysis 
of KAM20 and KAM21 binding to EGA-408 and 17978 (WT) A. baumannii (microscopy 
images with 2 µM peptide in presence of 1 mg/mL BSA, flow data obtained in presence 

























































Figure 4-6. EGA-408 binding peptides KAM20 and KAM21 also bind to LOS- A. 
baumannii, as depicted by replicate flow cytometry analysis (data collected by Dr. Kelly 
A. McCarthy, 1000 nM peptide in presence of 1 mg/mL BSA). Error bars represent 
standard deviation of triplicate measurements. 
 
Additionally, we acquired several mcr-1 carrying Gram-negative strains of 
bacteria, which display amine-presenting PE modifications, similar to those of the EGA-
408 strain. Thus, we also aimed to determine if pmrAB mutant detecting peptide probes 
would also act as probes of mcr-1 mediated colistin resistance, given the similarities in 
cell surface modifications conferred by each mechanism. The strains of bacteria 
referenced throughout are summarized in Table 4-2.  
Table 4-2. Summary of colistin resistant Gram-negative bacterial strains. 
Strain Species Genotype 
EGA-408 A. baumannii  pmrB 
17978 A. baumannii WT 
LOS- A. baumannii LOS- 
AR497 K. pneumoniae mcr-1 































4.2 Negative Screen APBA Dimer Phage Library Selection of EGA-408 and LOS- 
Peptide Probes 
 
4.2.1 APBA Dimer Phage Library Negative Screen Selection for Identification of EGA-
408 and LOS- Specific Binders 
 
 In order to identify iminoboronate capable peptide probes that selectively bind to 
the EGA-408 pmrB mutant A. baumannii strain or alternatively to the LOS- A. baumannii 
strain, we devised a negative selection APBA dimer phage library screening scheme that 
aimed to eliminate any phage binders to the non-target strain (Figure 4-7).  
We carried out two individual screens with the APBA dimer phage library: 1) 
EGA-408 positive selection with an LOS- negative selection, and 2) LOS- positive 
selection with an EGA-408 negative selection. Unique peptide hits from each screen were 
synthesized and fluorophore/APBA labeled  (Table 4-3). 
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Table 4-3. Sequences of EGA-408, LOS- and control peptides. 
 
Peptide Sequence Screen 
SEC5 ACmKPLHSRSCmGGGDap* EGA-408 
SEC6 ACmFLEYAPTCmGGGDap* EGA-408 
SEC8 ACmSIIPEKYCmGGGDap* LOS- 
SEC9 ACmGSFWSLTCmGGGDap* LOS- 
SEC14 ACmPLTAVISCmGGGDap* Naïve Library 
Cm= APBA-IA modified Cys; Dap*= fluorophore (FAM/TAMRA) modified Dap 
 
 
4.2.2 Analysis of EGA-408 and LOS- Binding of Peptide Hits 
 To analyze the specificity of A. baumannii binding for each of the peptide hits, the 
peptides were assessed by both microscopy and flow cytometry. Fluorescence 
microscopy studies first showed that while SEC8 and SEC9, the peptides extracted from 
the LOS- specific screen, were indeed selective for LOS- binding in comparison to EGA-
408, the EGA-408 peptides, SEC5 and SEC6, exhibited binding to both strains, and thus 


















Figure 4-8. Fluorescence microscopy analysis of EGA-408 and LOS- binding of SEC5, 





















The selectivity of the LOS- peptides, and lack thereof of the EGA-408 peptides 
was confirmed by flow cytometry (Figure 4-9). In comparison to a negative control 
peptide (SEC14) extracted from a naïve phage library, the EGA-408 and LOS- peptides 
display clear binding to the A. baumannii colistin resistant strains. Also compared to 
KAM8, a peptide previously extracted from a screen directly against LOS-21, the SEC8 











Figure 4-9. Flow cytometry analysis of EGA-408 and LOS- binding of SEC5, SEC6, 
SEC8, SEC9, SEC14 and KAM8 (1 µM peptide, 1 mg/mL BSA). Error bars represent 
standard deviation of triplicate measurements. 
 
4.2.3 Selectivity of SEC5 for Binding EGA-408 in Comparison to WT (17978) A. 
baumannii  
 
Intrigued by the lack of specificity of SEC5 for binding to EGA-408 in 
comparison to the LOS- A. baumannii strain, we aimed to assess the selectivity of this 


































peptide in comparison to WT strain binding. The WT strain from which EGA-408 was 
derived does not carry the pmrB mutation, and thus is not anticipated to display either of 
the amine presenting cell surface modifications to which the SEC5 peptide should be 
selectively binding. Consistent with our hypothesis, SEC5 displays selective binding to 
EGA-408 over the WT strain, as assessed by fluorescence microscopy and flow 
cytometry (Figure 4-10). Additionally, a co-culture experiment carried out with an 
increasing ratio of the EGA-408 strain relative to 17978 (WT) exhibited an increase in 
the proportion of cells fluorescently labeled consistent with the proportion of EGA-408 
cells in the mixture in the presence of human serum (Figure 4-11). 
 
Figure 4-10. SEC5 displays selective binding to EGA-408 over 17978. Fluorescence 
microscopy (left) and flow cytometry (right) analysis of SEC5 binding to EGA-408 and 












































Figure 4-11.  Varying ratios of 17978:EGA-408 co-cultures labeled with SEC5-
TAMRA. Percentage of stained cells shown in left corner of fluorescence images (2 µM 
peptide, 20% human serum, scale bar = 10 µm). 
 
Together, the fluorescence microscopy and flow cytometry data show that while 
SEC5 is specific for EGA-408 binding in comparison to the wild type A. baumannii 
strain, identification of peptides that do not bind to the LOS- strain of A. baumannii is 
much more challenging. Given the overexpression of lipoproteins on the surface of these 
bacteria, it is possible that the lipoproteins may present a sticky surface for the non-
specific binding of our APBA handles, which may prohibit the identification of binding 
selectivity conferred by unique peptide sequences. Nonetheless, implementation of a 
negative screen selection was successful in development of peptides that display 
weakened binding to an alternative A. baumannii strain, EGA-408.  
4.3 mcr-1 AR497 Phage APBA Dimer Screening Selection 
 As an alternative to the pmrB and LOS- mechanisms of colistin resistance, we 
acquired several alternative Gram-negative colistin resistant bacterial strains that carry 
the mcr-1 gene, which upregulates PE Lipid A modifications in the bacterial cell walls 
(Table 4-2). Given our knowledge with the screening of EGA-408 and LOS- towards 
development of strain specific peptide binders, we were interested to determine if a 
100:0  75:25 50:50 25:75 0:100 
0% 95% 22% 53% 71% 
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peptide selected to bind to one of the mcr-1 carrying strains would display similar 
binding affinity to the other mcr-1 strains given the similarities in cell surface 
modifications.  
4.3.1 APBA Dimer Phage Library Screening Against AR497 
 The APBA dimer phage library was screened directly against the AR497 K. 
pneumoniae strain, which yielded several repeating peptide hits that were subsequently 
synthesized and labeled with FAM/TAMRA and APBA (Table 4-4). This screen differed 
from the EGA-408/LOS- screen in that no negative selections were carried out, as the 
aim of this experiment was to determine if peptides that bind to one mcr-1 carrying 
Gram-negative bacterial strain are capable of binding to alternative mcr-1 carrying 
strains. 
 





Cm= APBA-IA modified Cys; Dap*= fluorophore (FAM/TAMRA) modified Dap 
 
 
4.3.2 Analysis of SEC18-20 Binding to mcr-1 Carrying Gram-Negative Bacterial Strains 
 Fluorescence microscopy of the TAMRA labeled peptides revealed that while 
SEC18-20 exhibit strong binding to the AR497 K. pneumoniae strain as expected, their 
binding to the alternative mcr-1 carrying strains is diminished (Figure 4-12). These 
results were confirmed by replicate flow cytometry analysis, whereby the SEC18 and 
SEC19 peptides exhibit concentration-dependent binding up to ~1000 a.u. at 1000 nM, 
whereas the median fluorescence intensity values for AR493 (E. coli) and AR496 
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(Salmonella enteritiditis) were ~3-4x less at the same concentrations (Figure 4-13, 
Figure 4-14). Thus, while the peptides do exhibit binding to the varying mcr-1 carrying 
bacterial strains, there is a significant difference in fluorescence intensity imparted by the 





Figure 4-12. Fluorescence microscopy analysis of the binding of SEC18, SEC19 and 


































Figure 4-13. Flow cytometry analysis of the binding of SEC18 (red), SEC19 (blue) and 
SEC20 (green) to AR493, AR496 and AR497. All samples contain 1 mg/mL BSA. 














































































































































































Figure 4-14. Average median fluorescence intensity of 1000 nM SEC18 and SEC19 
binding to AR493, AR496 and AR497. Error bars represent standard deviation of 
triplicate readings. Measurements carried out in the presence of 1 mg/mL BSA.  
 
4.4 Cross Analysis of mcr-1 and pmrB Peptide Binders 
 Intrigued by the lack of cross-species peptide binding exhibited by the mcr-1 
selected peptides, we aimed to determine if the EGA-408 and mcr-1 peptides would 
display any cross-strain binding capabilities given the overlap in modifications enabled 
by the mcr-1 gene and pmrB gene mutations, respectively.  
5.4.1 Flow Cytometry Analysis of SEC5 and SEC18-29 Binding to EGA-408, AR497, 
AR496 and AR493 
 
 Flow cytometry analysis of the binding of SEC5, a peptide selected for EGA-408 
binding, and the SEC18/19, peptides selected for AR497 binding display the cross-
reactivity of peptides for binding to strains carrying plasmids or mutations that up-


































(Figure 4-15). Interestingly, all peptides show strongest binding to the AR497 strain, 
which may indicate either a greater presence of these amine-presenting modifications on 
the cell surface, or alternative cell surface features that promote binding of these amine-
targeting peptides. SEC5, the peptide selected for EGA-408 binding, also displays 
significant binding to the mcr-1 carrying strains, especially in comparison to the A. 
baumannii WT strain 17978. SEC18 and SEC19 also display binding to the EGA-408 
strain. Importantly, the control peptide, SEC14, displays no significant binding to any of 
the strains. Thus, it appears that the peptides identified are general sensors of similar 
mechanisms of colistin resistance that append amine presenting groups to Lipid A in the 

















Figure 4-15. Average median fluorescence intensity of 1000 nM SEC5, SEC18, SEC19 
and SEC14 binding to EGA-408, AR493, AR496, AR497 and 17978 (A. baumannii WT). 
Error bars represent standard deviation of triplicate readings. Measurements carried out in 
the presence of 1 mg/mL BSA. 
 To assess the significance of the median fluorescence intensity readouts for the 
mcr-1 carrying strains AR496 and AR493, two K. pneumoniae strains that do not have 




































any amine-presenting modifications on their surfaces were used as controls to assess 
peptide binding readouts relative to background fluorescence. Fluorescence microscopy 
analysis (Figure 4-16) shows a distinct difference in binding of the SEC5, SEC18 and 
SEC19 peptides to the mutant amine-presenting modification containing strain, AR497, 
and a strain that contains no such mutation (AR347), as well as a wild-type K. 
pneumoniae strain. Assessing the binding by flow cytometry shows that while SEC5, 
SEC18 and SEC19 exhibit diminished binding in comparison to AR497, the fluorescence 
intensity readout is higher than that of these other strains, indicating that the peptides do 
bind, although at lower affinity (Figure 4-17). This could be a result in a differing 
number of PE modifications on the cell surfaces, or alternative cell surface features that 
contribute to peptide binding. Nonetheless, these peptides remain selective for binding 
colistin-resistant strains of bacteria, as desired. 
 
Figure 4-16. Fluorescence microscopy analysis of the binding of SEC5, SEC18 and 
SEC19 to AR497, AR347 and WT K. pneumoniae (2 µM peptide, 1 mg/mL BSA, scale 
bar = 10 µm). 
 



































Figure 4-17. Average median fluorescence intensity of 1000 nM SEC5, SEC18, SEC19 
and SEC14 binding to AR497, AR493, AR496, AR347, AR348, WT K. pneumoniae and 
17978 (A. baumannii WT). Error bars represent standard deviation of triplicate readings. 
Measurements carried out in the presence of 1 mg/mL BSA. 
 
4.5 Conclusions 
The APBA dimer library phage display screening platform was successful in 
identifying peptides that selectively bind to Gram-negative bacterial strains of interest 
that harness mutations or genes which cause the expression of amine-presenting Lipid A 
modifications on the cell surface. For example, the peptide SEC5, which was initially 
selected for EGA-408 binding, displays robust binding to the A. baumannii strain EGA-
408, but no binding to the WT A. baumannii strain, which displays no amine-presenting 











































The LOS- A. baumannii strain presented a challenge for the development of strain 
selective peptide probes of EGA-408 in that all the EGA-408 selected peptides also 
showed significant binding to the LOS- strain, even with negative selection against the 
LOS- strain during phage library screening. On the other hand, selection of LOS- 
selective peptides was successful, as SEC8 and SEC9 display targeted LOS- binding in 
comparison to EGA-408. Therefore, the overexpression of lipoproteins on the surface of 
the LOS- strain may make the cells capable of binding strongly to APBA dimer peptides 
that were selected for A. baumannii binding in general.  
We also explored the identification of peptide probes for alternative mechanisms 
of colistin resistance, such as mcr-1. Screening of a K. pneumoniae strain carrying mcr-1 
revealed several peptides that also exhibited binding to alternative mcr-1 carrying strains, 
although at lower fluorescence intensity. Interestingly, SEC5, an EGA-408 derived 
peptide, also exhibited strong binding to AR497, which may indicate the presence of a 
larger proportion of Lipid A PE modifications relative to the other species of mcr-1 
carrying Gram-negative bacteria, AR493 and AR496. Nonetheless, these results imply a 
capacity for cross-reactivity of these peptides for detecting PE Lipid A modifications 
presented by a variety of colistin resistant Gram-negative bacteria. Thus, while the phage 
screening platform enables isolation of peptides that are selective for identification of 
colistin-resistant versus colistin-sensitive strains of bacteria, these peptides may also be 
able to be extended to alternative species and mechanisms of resistance that cause the 




4.6 Experimental Procedures 
4.6.1 General Methods 
The Ph.D.TM-C7C Phage Display Peptide Library Kit and the E. coli K12 ER2738 
strain were purchased from New England Biolabs. The E. coli K12 ER2738 used for 
amplification and titering steps was grown on LB+Tetracycline plates prior to culturing 
in LB media. All reagents used for panning were made and used in accordance with the 
NEB Ph.D.TM Phage Display Libraries Instruction Manual. The A. baumannii EGA-408, 
A. baumannii LOS-, A. baumannii 17978, K. pneumoniae AR497, E. coli AR493 and S. 
enteritiditis AR493, E. coli AR348 and K. pneumoniae AR347 strains were provided by 
the laboratory of Prof. Tim van Opijnen at Boston College. The K. pneumoniae WT 
strain (ATCC 4352) was purchased from ATCC as a lyophilized cell pellet. All strains 
were grown in LB media, while the EGA-408 strain was additionally grown in the 
presence of 8 µg/mL colistin.  
All amino acids and Rink-Amide resin were purchased from Creosalus, Chem 
Impex International and EMD Millipore. All reagents for peptide synthesis, including 
dimethylformamide, dichloromethane N-methylmorpholine, triisopropylsilane and 
piperidine were purchased from Fisher Scientific. Trifluoroacetic acid was purchased 
from Protein Technologies. Peptide synthesis was carried out on a Tribute peptide 
synthesizer, and peptides were purified via RP-HPLC on a Waters Prep LC with a Jupiter 
C18 column (Phenomenex) with water/acetonitrile and 0.1% TFA as eluent (Buffer 
A=95% water, 5% acetonitrile, 0.1% TFA; Buffer B= 95% acetonitrile, 5% water, 0.1% 
TFA) with a gradient to 60% Buffer B. The peptide concentration of all fluorescent 
peptide stocks (made in DMSO) was determined by measuring their absorbance at 495 
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nm for fluorescein (E=75,000 M-1cm-1) or 556 nm for TAMRA (E=89,000 M-1cm-1) on a 
Nanodrop 2000c UV-Vis spectrometer.  
 Fluorescence images were obtained on a Zeiss Axio Observer A1 inverted 
microscope with rhodamine filter. Flow cytometry analysis was performed on a BD 
FACSAria cell sorter by Dr. Patrick Autissier in the Biology department at Boston 
College.  
4.6.2 APBA Dimer Phage Library Screening Against EGA-408, LOS- and AR497 
 For all phage display panning experiments, 3 µL (~1x1010 pfu) of the C7C library 
was diluted into 172 µL of 1X PBS pH 9.0 with 25 µL iTCEP and stirred for 48 hours at 
4oC. The reduced C7C library was then labeled with 2 mM APBA-IA (synthesized as 
previously reported, stored at 200 mM in DMSO)23 and stirred at room temperature for 2 
hours. The iTCEP mixture was then centrifuged, and the APBA-IA labeled phage-
containing supernatant was collected. The phage precipitated with 1/5 volume of 20% 
PEG8000/2.5M NaCl on ice for 5 hours. The mixture was centrifuged at 14,000 rpm at 
4oC for 30 minutes. The APBA-IA labeled phage was then dissolved in 100 µL of PBS 
pH 7.4 and used for phage panning experiments.  
For the negative screens against EGA-408 and LOS-, EGA-408 and LOS- were 
grown to an OD600≈1.0 (~1x109 cfu/mL) in LB media. For the first round, a 1 mL aliquot 
of cells (aliquoted into a 10 mg/mL BSA in 1X PBS pH 7.4 in a pre-blocked eppendorf 
tube) was washed twice with chilled PBST (0.05%), then re-suspended in 1X PBS pH 7.4 
with 10 mg/mL BSA (950 µL) and incubated on ice for 0.5 hours. 50 µL of the APBA-
labeled phage library was added to the cell suspension, which was incubated on ice for 1 
hour. The cells were then washed 3 times with PBST (0.05%) and 3 times with PBS to 
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remove unbound phage. Cell-bound phage were incubated with 200 µL elution buffer 
(glycine-HCl, pH 2.2, 1 mg/mL BSA) for 15 minutes, followed by cell centrifugation at 
5000 rcf for 5 minutes. The supernatant containing the eluted phage was then removed 
and neutralized with 150 µL Tris-HCl (pH 9.1). The eluted phage solution was added to 
early log phase ER2738 and amplified 5 hours, followed by precipitation to isolate the 
amplified phage, which was again subjected to APBA-IA labeling protocols. In the 
second and third rounds, the APBA labeled phage library was first incubated with the 
negative screen species of bacteria for 1 hour on ice as described above. The cells were 
then centrifuged at 5000 rcf for 5 minutes, and the phage-containing supernatant was then 
directly removed and added to a washed cell pellet of the positive screen bacterial 
species. The remainder of the panning protocol was kept consistent. The phage titer was 
calculated before and after each round of panning with LB/IPTG/Xgal plating to 
determine input and output populations. Individual phage colonies from the third round 
of panning were amplified in ER2738, then phage DNA was isolated using a GeneJet 
MiniPrep kit and sent for sequencing analysis to Eton Bioscience, Inc. The screen against 















Table 4-5. Sequencing analysis of EGA-408 positive/LOS- negative selection (sequences 
chosen for peptide synthesis shown in bold). 
Hit 
# 
DNA Sequence Peptide Sequence 
1 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
2 n/a Blank 
3 n/a Blank 
4 n/a Blank 
5 n/a Blank 
6 n/a Blank 
7 GCTTGTGGGTGGATGAATGGTCATCATTGC ACGWMNGHHC 
8 n/a Blank 
9 n/a Blank 
10 n/a Blank 
11 GCTTGTATGCGGGCTGGTTCTCATAATTGC ACMRAGSHNC 
12 n/a Blank 
13 n/a Blank 
14 GCTTGTAAGCCGCTGCATTCGAGGTCGTGC ACKPLHSRSC 
15 n/a Blank 
16 n/a Blank 
17 GCTTGTCCGGCGCTTGAGAAGGCTAATTGC ACPALEKANC 
18 n/a Blank 
19 n/a Blank 
20 GCTTGTCCTCAGAGTAATTTTAAGTCTTGC ACPQSNFKSC 
21 n/a Blank 
22 GCTTGTAGTGCTGGGCCGACGTTGAATTGC ACSAGPTLNC 
23 GCTTGTTTTCTTGAGTATGCTCCGACTTGC ACFLEYAPTC 
24 GCTTGTACTAAGGATCTTACGATGCGTTGC ACTKDLTMRC 




















26 n/a Blank 
27 GCTTGTCTGGATAGTCCTATTACTTCTTGC ACLDSPITSC 
28 GCTTGTAAGCCGCTGCATTCGAGGTCGTGC ACKPLHSRSC 
29 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
30 GCTTGTCAGAGTGAGATGCGTGAGTCGTGC ACQSEMRESC 
31 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
32 GCTTGTGTTGATCCGCATCCGAGGACTTGC ACVDPHPRTC 
33 GCTTGTTGGGGTGGGGGTTTTAGTAGTTGC ACWGGGFSSC 
34 GCTTGTCTGAATACTAATGTTAATCATTGC ACLNTNNVNHC 
35 GCTTGTGATCTTTGGGGTGCTCGTACGTGC ACDLWGARTC 
36 GCTTGTATGCGGGCTGGTTCTCATAATTGC ACMRAGSHNC 
37 GCTTGTGCTCCGAATAATCGTCTTCAGTGC ACAPNNRLQC 
38 GCTTGTGATCTGACGAGTTATGAGTGGTGC ACDLTSYEWC 
39 GCTTGTTCGTATAGTCGGGATTTGACTTGC ACSYSRDLTC 
40 n/a Blank 
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Table 4-6. Sequencing analysis of LOS- positive/EGA-408 negative selection (sequences 
chosen for peptide synthesis shown in bold). 
Hit 
# 
DNA Sequence Peptide Sequence 
1 GCTTGTGCTCCGAATTCGCATAAGGATTGC ACAPNSHKDC 
2 n/a Blank 
3 n/a Blank 
4 GCTTGTGAGGGTGCGGTGGGTCCTGCGTGC ACEGAVGPAC 
5 n/a Blank 
6 GCTTGTTATCCTTATTCTCTTTCTCAGTGC ACYPYSLSQC 
7 GCTTGTACGAATCTGGTTTATCAGCAGTGC ACTNLVYQQC 
8 GCTTGTCATCTTCCGCCTTCGCATTATTGC ACHLPPSHYC 
9 GCTTGTTCGAATCCGCAGTCTTATAAGTGC ACSNPQSYKC 
10 GCTTGTGGTCCGTATCCGGGGAGGGTTTGC ACGPYPGRVC 
11 n/a Blank 
12 GCTTGTTCGAAGTATCCTCGTGAGATGTGC ACSKYPREMC 
13 GCTTGTGGTCCGCGGGCTGCTACTTCTTGC ACGPRAATSC 
14 n/a Blank 
15 GCTTGTGTGCGTACGCTGTCGCCGTTTTGC ACVRTLSPFC 
16 GCTTGTGTTGATCCGCATCCGAGGACTTGC ACVDPHRPTC 
17 GCTTGTGCTCCGAATAATCGTCTTCAGTGC ACAPNNRLQC 
18 n/a Blank 
19 GCTTGTAATCAGTGGTTGACGCAGAATTGC ACNQWLTQNC 
20 n/a Blank 
21 GCTTGTATGCGGGCTGGTTCTCATAATTGC ACMRAGSHNC 
22 GCTTGTAATAAGAAGGTGGGTAAGCATTGC ACNKKVGKHC 
23 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
24 GCTTGTACGTCTCCGGAGCGGTATTCGTGC ACTSPERYSC 






















26 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
27 GCTTGTGCTCCGAATAATCGTCTTCAGTGC ACAPNNRLQC 
28 n/a Blank 
29 GCTTGTGCTCCGAATAATCGTCTTCAGTGC ACSSTGLSKC 
30 n/a Blank 
31 GCTTGTAATACGAAGATGGGTAAGACTTGC ACNTKMGKTC 
32 GCTTGTGATCAGCGGGATGATAGGTTTTGC ACDQRDDRFC 
33 GCTTGTGGGTCTTTTTGGTCGCTGACGTGC ACGSFWSLTC 
34 n/a Blank 
35 GCTTGTGTTGATCCGCATCCGAGGACTTGC ACVDPHPRTC 
36 GCTTGTGTTGATCCGCATCCGAGGACTTGC ACVDPHPRTC 
37 n/a Blank 
38 GCTTGTAAGATTAGTTCGTTTACTCAGTGC ACKISSFTQC 
39 GCTTGTCCTTTGGCTCCGATGCCGGCGTGC ACPLAPMPAC 
40 n/a Blank 
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Table 4-7. Sequencing analysis of the naïve C7C library (sequences chosen for peptide 








DNA Sequence Peptide Sequence 
1 GCTTGTGTGCGTGCGTATGATGGTATTTGC ACVRAYDGIC 
2 n/a Blank 
3 GCTTGTGATGGTAAGTATATTCAGAATTGC ACDGKYIQNC 
4 GCTTGTCCGAAGAGTATGTTGCCTTGGTGC ACKSMLPWC 
5 GCTTGTTAGGTGGATGGTTCTCCTCGGTGC ACQVDGSPRC 
6 GCTTGTGTTTCGACTTGGCTGACTTCTTGC ACVSTWLTSC 
7 GCTTGTACTATTCCTGGTATTGATACGTGC ACTIPGIDTC 
8 GCTTGTCCGCTTACGGCGGTTATTTCTTGC ACPLTAVISC 
9 GCTTGTAGTCATGGTCATTAGGCTCAGTGC ACSHGHQAQC 
10 GCTTGTACGAATCCGCCTACGGCGTCTTGC ACTNPPTASC 
11 GCTTGTCAGATGGCTCCGACGGATGGTTGC ACQMAPTDGC 
12 GCTTGTCTGGCGACTAAGACTGCTGGTTGC ACLATKTAGC 
13 GCTTGTCCTGCTTATACGTCTCATGCGTGC ACPAYTSHAC 
14 GCTTGTAATCTGTCTACGGCGCATGCTTGC ACNLSTAHAC 
15 GCTTGTCAGATTACTGGGTTTTTGAGGTGC ACQITGFLRC 
16 n/a Blank 
17 GCTTGTCTGCCTCTGCCTACTGTGGGGTGC ACLPLPTVGC 
18 GCTTGTGATGTTCGTGATTCGACTGCTTGC ACDVDRSTAC 
19 GCTTGTTCGAATCCTTCGACGGAGTGTTGC ACSNPSTECC 
20 GCTTGTCATGGTGCTCCGGGGCCTTCTTGC ACHGAPGPSC 
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Table 4-8. Sequencing analysis of the AR497 selection (sequences chosen for peptide 
synthesis shown in bold). 
Hit 
# 
DNA Sequence Peptide Sequence 
1 GCTTGTACGCCGACGGCTCGTGGTACTTGC ACTPTARGTC 
2 GCTTGTCATTATGGGGATTCTCGTACTTGC ACHYGDSRTC 
3 GCTTGTTTGGCTACTAAGGGGTCGATTTGC ACLATKGSIC 
4 GCTTGTGGGGTGGGTATGAATATTATGTGC ACGVGMNIMC 
5 n/a Blank 
6 n/a Blank 
7 GCTTGTTTGGCTACTAAGGGGTCGATTTGC ACLATKGSIC 
8 GCTTGTACGCCGACGGCTCGTGGTACTTGC ACTPTARGTC 
9 GCTTGTTCTGAGCGGCAGCATCTTCAGTGC ACSERQHLQC 
10 GCTTGTCGTTCTCATGATTCGGCGATGTGC ACRSHDSAMC 
11 GCTTGTCGTTCTCATGATTCGGCGATGTGC ACRSHDSAMC 
12 n/a Blank 
13 n/a Blank 
14 n/a Blank 
15 GCTTGTCATGTTTCTAATCATAAGACTTGC ACHVSNHKTC 
16 n/a Blank 
17 n/a Blank 
18 n/a Blank 
19 GCTTGTCGTTCTCATGATTCGGCGATGTGC ACRSHDSAMC 
20 n/a Blank 
21 n/a Blank 
22 GCTTGTCGTTCTCATGATTCGGCGATGTGC ACRSHDSAMC 
23 n/a Blank 
24 n/a Blank 





26 n/a Blank 
27 n/a Blank 
28 n/a Blank 
29 GCTTGTTCTACTTCTCAGGTTCGGTGGTGC ACSTSQVRWC 
30 n/a Blank 
31 GCTTGTCATTATGGGGATTCTCGTACTTGC ACHYGDSRTC 
32 n/a Blank 
33 n/a Blank 
34 n/a Blank 
35 n/a Blank 
36 n/a Blank 
37 GCTTGTTCTGAGCGGCAGCATCTTCAGTGC ACSERQHLQC 
38 GCTTGTTCTGAGCGGCAGCATCTTCAGTGC ACSERQHLQC 
39 GCTTGTCAGCATGAGGAGTATCGGACGTGC ACQHEEEYRTC 
40 n/a Blank 
41 GCTTGTTCTGAGCGGCAGCATCTTCAGTGC ACSERQHLQC 
42 n/a Blank 
43 n/a Blank 
44 GCTTGTTTGGCTACTAAGGGGTCGATTTGC ACLATKGSIC 
45 n/a Blank 
46 n/a Blank 
47 GCTTGTGGGAATTGGTCGATGAATCAGTGC ACGNWSMNQC 
48 GCTTGTTCTGAGCGGCAGCATCTTCAGTGC ACSERQHLQC 
49 GCTTGTCATTATGGGGATTCTCGTACTTGC ACHYGDSRTC 
50 n/a Blank 
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4.6.3 Synthesis of APBA Dimer Peptides 
SPPS was carried out on Rink Amide MBHA resin with Fmoc/Tbu chemistry on 
a 0.05 mmol scale. Five equivalents of commercially available amino acids and 4.9 
equivalents of HBTU were used for each coupling reaction. An Alloc-protected Dap 
residue was installed at the C-terminus for on-resin coupling of the 5(6)-FAM/5(6)-
TAMRA fluorophores, followed by a triple glycine linker and the peptide hit sequence at 
the N-terminus. 5(6)-FAM or 5(6)-TAMRA were conjugated to the peptide on resin after 
removal of the Alloc protecting group, as described in 4.6.5, followed by HBTU-
mediated amide bond coupling of the fluorophore in 0.4M NMM in DMF. The peptides 
were cleaved off resin and globally deprotected with 95% TFA, 2.5% water and 2.5% 
TIS. Crude peptides were obtained by ether precipitation and purified by RP-HPLC. For 
APBA-IA cysteine labeling, each peptide hit was treated with 3 equivalents of APBA-IA 
in the presence of TCEP (2 equivalents) in 2M NMM in DMF for 3 hours and directly 



















Table 4-9. LC-MS analysis of EGA-408, LOS- and AR497 peptide hits (Cm: APBA-IA 
modified Cys, CI: IA modified Cys, Dap*: FAM-labeled Dap, Dap*: TAMRA-labeled 
Dap) 
































































































































































































































































4.6.4 Fluorescence Microscopy Analysis of TAMRA/APBA Labeled Peptide Hits 
 Each bacterial strain was grown to an OD600≈1.0 (~1x109 cfu/mL), washed and 
diluted with 1X PBS pH 7.4. The cells were incubated with 2 µM of TAMRA-labeled 
peptide in 1 mg/mL BSA in 1X PBS pH 7.4 for 1 hour. White light and fluorescent 
images were obtained on a Zeiss microscope equipped with filter set 20 HE 
(excitation=BP 546/12, emission=BP 607/80) suitable for detection of TAMRA 
fluorescence. Images were captured using the 100X oil immersion objective with 1000 
ms exposure time. All images were processed consistently using ImageJ software.  
4.6.5 Flow Cytometry Analysis of FAM/APBA Labeled Peptide Hits 
Each bacterial strain was grown to an OD600≈1.0 (~1x109 cfu/mL), washed and 
diluted to ~1x107 cfu/mL with 1X PBS pH 7.4. The cells were incubated with various 
concentrations (250, 500 or 1000 nM) of FAM-labeled peptide in 1 mg/mL BSA in 1X 
PBS pH 7.4. After incubation for 1 hour at room temperature, the samples were filtered 
through Corning 0.35 µm cell strainer filter caps, and subjected to flow cytometric 
analysis. Data obtained was analyzed with BD FACSDiva software, and median 
fluorescent values were computed from the generated histograms. All flow cytometry 
experiments were repeated and generated consistent results.  
4.6.6 Microscopy Analysis of EGA-408 and 17978 Co-Cultures 
Each bacterial strain was grown to an OD600≈1.0 (~1x109 cfu/mL), washed and 
diluted with 1X PBS pH 7.4. The cells were combined at varying ratios as indicated, and 
incubated with 2 µM of TAMRA-labeled peptide in 25% human serum in 1X PBS pH 7.4 
for 1 hour. White light and fluorescent images were obtained on a Zeiss microscope 
equipped with filter set 20 HE (excitation=BP 546/12, emission=BP 607/80) suitable for 
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detection of TAMRA fluorescence. Images were captured using the 100X oil immersion 
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CHAPTER 5  
 
Selection of Targeted APBA Dimer Peptide Binders for the Chemotactic Innate 




























 Towards our goal of developing novel solutions to the antibiotic crisis, recent 
work in our group has focused on the application of APBA-presenting phage libraries for 
identification of peptides that selectively bind defined strains of bacteria with varying 
amine presenting modifications on their cell walls.1 This approach has been successful in 
identifying peptides capable of distinguishing S. aureus as well as several colistin 
resistant strains of bacteria as will be discussed in Chapter 5. We envisioned that this 
iminoboronate-capable high throughput peptide screening platform could be applied to 
identifying selective binders of proteins in addition to the aforementioned whole bacterial 
cell application. With our targeted protein binding in mind, we came across the protein 
human beta defensin 3 (hBD3), which is an innate immune peptide that exerts both 
antimicrobial as well as chemotactic activities, and plays an important role in aggressive 
head and neck cancers. Thus, we sought to identify selective binders to this protein 
through our phage display screening approach.  
5.1.1 Classification of Defensins 
Defensins are a group of small cationic peptides, which are classified by their 
disulfide bonding patterns, and exert both antimicrobial and immunomodulatory effects.2 
Human defensins are separated into two distinct families, α and β, depending on their 
sequence homology and disulfide pairing (Figure 5-1). Humans have six known α-
defensins, and four known β-defensins, all of which display markedly distinct functions 
despite striking structural similarity (Table 5-1). The human α-defensins were initially 
discovered as natural peptide antibiotics, which are released from neutrophils and Paneth 
cells to kill ingested foreign microbes during phagocytosis.3,4 Alternatively, human β-
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defensins (hBDs) are found predominantly in epithelial cells and tissues,5 and display 
varying antimicrobial potency towards different species of bacteria. For example, hBD1 
and 2 are only potent against gram-negative species, such as E. coli, whereas hBD3 
displays potent broad-spectrum activity. Notably, the antimicrobial activity of most 
defensins is dependent upon salt concentrations, thus highlighting the importance of 
electrostatic interactions between the cationic peptides and the negatively charged 





Figure 5-1. Structural differences between α and β defensins. 
 
 
Table 5-1. Sample of defensin sequences and their disulfide connectivities.  
Class Name Sequence Disulfides 
α HNP1 ACYCRIPACIAGERRYGTCIYQGRLWAFCC 1-6, 2-4, 
3-5 
 HNP2 CYCRIPACIAGERRYGTCIYQGRLWAFCC  
 HNP3 DCYCRIPACIAGERRYGTCIYQGRLWAFCC  
 HNP4 VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV  
 HD5 ATCYCRHGRCATRESLSGVCEISGRLYRLCCR  
















 β-Defensin GGIDGPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP 
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5.1.2 Human β-defensin 3 and its Antimicrobial Activity 
 Human β-defensin 3 (hBD3) is a 45 residue cationic peptide that displays uneven 
C-terminal clustering of its positively charged residues. Initially isolated from psoriatic 
scales, hBD3 forms amphipathic symmetrical dimers through one of its three β strands 
(β2), which affords the peptide unique characteristics including broad-spectrum and salt-
insensitive activity, with low micromolar activity towards P. aeruginosa, S. aureus, 
Enterococcus faecalis and Streptococcus pyogenes (Figure 5-2).6,7 Further mechanistic 
investigation has also revealed that hBD3 does not preferentially fold into its native 
disulfide configuration in vivo; however, hBD3’s bactericidal activity has been shown to 
be independent of the arrangement of disulfide connectivity, indicating that the structure 
of hBD3 is less important for antimicrobial activity than the arrangement of amino acids 
(Table 5-2).7,8 
 
Figure 5-2. Structural features of hBD3, including the interaction between the two β2 
strands, which are stabilized by salt bridge formation between Glu28 and Lys32 in an 





Table 5-2. Bactericidal and chemotactic activity of hBD3 and structural analogues 
(adapted from Ref. 7)  
Peptide Disulfide 
Connectivity 
LD50 E. coli, ug/mL Concentration for 
Chemotaxis, 
ng/mL 
hBD3 (1)* 1-5, 2-4, 3-6 0.08 10 
hBD3 (2) 1-5, 2-4, 3-6 0.06 100 
hBD3 (3) 1-5, 2-3, 4-6 0.03 1,000 
hBD3 (4) 1-6, 2-4, 3-5 0.08 1,000 
hBD3 (5) 1-6, 2-3, 4-5 0.05 100 
hBD3 (6) 1-6, 2-5, 3-4 0.02 100 
Abu-hBD3 None 0.04 >10,000 
*=natively folded peptide; Abu=α-aminobutyric acid capped cysteine (eg. no disulfide 
bonds) 
 
5.1.3 Chemotactic Activity of Human β-defensin 3 and its Implication in Cancer 
 In addition to their wide-ranging antimicrobial activity, defensins have also been 
shown to possess important functions in the modulation of adaptive immunity by 
selectively chemoattracting different subsets of T lymphocytes and immature dendritic 
cells.9 In contrast to antimicrobial activity, the arrangement of disulfide bonds, as well as 
the presence of cysteine, do affect the chemotactic activity of hBD3 (Table 5-2).8 In 
general, defensins are considered to be pro-inflammatory since their expression increases 
in response to toll-like receptor (TLR) ligands, such as TNF- α, IL-1 β, IFN-γ and PMA 
under infection conditions. Additionally, defensins have been shown to chemoattract 
CD4 T cells and immature dendritic cells through chemokine receptors to induce 
chemotaxis.10 hBD3 specifically chemoattracts monocytes and myeloid dendritic cells 
and activates them through TLR-1/2 by inducing expression of co-stimulatory molecules 
and NF-κB.11  
 A number of studies have been carried out to dissect the interaction of hBD3 with 
the adaptive immune system. In vivo studies have shown that hBD3 functions as a 
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chemoattractant to recruit macrophages via C-C chemokine receptor 2 (CCR2), as the 
monocytic cell migration was inhibited by the cross-desensitization with monocyte 
chemoattractant protein 1 (MCP-1), a tumor cell associated chemokine and a CCR2-
specific inhibitor (Figure 5-3).11 Additionally, hBD3 expressing tumorogenic cells have 
been shown to induce massive tumor infiltration of host macrophages, as well as induce 
expression of a wide variety of tumor promoting cytokines (IL-1α, IL-6/8, TNF- α).11  
Figure 5-3. hBD3 induces CCR2-mediated monocytic cell migration. (a) Migration of 
Mono-Mac (CCR2-expressing) cells in response to hBD3. (b) Migration of Mono-mac 
and (c) monocytic (also express CCR2) cells in the absence (white bars) and presence 
(black/striped bars) of CCR2 inhibitors (Images from Ref. 11). 
 
 
 Importantly, head and neck cancers overexpress hBD3, which stimulates human 
macrophages to express tumor-promoting chemokines. This may result in a positive 
feedback loop to drive tumor progression (Figure 5-4). hBD3 expression was found to be 
induced by the activation of epidermal growth factor (EGFR)12 and the inactivation of 
p5313, and also correlates with increased levels of myeloid-derived suppressor cells, 
which are immune cells that are up-regulated in cancer disease states.14 Thus, it appears 
that hBD3 functions as an immunomodulator to recruit and activate tumor-assisted 
a) b) c) 
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macrophages and myeloid-derived suppressor cells to promote progression of tumors 
using CCR2 to regulate monocyte/macrophage trafficking.  
Figure 5-4. Overexpression of hBD3 in head and neck cancers induces expression of 
chemokines. (a) Immunofluorescent staining of in situ cancer biopsy shows extensive 
hBD3 expression (red) in comparison to normal tissue. (b) RT-PCR quantification of 




5.1.4 Application of Phage Display Technology to Identify Protein Binders 
The implication of the innate immune defensin hBD3 in aggressive head and neck 
cancers makes it an interesting therapeutic target. While literature indicates substantial 
proof of CCR2-mediated cheomattraction of hBD315, no structural studies have been 
conducted to elucidate the nature of the interaction between hBD3 and CCR2. Although 
rational design of an hBD3-binding peptide that would disrupt the interaction between 
hBD3 and CCR2 is not possible, we envisioned that phage display selection of hBD3 
binders could provide a suitable starting point to generate peptide sequences that bind to 
the defensin.  
Phage display has been applied to generate high affinity peptide binders and 
inhibitors for a wide variety of small molecule and protein targets including proteases, 
viruses, bacteria and tumor cells. Our group has carried out extensive investigation on 
identifying whole bacterial cell peptide binders using an iminoboronate-capable phage 
a) b) 
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library.1 These CX7C phage are reduced in order to cap the cysteines with APBA-IA, 
which enables them to form stabilized iminoboronate linkages with amines presented by 
the target (Figure 5-5). Since hBD3 carries several lysine residues throughout its 
sequence, we envisioned that the APBA warheads presented on the phage library would 
provide greater stabilization to the peptide-hBD3 interaction. Thus, we aimed to screen 
streptavidin-immobilized hBD3 with our APBA modified phage library in order to 








Figure 5-5. Schematic of APBA-IA labeling of CX7C phage to generate an 
iminoboronate capable randomized peptide library on the surface of M13 phage. 
 
5.2 Synthesis of Biotin-hBD3 and Biotin-hBD2 
 For our phage display panning against hBD3, we envisioned that we could biotin 
tag the hBD3 protein in order to immobilize it on streptavidin beads for phage panning. 
Given that isolation of overexpressed hBD3 protein in bacteria has lead to isolation of not 
only the native form, but also alternatively folded hBD38, we envisioned that solid phase 
peptide synthesis (SPPS) would enable us to control the folding of hBD3 to into the 



















easily biotin tag the protein. However, given the long length (45 residues) of hBD3, 
straightforward SPPS of the protein in its entirety was unlikely to yield substantial 
amounts of full-length peptide. 
5.2.1 Native Chemical Ligation  
 Recent interest in the chemical synthesis of proteins has uncovered the power of 
native chemical ligation towards generating longer peptides than previously enabled. 
While peptides of lengths up to 50 residues have been successfully synthesized by SPPS, 
these findings are generally sequence dependent and do not speak to the totality of 
peptides due to sequence-specific aggregation and diminished coupling efficiency of 
certain residues and residue combinations.16 To work around these issues, native 
chemical ligation (NCL) has emerged as an efficient, tag-free approach to generating 
long peptides through the fusing of two shorter peptides.17 To do so, one peptide must be 
synthesized on Dawson Dbz resin, which undergoes N-acylurea formation at the C-
terminus by acylation with nitrophenylchloroformate, and is then subjected to 
intramolecular cyclization when treated with base to obtain the N-acyl-
benzimidazolinone (Nbz) peptide fragment. Nbz can then undergo rapid thiolysis in 
neutral conditions, and ligate to an N-terminal cysteine containing peptide to yield the 




















Figure 5-6. Schematic of native chemical ligation via formation of C-terminal N-
acylurea followed by thioester formation and a final S-N acyl transfer to yield the native 
peptide (adapted from Ref. 17). 
 
 
 Towards this end, we synthesized two hBD3 fragments (hBD3a and hBD3b for 
hBD3, or hBD2a and hBD2b for hBD2) that could undergo native chemical ligation 
(Figure 5-7). The hBD2/3a fragment, which constitutes the N-terminus of full-length 
hBD2/3, was synthesized on Dawson-Dbz resin. The hBD2/3b fragment was synthesized 
on Wang resin, with cysteine as the N-terminal residue to enable facile conjugation to the 
Nbz modified hBD3a. One challenge encountered in the synthesis of hBD2/3a was 
coupling of the first residue. Instead of standard HBTU coupling with NMM, HATU with 
DIPEA was used instead to improve coupling efficiency. Additionally, we observed that 
peptides were not synthesized in pure form due to peptide elongation at the free, non-
Fmoc protected amine on the Dawson Dbz resin, despite reduced activation of that 
amine. To eliminate this problem, the Fmoc protected resin was first alloc protected to 


















































Figure 5-7. Peptide fragments of hBD3 and hBD2 synthesized for efficient NCL. The 
synthetic strategy of orthogonal cysteine protecting groups and peptide fragments for (a) 
hBD3 and (b) hBD2 enabled facile synthesis of the full length, natively folded peptide. 
 
 Once the two peptide fragments were synthesized, a native chemical ligation 
approach was taken to carry out their ligation. A pH screen (pH 6, 7 and 8) of the NCL 
conditions was carried out to determine the optimal pH of the ligation reaction to 
minimize hydrolysis of the Nbz modified peptide and maximize the yield of the ligated 
product. pH 8 was found to be most optimal for maximum yield of the ligated hBD3-
biotin or hBD2-biotin peptides (Table 5-1). Using this condition, the peptides were 
successfully ligated and purified to yield pure peptide. 







pH % Hydrolyzed Nbz % Ligated Peptide 
6 90 10 
7 25 75 













hBD2-a: Dawson Dbz-FVPHCIAGSKLCTVPDGIG-Aha-Biotin-NH2 
hBD2-b: Wang-PKKCCKTGPLGCTGIQKYRRP-NH2 
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5.2.2 Stepwise Oxidative Folding of hBD2 and hBD3 
 An orthogonal cysteine protection strategy was implemented in the design of 
hBD3-biotin and hBD2-biotin to afford selective disulfide bond formation (Figure 5-8). 
Firstly, the trityl protecting groups were removed following peptide cleavage from resin 
with TFA/EDT/water. After purification of the ligated peptide, oxidation of the trityl 
deprotected cysteines was carried out by stirring the peptide in 10% DMSO in water. The 
peptides were directly lyophilized and used without purification for the next 
deprotection/oxidation step. The Acm protecting groups were then removed and 
concomitantly the disulfide bond was formed with iodine in acetic acid and 0.1M HCl 
before the peptides were purified. Finally, the Tbu protecting groups were removed and 
the disulfide bonds were formed with TFA/DMSO/anisole prior to final peptide 
purification.  
Figure 5-8. Orthogonal cysteine protection strategy to enable native disulfide formation 
of hBD3 and hBD2. Selective protection of cysteine residues on (a) hBD3 and (b) hBD2 
enables sequential deprotection and oxidation of cysteines. 
  
 
5.3 APBA Dimer Phage Library Screening Against Biotin-hBD3 
5.3.1 Confirmation of Dimerization of Synthetic Biotin-hBD3 
 Upon successful synthesis of biotin-hBD3, the properties of the synthetic peptide 














as a result of a Lys32-Glu28 interaction6,18, whereas reduced hBD3 does not. To confirm 
that our synthetic biotin-hBD3 also forms dimers in the oxidized state, we analyzed the 
peptide by Tricine gel electrophoresis. Our analysis revealed that indeed synthetic biotin-
hBD3 (5.49 kDa) does form dimers under oxidized conditions, but this property is 
abolished when the peptide is reduced with 0.1M DTT (Figure 5-9). This suggests that 
the structural integrity and folding of hBD3 is not significantly impacted by our synthetic 
approach and modification with biotin, and confirms that our synthetic peptide should 
















Figure 5-9. 16% tricine gel analysis of hBD3 dimerization (Lane 1= 10 µg hBD3-biotin 
non-reduced, Lane 2= 10 µg hBD3-biotin reduced with DTT, stained with coomassie, 
PrecisionPlus Ladder used as standard). 
 
4.3.2 Phage Screening of Biotin-hBD3 
 For phage panning, a few key elements were introduced to the screening 
workflow to ensure stringency of selection, as well as to avoid isolation of binders to the 
affinity beads (Figure 5-10). Firstly, the beads were alternated between streptavidin and 
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neutravidin between panning rounds. Secondly, albumin was included in the wash steps 
to eliminate any peptides that would exhibit strong albumin binding. Finally, the phage 
library was pre-incubated with biotin to eliminate any biotin specific binders from the 
pool. Throughout the panning process, stringent washing steps were applied, with the 
concentration of Tween increasing from 0.1% in the first round to 0.2% in the second, 
and 0.3% in the third round. The phage titer results from each round (Table 5-2) show 
that the washes did increase stringency by decreasing the output population by several 













Table 5-4. Phage titers from each round of hBD3 panning.  
S=streptavidin; N=neutravidin 





1(S) 2.60x1010 pfu/mL N/A 4.65x107 pfu/mL 4.90x1013 
pfu/mL 
2 (N) 4.25x1011 pfu/mL 6.00x1011 pfu/mL 6.50x105 pfu/mL 2.70x1013 
pfu/mL 










3a) Incubate phage with Biotin, pulldown with 
streptavidin/neutravidin (alternate between 
rounds, only round 2 and beyond)
3b) Incubate phage (unbound phage from 3a
if round 2 or beyond) with hBD3-Biotin
 (in presence of albumin/cell lysate)














hBD3-Biotin Bound APBA Labeled
AC7C Phage Library
6) Acid elution of binders
ACXXXXXXXCGGG







5.4 hBD3 Peptide Hit Validation via hBD3 Binding Assays 
5.4.1 Analysis of Phage Binding to hBD3 Coated Beads 
Sequencing of the third round output only revealed one repeating sequence (ISL, 
Table 5-5), so a hBD3 coated bead binding phage experiment with isolated phage 
populations was attempted prior to carrying out any peptide synthesis. To do so, 
amplified phage from individual phage colonies that had been amplified for sequencing 
were isolated from the supernatant of the ER2738 cultures with PEG/NaCl. These 
isolated phage were then subjected to iTCEP reduction and APBA-IA labeling prior to 
bead binding experiments. For this experiment, the APBA-IA labeled phage were directly 
incubated with hBD3 coated beads, after which a FITC-pIII antibody was used to detect 
if the phage (which bear several copies of the pIII protein) were bound to the hBD3 
coated beads as a measure of hBD3 binding. A negative control test of the FITC-pIII 
antibody’s ability to bind to hBD3-coated beads was first carried out. No bead staining by 
the antibody alone was observed, indicating that the antibody doesn’t display any non-
specific binding to the hBD3 coated beads (Figure 5-11).  
Table 5-5. Sequences of hBD3 phage panning round 3 output.  
HPSNWKA GRTPSDK TSWSKRL TLTAYKV LNAGASK 
NSSASKN SLSNYHR YKTMYGL QPSRFVQ NTPAMLT 
TTKLPNS VMSPGKS RLPTSTG GKHFQKH LHKSVSG 
KHPLYRH MNPLYWR DRAGLEH MKALYWR KIPSXGR 
SSKHEAT VHSKPGR NSHRHGA VNPMKRH LWRPAAD 
HRAQGTA KNPQYRR TDSRGQK PAQNGWQ  
ISLTLNR* ISLTLNR* KEGIHMT SAGYSRN  
SAYERPP VSTMART TSLTVDR KAGHQYQ  





Figure 5-11. Fluorescence analysis of the binding of FITC-pIII antibody to biotin and 
hBD3-biotin coated streptavidin beads. 
 
The phage bearing unique sequences were then incubated with the hBD3 coated 
beads to assess their binding affinity. Interestingly, all phage including the blank, 
insertless (eg. No CX7C) phage displayed robust binding to the hBD3-coated beads 
(Figure 5-12). This phenomenon is likely due to electrostatic interactions between the 
highly positively charged hBD3 peptide (+11) and the phage’s negatively charged pVIII 
coat protein. Attempts at washing the beads gave no decease in non-specific phage 
binding. This observation has also been reported by groups that have applied polylysine 
and related polymers as “phage wrappers” to mask the negatively charged phage surface. 
While it does appear that the electrostatic interaction interferes with analysis of phage 
binding via microscopy, the observed enrichment of the phage population between 
rounds indicates that this non-specific interaction likely did not play a role in the 
selection of strong hBD3 binders. 
 
Biotin Alone (no phage) hBD3-Biotin Alone (no phage) 
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Figure 5-12. Fluorescence analysis of blank phage binding to hBD3 biotin coated beads 
with or without washing after phage incubation. 
 
5.4.2 Synthesis of hBD3 Peptide Hits 
 Given the challenges with identifying strongly binding peptide sequences via the 
phage microscopy experiment, four peptide sequences from the third round output were 
randomly selected for SPPS (Table 5-6). These peptides were fluorescently labeled with 
TAMRA to enable facile microscopy of the hits. To enable selective TAMRA and 
APBA-IA labeling of the peptides, a C-terminal Alloc-protected Dap residue was 
included. This residue was able to be selectively deprotected on resin to enable on-resin 
TAMRA labeling. Following cleavage from resin and purification, the peptides were then 
subjected to APBA labeling to yield TAMRA and APBA labeled peptides.  
 






Cm=APBA-IA labeled; *= TAMRA 
hBD3-Biotin Coated Beads (Wash 5x TBS pH 7.5) 
Biotin Coated Beads hBD3-Biotin Coated Beads 
Peptide Sequence 
SEC1 ACmISLTLNRCmGGGDap* 
SEC2 ACmDRAGLEHCm GGGDap* 
SEC3 ACmVSTMARTCm GGGDap* 
SEC4 ACmKAGHQYQCm GGGDap* 
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5.4.3 hBD3 Coated Streptavidin Bead Peptide Binding Analysis  
 To examine the binding of these peptides to hBD3, agarose beads were coated 
with hBD3-biotin, then incubated with each TAMRA and APBA-IA labeled peptide (10 
µM), and finally analyzed by fluorescent microscopy. SEC2 and SEC4 were observed to 
have the most potent hBD3 binding, whereas SEC1 and SEC3 displayed minimal binding 
to the hBD3-coated beads (Figure 5-13). This experiment was also carried out in the 
presence of 10 mg/mL BSA and 10% human serum (HS), neither of which diminished 
peptide binding to hBD3-coated beads. 
 To quantify the hBD3 binding of the peptides, a titration experiment was carried 
out in which the fluorescence of the highest concentration of peptide examined was 
adjusted to produce maximal fluorescence. These settings were then maintained to 
fluorescently image the beads at lower peptide concentrations to generate a saturating 
binding curve. The average fluorescence of the beads was then obtained to generate a 
titration plot for SEC2 and SEC4 (Figure 5-14). These experiments indicated that the 




















Figure 5-13. hBD3-coated bead fluorescence of APBA dimer peptide hits. Fluorescence 
of SEC2 (DRA), SEC3 (VST), SEC1 (ISL) and SEC4 (KAG) towards hBD3-coated 
beads was analyzed by fluorescence microscopy in the presence and absence of 10 
































































































Figure 5-14.  hBD3 peptide binding titration analysis. Increasing concentrations of SEC2 
(left) and SEC3 (right) were titrated with hBD3-coated beads to analyze the fluorescence 
of the beads and determine a binding dissociation constant.  
 
4.4.4 hBD2 Coated Streptavidin Bead Peptide Binding Analysis 
To assess the hBD3 specificity of the identified peptide binders, the same agarose 
bead binding experiment was carried out for the closely related hBD2 protein, which 
displays a similar sequence and cationic charge to that of hBD3. No labeling of the 
hBD2-coated beads was observed for any of the peptides examined (Figure 5-15), 















Figure 5-15. Analysis of hBD3 peptide hit binding to hBD2. The binding of (a) SEC3, 
(b) SEC4, (c) SEC2 and (d) SEC1 to hBD2 was analyzed by hBD2 coated agarose bead 
microscopy. 
10 uM DRA 
10 uM VST 
10 uM KAG 





















































5.4.5 BSA Binding Anisotropy Analysis of hBD3 Binding Peptides 
 To assess the binding affinity of the hBD3 peptide hits towards BSA, each 
TAMRA labeled peptide hit was titrated with increasing concentrations of BSA. The 
anisotropy readings were zeroed and normalized, then plotted against BSA concentration 
to extract binding dissociation constants. All three peptides examined display Kd 
measurements around 2-4 mg/mL for binding BSA (Figure 5-16). 
 
Figure 5-16. Analysis of hBD3 peptide hits BSA binding capacity. Anisotropy titrations 
of (a) SEC2, (b) SEC4 and (c) SEC3 with 0-20 mg/mL BSA enabled the determination of 
binding dissociation constants for BSA binding. 
 
4.5 Conclusions  
 By chemically synthesizing hBD3-biotin through a NCL approach, we were able 
to successfully synthesize natively folded hBD3 with a biotin tag that retained the 
dimerization property of the protein. Screening of an APBA modified phage library 
against immobilized hBD3 yielded peptide hits that were analyzed for their capacity to 
bind hBD3 via fluorescent analysis of hBD3 coated beads. These experiments revealed 
that two of the randomly selected hits, SEC2 and SEC3, displayed potent hBD3 binding 
with Kd values of 6 µM and 10 µM, respectively. Notably, these peptides did not exhibit 
any binding towards the similar protein hBD2. Thus, our screening approach was 
successful in selecting for targeted peptide binders of a therapeutically relevant protein. 
Kd=2.00 mg/mL Kd=3.95 mg/mL Kd=3.80 mg/mL 
SEC2-DRA SEC3-VST SEC4-KAG 
a) b) c) 
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 Further analysis of BSA binding of the peptides revealed that the peptides do 
indeed bind BSA; in the future, this phenomenon could be further mitigated by carrying 
out the screening in the presence of a higher concentration of BSA (eg. 10 mg/mL instead 
of 1 mg/mL). Despite the observed strong binding of our hBD3 targeting peptides, 
preliminary studies of the inhibition of hBD3 chemotactic activity haven’t revealed any 
significant inhibition of hBD3 function (data not shown). Further investigation of the 
behavior of the peptides in biologically relevant conditions (e.g. media) may be necessary 
to better understand if the lack of activity inhibition is due to either a lack of binding of 
the peptide in these conditions (such as due to peptide degradation or aggregation), or if 
the peptides bind to hBD3 in a manner that is compatible with hBD3 activity. 
Nonetheless, our results show promise for the selection of protein binding peptides via 
this phage display platform.  
5.6 Experimental Protocols 
5.6.1 General Methods 
Amino acids, HATU and HBTU were purchased from Creosalus and Chem 
Impex International. 5(6)-Tetramethylrhodamine was purchased from Chem Impex 
International. Dimethylformamide, dichloromethane, allyl chloroformate, piperidine, N-
methylmorpholine, diisopropylethylamine, phenylsilane, 
tetrakis(triphenylphosphine)palladium(0), p-nitrophenylchloroformate, guanidinium 
chloride, sodium phosphate, tris(2-carboxyethyl)phosphine hydrochloride, thiophenol, 
DMSO, acetic acid, iodine, anisole, triisopropylsilane, ethanedithiol, biotin, bovine serum 
albumin and human serum albumin were purchased from Fisher Schientific. Streptavidin 
agarose beads, Precision Plus Ladder and immobilized TCEP were purchased from 
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ThermoFisher Scientific. Anti-pIII-FITC antibody was purchased from Santa Cruz 
Biotechnologies. Trifluoroacetic acid was purchased from Protein Technologies. The 
phage display C7C library was purchased from NEB. APBA-IA was synthesized 
according to previously reported methods1 and used from a 200 mM DMSO stock for all 
phage labeling experiments, and a 10 mg/mL stock for peptide labeling. Defensins were 
synthesized on Dawson-Dbz (EMD Millipore) and Wang (EMD Millipore) resins using 
standard Fmoc chemistry procedures (0.4M NMM in DMF for amino acid couplings, 
20% piperidine in DMF for fmoc removal), unless indicated otherwise. All peptide hits 
were synthesized on Rink Amide resin (EMD Millipore).  
Peptides were synthesized on a Tribute Peptide Synthesizer from Protein 
Technologies. All peptides were purified via reverse phase high performance liquid 
chromatography (RP-HPLC) on a Waters Prep LC with a Jupiter C18 column 
(Phenomenex) with water/acetonitrile/0.1% TFA eluent (Buffer A= 95% water, 5% 
acetonitrile, 0.1% TFA, Buffer B= 95% acetonitrile, 5% water, 0.1% TFA) with a 
gradient from 100% Buffer A to 60% Buffer B. Mass spectrometry analysis was carried 
out on an Agilent 6230 LC TOF mass spectrometer. Fluorescence images were obtained 
on a Zeiss Axio Observer A1 inverted microscope. Fluorescence anisotropy data were 
generated on a SpectraMaxM5 plate reader. The concentration of TAMRA labeled 
peptides was determined by fluorescence readout on a Nanodrop 2000c UV/Vis 
spectrometer by cuvette (ε=90,000 M-1cm-1). 
5.6.2 Defensin Synthesis 
 hBD2/3-a were synthesized on Dawson-Dbz resin. Prior to amino acid couplings, 
the resin was alloc protected with 350 mM allylchloroformate and 1 equivalent DIPEA in 
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DCM for 24 hours. The first 5 residues were then coupled by hand with 5 equivalents 
amino acid and 4.9 equivalents HATU in 9 equivalents DIPEA in DMF. All subsequent 
amino acids were coupled with 0.4M NMM in DMF using an automated peptide 
synthesizer. The Fmoc-aminohexanoic acid linker and biotin molecule were coupled last 
by hand with 0.4M NMM in DMF and 4.9 equivalents HATU. Following completion of 
synthesis, alloc was removed with 0.7 equivalents 
tetrakis(triphenylphosphine)palladium(0) and 0.1 equivalents phenylsilane in DCM. 
Conversion to Nbz was achieved by stirring with triphenylchloroformate in DCM for 40 
minutes, then treating with 0.5M DIPEA in DMF for 30 minutes. The peptides were 
cleaved from resin with 95% TFA/5% water and isolated by cold ether precipitation. The 
peptides were then purified by RP-HPLC and their purity was confirmed by LC-MS 
(Table 5-7).  
 hBD2/3-b were synthesized on an automated peptide synthesizer on Wang resin 
with standard 0.4M NMM in DMF couplings. The completed peptides were cleaved from 
resin with 94% TFA, 3% EDT and 3% water, isolated via cold ether precipitation and 
purified by RP-HPLC with purity confirmed by LC-MS (Table 5-7). 
 To ligate the peptides, 3.8 mM hBD2/3a was stirred with 4.2 mM hBD2/3b in 2:3 
DMF: ligation buffer (3M Gdn-HCl, 0.2M sodium phosphate, 20 mM TCEP, 200 mM 
thiophenol, pH 8) for 1 hour. The peptides were then directly purified by RP-HPLC and 
their purity was confirmed by LC-MS (Table 5-7). 
 The Trt deprotected peptides (1.5 mM) were then oxidized with 10% DMSO in 
water for 18 hours. The peptides were directly lyophilized and used for the Acm 
deprotection/oxidation step, in which 3 mM peptide was stirred in 20 equivalents iodine 
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in acetic acid with 0.1M HCl for 1.5 hours. The peptides were isolated by cold ether 
precipitation and purified by RP-HPLC, and the purity was confirmed by LC-MS (Table 
5-7). 
 The peptides were finally Tbu deprotected and oxidized by stirring at 1 mM in 
TFA with 400 equivalents DMSO and 40 equivalents anisole for 5 hours. The peptides 
were then directly purified by RP-HPLC and their purity was confirmed by LC-MS 
(Table 5-7). 












*=[M+2H]2+; ×=[M+3H]3+; θ=[M+5H]5+; Aha=Aminohexanoic acid 
 
5.6.3 Phage Display Panning Protocols 
 5 µL (~5x1010 pfu) of the commercial CX7C library was stirred for 48 hours at 
4oC with 25 µL iTCEP in TBS pH 8.5. 2 mM APBA-IA was then added to the mixture, 
which was stirred for 2 hours at room temperature. The mixture was then centrifuged to 
isolate the phage mixture from the iTCEP beads, and the phage was precipitated from the 





hBD3-a* 1277.04 1276.66 
hBD3-b× 1127.59 1127.59 
Ligated hBD3 θ 1151.42 1151.81 
hBD3-1ox θ 1151.22 1151.61 
hBD3-2ox θ 1122.62 1122.59 
hBD3-3ox θ 1099.74 1099.77 
hBD2-a* 1270.53 1270.62  
hBD2-b* 1283.60 1283.17 
Ligated hBD2 × 1643.60 1643.51 
hBD2-1ox × 1643.27 1642.80 
hBD2-2ox × 1196.11 1196.35 
hBD2-3ox × 1167.42 1167.82 
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mixture was then centrifuged, and the phage pellet was re-suspended in 100 µL TBS pH 
7.5. The APBA-IA labeled phage was titered to determine an input population using 
standard M13 titering methods indicated by NEB.  
 For the pulldown experiment, streptavidin beads were washed with 0.1% TBST, 
then blocked with blocking buffer with 5 mg/mL BSA for 1 hour at 4oC. The beads were 
then washed with TBST. Concurrently, 12 µg hBD3-biotin was incubated with 50 µL 
APBA-IA labeled phage in 0.1% TBST for 30 minutes at room temperature with stirring. 
The phage mixture was then added to the blocked and washed streptavidin beads, which 
were stirred for 30 minutes at room temperature. Unbound phage was removed by 
washing with 0.1% TBST (5x), then TBS (5x), both with 1 mg/mL BSA. Phage binders 
were then eluted from the hBD3-coated beads by stirring with glycine elution buffer 
(0.2M glycine-HCl, pH 2.2, 1 mg/mL BSA) for 10 minutes. Eluted phage were 
neutralized with Tris pH 9.1. The phage output population was amplified by addition to 
an early-log ER2738 culture (ER2738 culture started from single colony inoculation from 
LB+Tet plate, grown overnight, then sub-cultured 1:100 in fresh LB media) and allowing 
the phage to amplify for 4.5 hours.  
 This panning procedure was repeated for subsequent rounds. Neutravidin beads 
were substituted in round 2. The washing stringency was increased with each round from 
0.1% Tween in round 1 to 0.2% and 0.3% in rounds 2 and 3, respectively. The DNA from 
phage output population from round 3 was isolated with a GeneJet miniprep kit following 
5 hours of incubation of individual phage colonies grown in 1:100 ER2738 from 
overnight culture in LB media. All DNA sequencing was carried out by Eton Bioscience 
Inc. (Table 5-8). 
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Table 5-8. DNA sequences from the round 3 hBD3 screen output. 












































5.6.4 PAGE Confirmation of hBD3 Dimerization 
 hBD3 dimerization was analyzed by 16% tricine gel electrophoresis. Untreated 
hBD3 (10 µg) or 0.1M DTT treated hBD3 (10 µg) were boiled at 100oC with non-
denaturing sample buffer, then subjected to 16% tricine PAGE alongside Precision Plus 
Ladder for 1 hour. The gel was then stained with Coomassie, destained and imaged. 
5.6.5 hBD3 Peptide Hit Synthesis  
 Peptide hits were synthesized by solid phase peptide synthesis on Rink Amide 
resin as previously detailed.1 An alloc protected diaminopropionic acid (Dap) residue was 
installed at the C-terminus for facile fluorophore labeling. 5(6)-TAMRA was conjugated 
to the resin after removal of the alloc protecting group with 0.7 equivalents of 
tetrakis(triphenylphosphine)palladium (0) and 0.1 equivalents phenylsilane in DCM. The 
TAMRA fluorophore was then conjugated on resin with HBTU-mediated amide bond 
coupling with 3 equivalents 5(6)-TAMRA and 2.9 equivalents HBTU in 0.4M NMM in 
DMF. The peptide was then Fmoc deprotected at the N-terminus using standard Fmoc 
deprotection conditions, and cleaved from resin with 95% TFA, 2.5% water and 2.5% 
triisopropylsilane. The peptides were then isolated by cold ether precipitation and 
purified by RP-HPLC. The peptides were then APBA-IA labeled with 3 equivalents 
APBA-IA in the presence of 2 equivalents TCEP with 2M NMM in DMF, and again 









Table 5-9. Sequence and LC-MS analysis of hBD3 binding peptides.  
Name Peptide Sequence Calculated Mass Observed Mass 
















Cm= APBA-IA labeled Cys; Dap*= TAMRA labeled Dap 
5.6.5 Streptavidin Bead Binding Microscopy Studies 
 For phage bead binding experiments, 50 µL streptavidin beads were washed with 
TBS pH 7.5, then incubated with 2 µL hBD3-biotin (10 mg/mL) for 1 hour at room 
temperature with stirring in TBS pH 7.5. The beads were then washed with TBS pH 7.5, 
incubated with 50 µL TBS pH 7.5 and 5 µL Anti-pIII-FITC for 30 minutes, then 2 µL of 
beads were imaged by fluorescence microscopy (FITC channel) at 10X magnification. 
 For peptide bead binding experiments, the same hBD3 coating procedures were 
carried out. Peptides at designated concentrations were added to the bead mixtures, which 
were incubated for 1 hour at room temperature in TBS pH 7.5 alone, or with 10% human 
serum or 10 mg/mL BSA. Then, 2 µL of beads were imaged by fluorescence microscopy 
(rhodamine channel) at 10X magnification. The same procedure was carried out for 
hBD2-coated bead binding. 
5.6.6 BSA Binding Anisotropy Analysis 
 Indicated concentrations of BSA (0-20 mg/mL) were incubated with 1 µM each 
TAMRA labeled peptide in PBS pH 7.4 for 1 hour at room temperature. Anisotropy 
readings were obtained in triplicate using TAMRA excitation and emission wavelengths 
(546/579 nm).  
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6.1 Conclusions  
 The overarching goal of the research outlined herein was to develop novel 
bioorthogonal chemical tools that enable species- and strain-selective bacterial targeting 
for development of diagnostic approaches, and eventually therapeutic scaffolds, towards 
efforts to combat antibiotic resistance. Antibiotic resistance accounts for ~2 million 
health care cases and >23,000 deaths in the US per year, while worldwide mortality rates 
are around 1 million per year. Additionally, antibiotic resistance generates massive 
excess health care costs, totaling nearly $20 billion annually in the US alone.1 For 
example, MRSA infections, of which there are about 80,000 cases annually, generate an 
average excess cost of ~$10,000 per incidence in comparison to MSSA infections as a 
result of the extra care demanded by these more challenging antibiotic resistant 
infections.2 More importantly, deaths resulting from antibiotic resistance are expected to 
grow to 10 million by 2050 due to increasingly challenging to treat infections and a lack 
of novel therapeutics.  
 From a scientific standpoint, the challenge of antibiotic resistance stems from two 
key factors: 1) a lack of effective novel antibiotic therapeutics, and 2) the widespread use 
of antibiotics, and especially broad-spectrum antibiotics.3 Fortunately, knowledge about 
the rise of antibiotic resistance has translated with some success to the clinic, as 
physicians have adopted more stringent practices for antibiotic prescription; however, 
these two key challenges remain to be seriously addressed by the scientific community. 
 Our research has sought to apply novel chemical tools towards identification of 
modalities that selectively label one species or strain of bacteria amongst all possible 
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species and strains of bacteria in complex biological settings. This aim has first required 
us to thoroughly examine the bioorthogonality of our chemical tools to ensure that they 
do not cause toxicity to the organism(s) of interest. This requirement for non-toxic 
chemical probes has also limited their working concentration in cellular contexts, which 
has demanded that we develop highly efficient chemical reactions that proceed with fast 
kinetics (≥103 M-1s-1) at low micromolar concentrations. Additionally, due to the 
physiological environments in which they are operating, these novel chemistries needed 
to be amenable not only to buffer conditions, but also to complicated cellular 
environments filled with countless proteins and metabolites. To examine this capacity, 
we tested the efficiency of the reactions in the presence of bovine or human serum, as 
well as various metabolites, including glutathione, cysteine, and fructose. Finally, the 
bioorthogonality requirement also demands that our probes are stable in and non-reactive 
towards these complex biological settings.  
 Our group’s work initial foray into iminoboronate chemistry stemmed from the 
knowledge that many species of Gram-positive bacteria, including the clinically relevant 
S. aureus, display amine-presenting lipids on their cell surfaces. Iminoboronate chemistry 
of acetylphenyl boronic acid (APBA) enabled bacterial detection by incorporation of this 
chemical motif into a defined cationic peptide, H-Lys, to afford target binding synergism 
of electrostatic bacterial cell surface interactions and iminoboronate formation with 
amine-presenting lipids. Given the aforementioned requirement for bioorthogonality, we 
sought to determine if we could improve upon the equilibrium dissociation constant (Kd) 
of simple APBA binding to these amines (1-20 mM) by incorporating a variety of 
electron-donating and -withdrawing substituents on the APBA scaffold. Our hypothesis 
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for this endeavor was that analogues containing electron-withdrawing groups would 
increase the electron deficiency of boron in the boronic acid to promote amine 
conjugation. Unfortunately we did not foresee that increasing the Lewis acidity would 
also enhance a competing boroxole formation mechanism, which diminishes the 
conjugation of the APBA analogue to amines. 
 Although our APBA analogues did not exhibit the desired improvement in amine 
conjugating potency, other research groups have reported success with the incorporation 
of APBA into non-covalent ligand core structures, which has afforded protein inhibitors 
with greatly improved binding potency (IC50~3 nM) in comparison to simple APBA.4 
Thus, improvement of the binding of APBA appears to be best achieved when 
incorporated into scaffolds designed specifically for the target of interest, rather than by 
substituent effects.  
 Towards an alternative aim of utilizing APBA for facile free and N-terminal 
cysteine conjugation, the APBA analogues were successful in slightly improving the 
binding potency towards L-cysteine in comparison to simple APBA (~3x improvement).  
The binding dissociation constant of thiazolidinoboronate formation of APBA and L-
cysteine, however, is ~40x less than that of iminoboronate formation with 2-
methoxyethylamine (0.5 mM versus 20 mM), which may mitigate the interfering effects 
of boroxole formation observed with iminoboronate formation. Thus, while the APBA 
analogues didn’t prove to be successful for improving the binding potency towards 
forming iminoboronates, their application in thiazolidinoboronate formation did show 
some utility.  
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 Considering our lack of success with discovering improved amine-binding APBA 
molecules, we turned to an alternative bioorthogonal chemistry, diazaborine formation, to 
achieve efficient bacterial labeling. Initially discovered for the conjugation of APBA and 
phenylhydrazine, diazaborine formation is a fast conjugation chemistry that forms stable 
conjugates. Phenylhydrazine, however, is neither stable in biological contexts, nor non-
toxic, so we substituted semicarbazide as our nucleophile to generate a truly 
biocompatible chemistry.  
 By synthesizing D-amino acid variants of APBA and semicarbazide, we were able 
to efficiently incorporate these chemical motifs into the cell walls of bacteria via a cell 
wall remodeling mechanism that employs the transpeptidase function of PBPs. 
Interestingly, the APBA unnatural amino acid, D-AB3, showed significantly more 
efficient incorporation into E. coli cell walls in comparison to several other bacterial 
species through an unknown mechanism. While we hypothesize that the differences in 
incorporation efficiency could be due to differences in the PBPs and their related 
transpeptidases between the various species of bacteria, the actual mechanism has yet to 
be elucidated. This could be carried out by confirming the PBP responsible for 
incorporation of the amino acids by studying PBP mutants, and subsequently comparing 
structures of the related PBPs. Nonetheless, the diazaborine forming chemistry enables a 
facile method of labeling bacteria in a relatively selective manner.  
 We were also able to transform the diazaborine chemistry into a turn-on 
fluorescent bacterial labeling system, whereby we incorporated a semicarbazide 
containing D-unnatural amino acid into the bacterial cell wall, which underwent 
diazaborine formation with a non-fluorogenic APBA coumarin analog that became 
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fluorescent when conjugated to semicarabzide. This feature enables no-wash labeling of 
the bacteria at up to low millimolar concentrations, which is prohibited with fluorescent 
probes. Notably, the semicarbazide amino acid shows greater incorporation efficiency for 
S. aureus in comparison to E. coli, which is in contrast to the APBA amino acid. The 
species selectivity for the incorporation of APBA and semicarbazide amino acids is a 
serendipitous discovery, rather than a consequence of design. Thus, we sought out a 
platform that would enable us to develop highly selective bacterial species and strain 
specific chemical probes.  
 Over the past few years, our group has developed a method to label a randomized 
phage-display peptide library with APBA handles. This APBA dimer phage library has 
been successfully applied to identify peptides that are selective probes of several bacterial 
species including the clinically relevant S. aureus and LOS deficient (LOS-) A. 
baumannii.5 Looking to expand upon the species-selectivity we have been able to achieve 
with this library, we sought to determine if we could generate strain-selective peptide 
probes that differentiate between different mechanisms of colistin resistance (pmrA/B 
and LOS-) in the same bacterial species (A. baumannii). Through this investigation, we 
discovered that the LOS- strain is capable of binding peptides that are meant to be 
selective for detecting the pmrA/B mechanism of colistin resistance, even if the library is 
first screened against the LOS- strain to eliminate any LOS- binders, which prohibits 
development of pmrA/B-specific peptide probes. Alternatively, we were successful in 
identifying probes that selectively bind to LOS- strains and not pmrA/B strains (SEC8 
and SEC9). Therefore, it appears that the LOS- cell surface has features that result in 
some non-specific binding of the APBA dimer colistin resistance detecting peptides. 
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Despite a lack of resistance mechanism-specific binding of some of the hits, the peptide 
probes identified do selectively bind colistin resistant strains of bacteria, and do not bind 
colistin sensitive strains, which is important towards our efforts to create novel methods 
of detecting antibiotic resistant bacteria. 
 Furthermore, we sought to determine if we could identify peptide probes that are 
specific for the mcr1 mechanism of colistin resistance in non-A. baumannii bacterial 
species. Indeed, SEC18-20 display strong binding to AR497, a K. pneumoniae strain, yet 
these peptides show diminished binding to alternative mcr1-carrying bacterial strains, 
AR493 (E. coli) and AR496 (S. enteritiditis). Interestingly, a pmrA/B A. baumannii-
derived peptide, SEC5, also showed strong binding to the AR497 strain, indicating a 
potentially similar LOS- binding phenomenon, whereby the AR497 strain is sticky for 
colistin resistance detecting peptides. (Further investigation about other strains….) 
 Beyond identification of bacterial cell surface binding peptides, we also applied 
the APBA dimer phage library to identify peptide binders of a small protein, human beta 
defensin 3. Screening of the library against immobilized hBD3 resulted in peptide hits 
that were selective for hBD3 binding in comparison to the similar defensin, hBD2, and 
displayed low micromolar binding potency. This application of the phage library platform 
towards identification of protein binding peptides represents a new area of exploration in 
our lab. Identification of protein binders, and potentially protein inhibitors with this high 
throughput platform has many important applications in the development of novel probes 
and therapeutics of a wide array of proteins and disease states both within and beyond our 
current interests in antibiotic resistance.  
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 Throughout all of the successes and failures of the projects explored herein, the 
importance of target-specific binding elements becomes apparent. The case of APBA 
analogues in comparison to a non-covalent ligand incorporated APBA highlights the 
improvement in target specificity that can be achieved by including additional specificity 
elements in our chemistries, including phage libraries. Towards the future, the phage 
screening platform presents an important opportunity to include additional specificity 
elements to improve targeted binding of our probes. Efforts in this area are currently 
being undertaken with a dual labeled phage library that can display a specificity element 
at the N-terminus and an APBA handle within the peptide sequence to afford additional 
improvements in binding potency to amine-presenting targets.  
 Additionally, through our library screens of many different bacterial strains, we 
were able to discover a variety of peptides that exhibit binding to one or more strains of 
interest; however, we remain uncertain about the cell wall features to which these 
peptides are binding. While the key difference between the antibiotic resistant strains and 
wild-type strains from which they were derived is the amine presenting modifications, 
there may be other differences between the cell surfaces that contribute to the varied 
binding of these peptides. Therefore, it may be helpful to better characterize the cell wall 
features of the strains studied, as well as which features the peptides are binding to in 
order to understand the mechanism of bacterial binding afforded by each peptide. 
 Overall, we have successfully developed several different approaches to selective 
detection of different bacterial strains by both serendipity as well as careful design. Our 
goal is that these probes can be translated to the clinic not only as diagnostic tools, but 
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also eventually as targeted therapeutics towards our efforts to improve the current state of 
antibiotic resistance.  
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